Functional AAV capsids for systemic administration
Engineered AAV capsids with altered tropism and enhanced infectivity address the limitations of current capsids by preferentially targeting CNS tissues, improving gene delivery efficacy and safety.
Patent Information
- Application Number
- JP2024532790
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-08-18
- Filing Date
- 2022-11-30
- Publication Date
- 2024-11-19
AI Technical Summary
Current AAV capsids used in gene therapy exhibit poor infectivity and liver tropism, leading to hepatotoxicity and immunological challenges, limiting their effectiveness in targeting tissues like muscle and central nervous system (CNS) and preventing repeated administration in immunonaïve patients.
Development of recombinant AAV capsids with altered tropism, specifically engineered VP capsid polypeptides containing the 581-589 region with amino acid substitutions, which enhance infectivity and preferentially target CNS tissues with up to 1000-fold higher DNA or RNA enrichment compared to wild-type AAV9 or AAV5.
The engineered capsids achieve significant enrichment in CNS tissues, reducing liver tropism and hepatotoxicity, enabling effective gene delivery and therapeutic payload transmission with reduced immune response and lower doses.
Smart Images

Figure 2024543211000001_ABST
Abstract
Description
[Technical Field]
[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 63 / 284,977, entitled "FUNCTIONAL AAV CAPSIDS FOR SYSTEMIC ADMINISTRATION," filed December 1, 2021; U.S. Provisional Patent Application No. 63 / 342,032, entitled "FUNCTIONAL AAV CAPSIDS FOR SYSTEMIC ADMINISTRATION," filed May 13, 2022; U.S. Provisional Patent Application No. 63 / 354,635, entitled "FUNCTIONAL AAV CAPSIDS FOR SYSTEMIC ADMINISTRATION," filed June 22, 2022; and U.S. Provisional Patent Application No. 63 / 399,164, entitled "FUNCTIONAL AAV CAPSIDS FOR SYSTEMIC ADMINISTRATION," filed August 18, 2022, each of which is incorporated by reference in its entirety for all purposes.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in eXtensible Markup Language (XML), which is incorporated herein by reference in its entirety. A copy of said XML, created on November 28, 2022, is named "421688-705021_SL.xml" and is 5 megabytes in size. [Background technology]
[0003] Recombinant adeno-associated viruses (rAAVs) provide a leading platform for in vivo delivery of gene therapy agents. Current clinical trials use a limited number of AAV capsids, primarily derived from natural human or primate serotypes, such as AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAVrh.10, AAV4rh.74, and AAVhu.67. These capsids are often suboptimal for targeting target tissues due to both poor infectivity and competitive hepatotropism. Increasing doses to ensure infection of the desired tissue can result in dose-dependent hepatotoxicity. Additionally, the use of natural capsids poses challenges due to immunological memory, which excludes immune patient populations from treatment and often precludes repeated administration in previously immune-naive patients. Thus, there is a need for additional AAV capsids for use in gene therapy, particularly capsids that enhance the infectivity of rAAV for certain tissues, such as muscle tissue and tissues of the central nervous system, while reducing liver tropism. Summary of the Invention
[0004] Described herein is a system for high-throughput engineering of functional AAV capsids with altered tropism for various tissues, and capsid variants with improved tropism for target tissues, such as muscle tissue or central nervous system (CNS) tissue.
[0005] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system (CNS) tissue with at least 100-fold greater DNA enrichment than wild-type AAV9.
[0006] In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3846, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:2168, SEQ ID NO:54, SEQ ID NO:429, SEQ ID NO:708, SEQ ID NO:428, SEQ ID NO:4119, SEQ ID NO:3906, SEQ ID NO:2456, SEQ ID NO:2278, SEQ ID NO:5006, SEQ ID NO:426, SEQ ID NO:307, SEQ ID NO:5155, SEQ ID NO:2640, SEQ ID NO:4317, SEQ ID NO:1145, SEQ ID NO:430, and SEQ ID NO:885. In some embodiments, the recombinant viral capsid is capable of preferentially targeting CNS tissue with at least 200-fold greater DNA enrichment than wild-type AAV9. In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 3306, SEQ ID NO: 2028, SEQ ID NO: 2791, SEQ ID NO: 424, SEQ ID NO: 2536, SEQ ID NO: 1971, SEQ ID NO: 415, SEQ ID NO: 3846, SEQ ID NO: 3283, SEQ ID NO: 1956, and SEQ ID NO: 3297. In some embodiments, the recombinant viral capsid is capable of preferentially targeting CNS tissue with at least 1000-fold greater DNA enrichment than wild-type AAV9. In some embodiments, the 581-589 region has the sequence of SEQ ID NO: 18.
[0007] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system (CNS) tissue with at least 100-fold greater RNA enrichment than wild-type AAV9.
[0008] In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 3306, SEQ ID NO: 2028, SEQ ID NO: 2791, SEQ ID NO: 424, SEQ ID NO: 2536, SEQ ID NO: 1971, SEQ ID NO: 415, SEQ ID NO: 3283, SEQ ID NO: 1956, SEQ ID NO: 3297, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 1576, SEQ ID NO: 425, SEQ ID NO: 709, SEQ ID NO: 54, SEQ ID NO: 429, SEQ ID NO: 428, SEQ ID NO: 426, and SEQ ID NO: 430. In some embodiments, the recombinant viral capsid is capable of preferentially targeting CNS tissue with at least 200-fold greater RNA enrichment than wild-type AAV9. In some embodiments, the 581-589 region comprises a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:430, SEQ ID NO:569, and SEQ ID NO:719. In some embodiments, the recombinant viral capsid is capable of preferentially targeting CNS tissue with at least 500-fold greater RNA enrichment than wild-type AAV9. In some embodiments, the 581-589 region comprises a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, and SEQ ID NO:2028.
[0009] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system (CNS) tissue with at least 5-fold higher DNA enrichment than wild-type AAV5.
[0010] In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3846, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, and SEQ ID NO:1576. In some embodiments, the recombinant viral capsid is capable of preferentially targeting CNS tissue with at least 10-fold greater DNA enrichment than wild-type AAV5. In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, and SEQ ID NO:424.
[0011] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system (CNS) tissue with at least 5-fold greater RNA enrichment than wild-type AAV5.
[0012] In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 3306, SEQ ID NO: 2028, SEQ ID NO: 2791, SEQ ID NO: 424, SEQ ID NO: 2536, SEQ ID NO: 1971, SEQ ID NO: 415, SEQ ID NO: 3283, SEQ ID NO: 1956, SEQ ID NO: 3297, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 1576, SEQ ID NO: 425, SEQ ID NO: 709, SEQ ID NO: 54, SEQ ID NO: 429, SEQ ID NO: 708, SEQ ID NO: 428, SEQ ID NO: 426, SEQ ID NO: 307, SEQ ID NO: 4317, SEQ ID NO: 430, and SEQ ID NO: 885. In some embodiments, the recombinant viral capsid is capable of preferentially targeting CNS tissue with at least 20-fold greater RNA enrichment than wild-type AAV5. In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:430, SEQ ID NO:569, and SEQ ID NO:719.
[0013] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region being selected from the group consisting of (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3946, (j) SEQ ID NO: 3946, (k) SEQ ID NO: 3946, (l ... having a sequence that is at least 85% identical to sequence number 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006 or (dd) SEQ ID NO: 426.
[0014] In some embodiments, the 581-589 region is selected from the group consisting of (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: No. 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006 or (dd) SEQ ID NO: 426.
[0015] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region having a sequence at least 85% identical to any one of SEQ ID NOs: 12 through 3937 or SEQ ID NOs: 3938 through 4237.
[0016] In some embodiments, the 581-589 region has the sequence of any one of SEQ ID NO: 12 through SEQ ID NO: 3937 or SEQ ID NO: 3938 through SEQ ID NO: 4237. In some embodiments, the VP capsid polypeptide is capable of assembling into a recombinant viral capsid.
[0017] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide capable of assembling into a recombinant viral capsid, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, and capable of imparting central nervous system (CNS) tissue tropism at least three-fold greater to the infectivity of the recombinant viral capsid for CNS tissue than the wild-type VP capsid polypeptide of SEQ ID NO:1, the VP capsid polypeptide comprising at least one amino acid substitution compared to each of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8.
[0018] In some embodiments, the 581-589 region is X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 In the sequence, X 1 , X 2 , X 3 , X 4 , X 5 , X 6, X 7 , X 8 and X 9 are each individually selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, and V. In some embodiments, the VP capsid polypeptide has the sequence of SEQ ID NO:2, and is comprised of residues 581-589 (X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 ) corresponds to the 581-589 region thereof. In some embodiments, the 581-589 region has a sequence that is at least 70%, at least 77%, at least 80%, at least 88%, at least 90%, or at least 95% identical to any one of SEQ ID NOs: 12 through 3937. In some embodiments, the 581-589 region has a sequence that is at least 70%, at least 77%, at least 80%, at least 88%, at least 90%, or at least 95% identical to any one of SEQ ID NOs: 3938 through 4237. In some embodiments, the 581-589 region has the sequence of any one of SEQ ID NOs: 3938 through 4237.
[0019] In some embodiments, the VP capsid polypeptide comprises an amino acid sequence at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 98.5%, at least 99%, or at least 99.5% identical to SEQ ID NO: 1. In some embodiments, the infectivity of CNS tissue is at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 75-fold, at least 100-fold, at least 200-fold, at least 500-fold, or at least 1000-fold higher than the infectivity of CNS tissue of the wild-type VP capsid polypeptide. In some embodiments, the 581-589 region improves the stability of recombinant viral capsids assembled from the VP capsid polypeptide compared to wild-type AAV5 capsids comprising the peptide of SEQ ID NO: 1. In some embodiments, the 581-589 region reduces toxicity when administered to a subject compared to the wild-type VP capsid polypeptide of SEQ ID NO: 1. In some embodiments, the CNS tissue is selected from the forebrain cortex, occipital cortex, temporal cortex, thalamus, hypothalamus, substantia nigra, hippocampal DG, hippocampal CA1, hippocampal CA3, cerebellum, and any combination thereof.
[0020] In various aspects, the disclosure provides pharmaceutical compositions comprising a VP capsid polypeptide as described herein.
[0021] In some embodiments, the VP capsid polypeptide is assembled into a recombinant viral capsid. In some embodiments, the pharmaceutical composition further comprises a payload encapsulated in the recombinant viral capsid. In some embodiments, the payload encodes a therapeutic polynucleotide or a therapeutic peptide. In some embodiments, the payload encodes a guide RNA, a tRNA, a suppressor tRNA, an siRNA, a miRNA, an mRNA, an shRNA, a circular RNA, an antisense oligonucleotide (ASO), a ribozyme, a DNAzyme, an aptamer, or a combination thereof. In some embodiments, the payload encodes a component of a CRISPR / Cas system, an adenosine deaminase acting on RNA (ADAR) enzyme, a transcriptional activator, or a transcriptional repressor.
[0022] In various aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) comprising a VP capsid polypeptide as described herein assembled into a recombinant viral capsid and a payload encapsulated in the recombinant viral capsid.
[0023] In some embodiments, the rAAV further comprises a VP2 polypeptide comprising the 581-589 region of the present invention and a VP3 polypeptide comprising the 581-589 region. In some embodiments, the payload encodes a therapeutic polynucleotide or a therapeutic peptide. In some embodiments, the payload encodes a guide RNA, tRNA, suppressor tRNA, siRNA, miRNA, mRNA, shRNA, circular RNA, antisense oligonucleotide (ASO), ribozyme, DNAzyme, aptamer, or a combination thereof. In some embodiments, the payload encodes a component of the CRISPR / Cas system, an adenosine deaminase acting on RNA (ADAR) enzyme, a transcriptional activator, or a transcriptional repressor.
[0024] In various aspects, the present disclosure provides a method for delivering a payload to central nervous system (CNS) tissue of a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV) having the payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting the CNS tissue with the rAAV; and preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment that is at least 100-fold higher than wild-type AAV9.
[0025] In some embodiments, the DNA enrichment is at least 200-fold higher than wild-type AAV9, hi some embodiments, the DNA enrichment is at least 1000-fold higher than wild-type AAV9.
[0026] In various aspects, the present disclosure provides a method for transcribing a payload in central nervous system (CNS) tissue of a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having the payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting the CNS tissue with the rAAV; and preferentially transcribing the payload in the CNS tissue infected with the rAAV at an RNA enrichment that is at least 100-fold greater than wild-type AAV9.
[0027] In some embodiments, the DNA enrichment is at least 200-fold higher than wild-type AAV9. In some embodiments, the DNA enrichment is at least 500-fold higher than wild-type AAV9.
[0028] In various aspects, the present disclosure provides a method for delivering a payload to central nervous system (CNS) tissue of a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having the payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting the CNS tissue with the rAAV; and preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 5-fold higher than wild-type AAV5.
[0029] In some embodiments, the DNA enrichment is at least 10-fold higher than wild-type AAV5.
[0030] In various aspects, the present disclosure provides a method for transcribing a payload in central nervous system (CNS) tissue of a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having the payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting the CNS tissue with the rAAV; and preferentially transcribing the payload in the CNS tissue infected with the rAAV at an RNA enrichment that is at least 5-fold higher than wild-type AAV5.
[0031] In some embodiments, the DNA enrichment is at least 20-fold higher than wild-type AAV5.
[0032] In various aspects, the present disclosure provides a method for delivering a payload to central nervous system (CNS) tissue of a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having the payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region being selected from the group consisting of: (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3283, (m) SEQ ID NO: (aa) SEQ ID NO:2456, (b) SEQ ID NO:2278, (c) SEQ ID NO:5006, or (d) SEQ ID NO:426; and infecting the CNS tissue with at least three-fold increased CNS tissue tropism compared to a wild-type AAV5 capsid comprising a peptide of SEQ ID NO:1; and delivering the payload to the CNS tissue infected with the rAAV.
[0033] In various aspects, the present disclosure provides a method of delivering a payload to central nervous system (CNS) tissue of a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV) having the payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581-589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to residues 581-589 of SEQ ID NO:1, and the VP capsid polypeptide comprising at least one amino acid substitution compared to each of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8; infecting the CNS tissue with the rAAV with at least three-fold increased CNS tissue tropism relative to a wild-type AAV5 capsid comprising the peptide of SEQ ID NO:1; and delivering the payload to the CNS tissue infected with the rAAV.
[0034] In various aspects, the present disclosure provides methods for delivering a payload to central nervous system (CNS) tissue of a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having the payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide as described herein, infecting the CNS tissue with the rAAV, and delivering the payload to the CNS tissue infected with the rAAV.
[0035] In some embodiments, the method further comprises expressing a therapeutic polypeptide or therapeutic polynucleotide encoded by the payload in CNS tissue infected with the rAAV. In some embodiments, the method further comprises producing a therapeutic effect in the CNS tissue of the subject. In some embodiments, the therapeutic effect is greater than 1 x 10 per kg of the subject's body weight. 5 ~5×10 14The therapeutic effect is exerted upon administration of a single rAAV. In some embodiments, the method comprises administering an amount of rAAV sufficient to produce a therapeutic effect in the subject without causing toxicity. In some embodiments, the CNS tissue comprises the forebrain cortex, the occipital cortex, the temporal cortex, the thalamus, the hypothalamus, the substantia nigra, the hippocampus DG, the hippocampus CA1, the hippocampus CA3, the cerebellum, or a combination thereof.
[0036] In various aspects, the present disclosure provides methods of treating a condition in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting central nervous system (CNS) tissue of the subject with the rAAV; preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 100-fold higher than wild-type AAV9; and producing a therapeutic effect in the CNS tissue, thereby treating the condition.
[0037] In some embodiments, the DNA enrichment is at least 200-fold higher than wild-type AAV9, hi some embodiments, the DNA enrichment is at least 1000-fold higher than wild-type AAV9.
[0038] In various aspects, the present disclosure provides methods of treating a condition in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting central nervous system (CNS) tissue of the subject with the rAAV; preferentially transcribing the payload in the CNS tissue infected with the rAAV with an RNA enrichment at least 100-fold higher than wild-type AAV9; and producing a therapeutic effect in the CNS tissue, thereby treating the condition.
[0039] In some embodiments, the DNA enrichment is at least 200-fold higher than wild-type AAV9. In some embodiments, the DNA enrichment is at least 500-fold higher than wild-type AAV9.
[0040] In various aspects, the present disclosure provides methods of treating a condition in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting central nervous system (CNS) tissue of the subject with the rAAV; preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 5-fold higher than wild-type AAV5; and producing a therapeutic effect in the CNS tissue, thereby treating the condition.
[0041] In some embodiments, the DNA enrichment is at least 10-fold higher than wild-type AAV5.
[0042] In various aspects, the present disclosure provides methods of treating a condition in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting central nervous system (CNS) tissue of the subject with the rAAV; preferentially transcribing the payload in the CNS tissue infected with the rAAV with an RNA enrichment at least 5-fold higher than wild-type AAV5; and producing a therapeutic effect in the CNS tissue, thereby treating the condition.
[0043] In some embodiments, the DNA enrichment is at least 20-fold higher than wild-type AAV5.
[0044] In various aspects, the present disclosure provides a method of treating a condition in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region being selected from the group consisting of: (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006, or (dd) SEQ ID NO: 426), infecting a CNS tissue of the subject with the rAAV, delivering the payload to the CNS tissue infected with the rAAV, and producing a therapeutic effect in the CNS tissue, thereby treating the condition.
[0045] In various aspects, the present disclosure provides methods of treating a condition in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581-589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to residues 581-589 of SEQ ID NO:1, and the VP capsid polypeptide does not have the sequence of any of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8; infecting CNS tissue of the subject with the rAAV with at least three-fold increased CNS tissue tropism relative to a wild-type AAV5 capsid comprising the peptide of SEQ ID NO:1; delivering the payload to the CNS tissue infected with the rAAV; and producing a therapeutic effect in the CNS tissue, thereby treating the condition.
[0046] In various aspects, the present disclosure provides methods of treating a condition in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide as described herein, infecting a CNS tissue of the subject with the rAAV, delivering the payload to the CNS tissue infected with the rAAV, and producing a therapeutic effect in the CNS tissue, thereby treating the condition.
[0047] In some embodiments, the condition is a neurological condition. In some embodiments, the neurological condition is aromatic L-amino acid decarboxylase (AADC) deficiency, Alzheimer's disease, tauopathy, synucleinopathy, Batten disease, mucopolysaccharidosis type III, frontotemporal dementia, Parkinson's disease, corticobasal degeneration, progressive supranuclear palsy, chronic traumatic encephalopathy, Gaucher disease, Canavan disease, Tay-Sachs disease, Huntington's disease, Potocki-Lupski syndrome, amyotrophic lateral sclerosis, Down syndrome, Sanfilippo disease type A, Sanfilippo disease type B, or Rett syndrome. In some embodiments, the condition is Rett syndrome. In some embodiments, the payload encodes a guide RNA that targets an mRNA encoded by MECP2 or a tRNA that targets a premature stop codon in MECP2. In some embodiments, the condition is Parkinson's disease. In some embodiments, the payload is selected from the group consisting of LRRK2, GBA, alpha-synuclein, AADC, GDNF, neurturin, GAD, FOXG1, K v 7.2, encodes a guide RNA that targets an mRNA encoding fragile X mental retardation protein, tau, or laforin. In some embodiments, the condition is Alzheimer's disease. In some embodiments, the payload encodes a guide RNA that targets an mRNA encoding amyloid precursor protein (APP), alpha-synuclein (SNCA), tau protein (MAPT), or apolipoprotein E (ApoE). In some embodiments, the payload encodes a transgene encoding amyloid precursor protein (APP), alpha-synuclein (SNCA), tau protein (MAPT), or apolipoprotein E (ApoE).
[0048] In some embodiments, the method comprises administering 1×10 per kg of the subject's body weight. 5 ~5×10 14In some embodiments, the method includes administering a rAAV to the CNS tissue with at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 75-fold, at least 100-fold, at least 200-fold, at least 500-fold, or at least 1000-fold greater tissue tropism than a wild-type AAV5 capsid comprising a peptide of SEQ ID NO:1.
[0049] In some embodiments, the payload encodes a therapeutic protein, a therapeutic polynucleotide, a guide RNA, a tRNA, a suppressor tRNA, an siRNA, an miRNA, an mRNA, an shRNA, a circular RNA, an antisense oligonucleotide (ASO), a ribozyme, a DNAzyme, an aptamer, or a combination thereof. In some embodiments, the guide RNA is a CRISPR / Cas guide RNA or an ADAR guide RNA. In some embodiments, the therapeutic protein is an L-amino acid decarboxylase (AADC), amyloid precursor protein (APP), alpha-synuclein, microtubule-associated protein tau (MAPT), ApoE, nerve growth factor (NGF), telomerase reverse transcriptase (TERT), CLN2, CLN3, CLN6, N-acetyl-alpha-glucosaminidase (NAGLU), granulin, glucosylceramidase beta (GBA), aspartoacylase, GDNF, neurturin (NTN), glutamic acid decarboxylase (GAD), FOXG1, K v7.2, laforin, leucine-rich repeat kinase 2 (LRRK2), hexosaminidase A (HEXA), hexosaminidase B (HEXB), huntingtin, cholesterol 24-hydroxylase, C9orf72, superoxide dismutase 1 (SOD1), dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRKA1), N-sulfoglucosamine sulfohydrolase (SGSH), surfeit locus protein 1 (SURF1), GABA transporter 1 (GAT1), and methyl-CpG binding protein 2 (MECP2). In some embodiments, the therapeutic polynucleotide is selected from the group consisting of aromatic L-amino acid decarboxylase (AADC), amyloid precursor protein (APP), alpha-synuclein, microtubule-associated protein tau (MAPT), ApoE, nerve growth factor (NGF), telomerase reverse transcriptase (TERT), CLN2, CLN3, CLN6, N-acetyl-alpha-glucosaminidase (NAGLU), granulin, glucosylceramidase beta (GBA), aspartoacylase, GDNF, neurturin (NTN), glutamic acid decarboxylase (GAD), FOXG1, K v7.2, laforin, leucine-rich repeat kinase 2 (LRRK2), hexosaminidase A (HEXA), hexosaminidase B (HEXB), huntingtin, cholesterol 24-hydroxylase, C9orf72, superoxide dismutase 1 (SOD1), dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRKA1), N-sulfoglucosamine sulfohydrolase (SGSH), surfeit locus protein 1 (SURF1), GABA transporter 1 (GAT1), and methyl-CpG binding protein 2 (MECP2). In some embodiments, the payload encodes a component of a CRISPR / Cas system, an adenosine deaminase acting on RNA (ADAR) enzyme, a transcriptional activator, or a transcriptional repressor. In some embodiments, the components of the CRISPR / Cas system include Cas3, Cas8, Cas10, Cas9, Cas4, Cas12, Cas13, guide RNA, or a combination thereof. In some embodiments, the ADAR enzyme is ADAR1 or ADAR2. In some embodiments, the transcriptional activator is VP64. In some embodiments, the transcriptional repressor is KRAB.
[0050] In some embodiments, the method includes systemically administering the rAAV to the subject. In some embodiments, the method includes administering the rAAV intravenously, intramuscularly, intraperitoneally, or orally. In some embodiments, the method further includes expressing a therapeutic polypeptide or therapeutic polynucleotide encoded by the payload in CNS tissue infected with the rAAV. In some embodiments, the method includes expressing the therapeutic polypeptide or therapeutic polynucleotide with increased CNS tissue tropism compared to a wild-type AAV5 capsid containing the peptide of SEQ ID NO: 1. In some embodiments, the method includes expressing the therapeutic polypeptide or therapeutic polynucleotide with at least 3-fold, at least 3.5-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 75-fold, at least 100-fold, at least 200-fold, at least 500-fold, or at least 1000-fold increased tropism compared to a wild-type AAV5 capsid.
[0051] In some embodiments, the method comprises causing less toxicity in the subject than would result from systemic administration of a comparable number of wild-type AAV5 capsids comprising the VP capsid polypeptide of SEQ ID NO: 1. In some embodiments, the method comprises causing less toxicity in the subject than would result from systemic administration of a comparable number of wild-type AAV5 capsids comprising the VP capsid polypeptide of SEQ ID NO: 1 in sufficient numbers to deliver a comparable number of payloads to the CNS tissue. In some embodiments, the method comprises producing a lower concentration of neutralizing antibodies in the subject than would result from systemic administration of a comparable number of wild-type AAV5 capsids comprising the VP capsid polypeptide of SEQ ID NO: 1. In some embodiments, the method comprises producing a lower concentration of neutralizing antibodies in the subject than would result from intravitreal administration of a comparable number of wild-type AAV2 capsids. In some embodiments, the method comprises producing a neutralizing antibody concentration in the subject that is lower than the concentration of neutralizing antibodies produced by intravitreal administration of a comparable number of wild-type AAV8 capsids. In some embodiments, the method comprises producing a neutralizing antibody concentration in the subject that is lower than the concentration of neutralizing antibodies produced by intravitreal administration of a comparable number of wild-type AAV9 capsids. In some embodiments, the VP capsid polypeptide further comprises one or more mutations outside the 581-589 region that contribute to reduced production of neutralizing antibodies compared to wild-type AAV capsids. In some embodiments, the method comprises producing a neutralizing antibody concentration in the subject that is lower than the concentration of neutralizing antibodies produced by systemic administration of wild-type AAV5 capsids comprising the VP capsid polypeptide of SEQ ID NO: 1 in sufficient numbers to deliver a comparable number of payloads to the CNS tissue.
[0052] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system tissue and myocardial tissue.
[0053] In some embodiments, the 581-589 region has a sequence that shares at least 85% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 2536, SEQ ID NO: 3846, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 1576, SEQ ID NO: 4317, SEQ ID NO: 23, SEQ ID NO: 22, SEQ ID NO: 964, SEQ ID NO: 4288, SEQ ID NO: 4338, SEQ ID NO: 5037, and SEQ ID NO: 4936. In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 2536, SEQ ID NO: 3846, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 1576, SEQ ID NO: 4317, SEQ ID NO: 23, SEQ ID NO: 22, SEQ ID NO: 964, SEQ ID NO: 4288, SEQ ID NO: 4338, SEQ ID NO: 5037, and SEQ ID NO: 4936.
[0054] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system tissue and skeletal muscle tissue.
[0055] In some embodiments, the 581-589 region has a sequence that shares at least 85% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 3306, SEQ ID NO: 2536, SEQ ID NO: 1971, SEQ ID NO: 3283, SEQ ID NO: 3297, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 307, SEQ ID NO: 4317, SEQ ID NO: 1268, SEQ ID NO: 4288, SEQ ID NO: 724, and SEQ ID NO: 5037. In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 3306, SEQ ID NO: 2536, SEQ ID NO: 1971, SEQ ID NO: 3283, SEQ ID NO: 3297, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 307, SEQ ID NO: 4317, SEQ ID NO: 1268, SEQ ID NO: 4288, SEQ ID NO: 724, and SEQ ID NO: 5037.
[0056] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system tissue and muscle tissue.
[0057] In some embodiments, the 581-589 region has a sequence that shares at least 85% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 2536, SEQ ID NO: 3846, SEQ ID NO: 3297, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 1576, SEQ ID NO: 4317, SEQ ID NO: 23, SEQ ID NO: 22, SEQ ID NO: 964, SEQ ID NO: 4288, SEQ ID NO: 4290, SEQ ID NO: 4338, and SEQ ID NO: 5037. In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 2536, SEQ ID NO: 3846, SEQ ID NO: 3297, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 1576, SEQ ID NO: 4317, SEQ ID NO: 23, SEQ ID NO: 22, SEQ ID NO: 964, SEQ ID NO: 4288, SEQ ID NO: 4290, SEQ ID NO: 4338, and SEQ ID NO: 5037.
[0058] In various aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising administering to the subject an rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9; infecting central nervous system (CNS) tissue of the subject with the rAAV; and preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment that is at least 100-fold greater than wild-type AAV9.
[0059] In various aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising administering to the subject an rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting central nervous system (CNS) tissue of the subject with the rAAV; and preferentially transcribing the payload in the CNS tissue infected with the rAAV with an RNA enrichment that is at least 100-fold greater than wild-type AAV9.
[0060] In various aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising administering to the subject an rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting central nervous system (CNS) tissue of the subject with the rAAV; and preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 5-fold higher than wild-type AAV5.
[0061] In various aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising administering to the subject an rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting central nervous system (CNS) tissue of the subject with the rAAV; and preferentially transcribing the payload in the CNS tissue infected with the rAAV with an RNA enrichment at least 5-fold higher than wild-type AAV5.
[0062] In various aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising administering to the subject an rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region being selected from the group consisting of: (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, and (k) SEQ ID NO: 3846. , (l) SEQ ID NO: 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006, or (dd) SEQ ID NO: 426), infecting a CNS tissue of the subject with the rAAV, and delivering the payload to the CNS tissue infected with the rAAV.
[0063] In various aspects, the disclosure provides a recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising administering to the subject an rAAV, the rAAV encapsulating a payload, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581-589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to residues 581-589 of SEQ ID NO:1, and the VP capsid polypeptide does not have the sequence of any of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8; infecting CNS tissue of the subject with the rAAV with at least three-fold increased CNS tissue tropism relative to a wild-type AAV5 capsid comprising the peptide of SEQ ID NO:1; and delivering the payload to the CNS tissue infected with the rAAV.
[0064] In various aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising administering to the subject an rAAV (wherein the rAAV has a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide as described herein), infecting CNS tissue of the subject with the rAAV, and delivering the payload to the CNS tissue infected with the rAAV.
[0065] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting myocardial tissue with at least 25-fold higher DNA enrichment than wild-type AAV9.
[0066] In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:1576, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:4964, SEQ ID NO:293, SEQ ID NO:4314, SEQ ID NO:4995, SEQ ID NO:4366, SEQ ID NO:4961, SEQ ID NO:4952, SEQ ID NO:5075, SEQ ID NO:4354, SEQ ID NO:5060, SEQ ID NO:5138, SEQ ID NO:5206, SEQ ID NO:4288, SEQ ID NO:5092, SEQ ID NO:4059, SEQ ID NO:4295, SEQ ID NO:5030, SEQ ID NO:4938, SEQ ID NO:2661, SEQ ID NO:5215, SEQ ID NO:4960, SEQ ID NO:4969, SEQ ID NO:5023, SEQ ID NO:4934, SEQ ID NO:4545, SEQ ID NO:4963, SEQ ID NO:4363, SEQ ID NO:5159, and SEQ ID NO:4973.
[0067] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region being selected from the group consisting of: (a) SEQ ID NO: 348, (b) SEQ ID NO: 2536, (c) SEQ ID NO: 1576, (d) SEQ ID NO: 4955, (e) SEQ ID NO: 5017, (f) SEQ ID NO: 4349, (g) SEQ ID NO: 4964, (h) SEQ ID NO: 293, (i) SEQ ID NO: 4314, (j) SEQ ID NO: 4995, (k) SEQ ID NO: 4366, (l) SEQ ID NO: No. 4961, (m) SEQ ID NO: 4952, (n) SEQ ID NO: 5075, (o) SEQ ID NO: 4354, (p) SEQ ID NO: 5060, (q) SEQ ID NO: 5138, (r) SEQ ID NO: 5206, (s) SEQ ID NO: 4288, (t) SEQ ID NO: 5092, (u) SEQ ID NO: 4059, (v) SEQ ID NO: 4295, (w) SEQ ID NO: 5030, (x) SEQ ID NO: 4938, (y) SEQ ID NO: 2661, (z) SEQ ID NO: 5215, (aa) SEQ ID NO: 4960, (bb) SEQ ID NO: 4969, (cc) SEQ ID NO: 5023 or (dd) SEQ ID NO: 4934.
[0068] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting skeletal muscle tissue with at least 15-fold higher DNA enrichment than wild-type AAV9.
[0069] In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:3472, SEQ ID NO:3297, SEQ ID NO:2661, SEQ ID NO:4545, SEQ ID NO:348, SEQ ID NO:18, SEQ ID NO:4349, SEQ ID NO:293, SEQ ID NO:5017, SEQ ID NO:4955, SEQ ID NO:4366, SEQ ID NO:5092, SEQ ID NO:210, SEQ ID NO:4059, SEQ ID NO:2536, SEQ ID NO:5206, and SEQ ID NO:1971.
[0070] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region being selected from the group consisting of: (a) SEQ ID NO: 3472, (b) SEQ ID NO: 3297, (c) SEQ ID NO: 2661, (d) SEQ ID NO: 4545, (e) SEQ ID NO: 348, (f) SEQ ID NO: 18, (g) SEQ ID NO: 4349, (h) SEQ ID NO: 293, (i) SEQ ID NO: 5017, (j) SEQ ID NO: 4955, (k) SEQ ID NO: 4366, (l) SEQ ID NO: No. 5092, (m) SEQ ID NO: 210, (n) SEQ ID NO: 4059, (o) SEQ ID NO: 2536, (p) SEQ ID NO: 5206, (q) SEQ ID NO: 1971, (r) SEQ ID NO: 262, (s) SEQ ID NO: 4343, (t) SEQ ID NO: 4995, (u) SEQ ID NO: 4009, (v) SEQ ID NO: 5190, (w) SEQ ID NO: 724, (x) SEQ ID NO: 4288, (y) SEQ ID NO: 4973, (z) SEQ ID NO: 4314, (aa) SEQ ID NO: 1561, (bb) SEQ ID NO: 5147, (cc) SEQ ID NO: 4238 or (dd) SEQ ID NO: 4961.
[0071] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of the VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO: 9, and a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting muscle tissue with at least 20-fold higher DNA enrichment than wild-type AAV9.
[0072] In some embodiments, the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:293, SEQ ID NO:1576, SEQ ID NO:2661, SEQ ID NO:4964, SEQ ID NO:4314, SEQ ID NO:4995, SEQ ID NO:4366, SEQ ID NO:4545, SEQ ID NO:4961, SEQ ID NO:5206, SEQ ID NO:5092, SEQ ID NO:3472, SEQ ID NO:5075, SEQ ID NO:4059, SEQ ID NO:4354, SEQ ID NO:5060, SEQ ID NO:4288, SEQ ID NO:4952, SEQ ID NO:5138, SEQ ID NO:18, SEQ ID NO:5030, SEQ ID NO:3297, SEQ ID NO:4295, SEQ ID NO:4363, SEQ ID NO:4963, SEQ ID NO:4973, SEQ ID NO:5159, SEQ ID NO:4960, SEQ ID NO:4938, SEQ ID NO:5157, SEQ ID NO:5023, and SEQ ID NO:4969.
[0073] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region being selected from the group consisting of (a) SEQ ID NO: 348, (b) SEQ ID NO: 2536, (c) SEQ ID NO: 4955, (d) SEQ ID NO: 5017, (e) SEQ ID NO: 4349, (f) SEQ ID NO: 293, (g) SEQ ID NO: 1576, (h) SEQ ID NO: 2661, (i) SEQ ID NO: 4964, (j) SEQ ID NO: 4314, (k) SEQ ID NO: 4995, (l) SEQ ID NO: No. 4366, (m) SEQ ID NO: 4545, (n) SEQ ID NO: 4961, (o) SEQ ID NO: 5206, (p) SEQ ID NO: 5092, (q) SEQ ID NO: 3472, (r) SEQ ID NO: 5075, (s) SEQ ID NO: 4059, (t) SEQ ID NO: 4354, (u) SEQ ID NO: 5060, (v) SEQ ID NO: 4288, (w) SEQ ID NO: 4952, (x) SEQ ID NO: 5138, (y) SEQ ID NO: 18, (z) SEQ ID NO: 5030, (aa) SEQ ID NO: 3297, (bb) SEQ ID NO: 4295, (cc) SEQ ID NO: 4363 or (dd) SEQ ID NO: 4963.
[0074] In various aspects, the present disclosure provides a viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising a sequence at least 85% identical to any one of SEQ ID NOs: 4238 to 4933 or SEQ ID NOs: 4934 to 5233.
[0075] In some embodiments, the 581-589 region has the sequence of any one of SEQ ID NOs: 4238 to 4933 or SEQ ID NOs: 4934 to 5233.
[0076] Incorporation by Reference Any reference cited herein is incorporated by reference to the same extent as if each individual publication, database entry (e.g., a Genbank sequence or GeneID entry), patent application, or patent were specifically and individually indicated to be incorporated by reference in its entirety for all purposes. This statement of incorporation by reference is intended by applicants to be in accordance with 37 CFR §1.57(b)(1) with respect to all individual publications, database entries (e.g., a Genbank sequence or GeneID entry), patent applications, or patents, each of which is expressly recognized in accordance with 37 CFR §1.57(b)(2), even if such citation is not immediately adjacent to the portion specifically incorporated by reference. If a portion specifically incorporated by reference is included within this specification, that portion in no way diminishes this general statement of incorporation by reference. The citation of any reference herein is not intended as an admission that the reference is pertinent prior art, nor is it to be construed as any admission as to the contents or date of such publications or documents.
[0077] These and other features, aspects and advantages of the present invention will become better understood with reference to the following description and accompanying drawings. [Brief explanation of the drawings]
[0078] [Figure 1] Schematic diagram of a high-throughput AAV capsid engineering system. [Figure 2A] Side (upper panel) and top (lower panel) views of key residues in known AAV capsids that have been shown to interact with target cells are shown. [Figure 2B] 1 shows the salient organization of the AAV capsid library described in Example 1, with regions where diversity was introduced indicated by residue numbers corresponding to the amino acid numbers in AAV5 VP1. [Figure 3A]1 shows the results of next-generation sequencing (NGS) analysis of purified secondary screening library viruses containing the engineered AAV5 variants of the present disclosure with barcoded control serotypes (AAV1, AAV2, AAV5, AAV9, or AAV PHP.B) spiked in at 1x, 10x, and 100x stoichiometric ratios. [Figure 3B] FIG. 1 is a schematic illustrating the results of post-selection NGS analysis of NHP tissues identifying AAV spike-in control DNA in the CNS, liver, heart, and skeletal muscle. [Figure 3C] We show that DNA from 94% of capsid variants predicted to target the CNS was found in the CNS. [Figure 3D] The CNS DNA abundance of three engineered AAV5 variants of the present disclosure, namely SEQ ID NO: 18 (AAGRFNYFG), SEQ ID NO: 54 (AEDYWDLGA), and SEQ ID NO: 2028 (MDDICEFYA), compared to spike-in wild-type AAV5 and wild-type AAV9, shows significantly higher infection rates than the highest ratio (100-fold) of controls. [Figure 3E] The engineered AAV5 variants of the present disclosure demonstrate reduced infectivity in the liver compared to the wild-type (parental) AAV5 control. [Figure 4]SEQ ID NO:415 (DARVYRALD), SEQ ID NO:569 (DSASPIMGM), SEQ ID NO:428 (DAWQMLSGN), SEQ ID NO:430 (DAWSYQCYH), SEQ ID NO:708 (EAWMYHQFH), SEQ ID NO:3906 (YSGVRVTGY), SEQ ID NO:709 (EAWSKLEQP), SEQ ID NO:3297 (TAGRFNYFD), SEQ ID NO:1956 (LVGWTLQHV), SEQ ID NO:885 (ESWMKLEWQ), SEQ ID NO:3283 (TAAFAYKYE), SEQ ID NO:3472 (TSHYITFTP), SEQ ID NO:426 (DAW 1 is a bar graph showing the relative accumulation of AAV capsid variants comprising the 581-589 region of SEQ ID NO: 18 (AAGRFNYFG), SEQ ID NO: 54 (AEDYWDLGA), or SEQ ID NO: 2028 (MDDICEFYA), expressed as a log 10 fold change in accumulation in the brain relative to other tissues. Accumulation was compared to wild-type AAV capsids of AAV9, AAV1, AAV PHP.B, AAV2, and AAV5. [Figure 5]SEQ ID NO:4318 (CKEWYVRDR), SEQ ID NO:4960 (CWREFSFQN), SEQ ID NO:4371 (CVSLHSISM), SEQ ID NO:3975 (QAHHYNILN), SEQ ID NO:5215 (CVRTLQSPD), SEQ ID NO:4598 (LAWSQLLTP), SEQ ID NO:4359 (CVATKSRML), SEQ ID NO:5665 (RQTTYDCLD), SEQ ID NO:257 (CAHYAQWGK), SEQ ID NO:344 (CSSGFHLFH), SEQ ID NO:5607 (QCGFIRLNE), SEQ ID NO:3528 (TVTHMSQHC), SEQ ID NO:5155 (C VIWYHKYE), SEQ ID NO: 5363 (GCMCIRHAY), SEQ ID NO: 4633 (MACWKNATE), SEQ ID NO: 2525 (QAGSSFHQA), SEQ ID NO: 386 (CYQFWSQYS), SEQ ID NO: 4970 (CINFIMKLG), SEQ ID NO: 5143 (CWRHNIISP), SEQ ID NO: 5178 (CIKWVDIFP), SEQ ID NO: 2505 (PTQFYGPAF), SEQ ID NO: 3709 (VSASFQQHV), SEQ ID NO: 5056 (CVLNYFQFG), SEQ ID NO: 5017 (CFYKIQHKG), SEQ ID NO: 5040 (CVLRMGTFC), SEQ ID NO:5161 (CTHMMGKSP), SEQ ID NO:1128 (GFANFMMNF), SEQ ID NO:2204 (MTMTATTFG), SEQ ID NO:4316 (CIRHAQDCY), SEQ ID NO:5463 (KISPWDGFY), SEQ ID NO:4944 (CWKWQMMFG), SEQ ID NO:4955 (CVWSQILGG), SEQ ID NO:4952 (CVILSTRDK), SEQ ID NO:3260 (SVSPCFCNS), SEQ ID NO:384 (CYMPFKMQH), SEQ ID NO:5038 (CVVWPVLGQ), SEQ ID NO:2371 (NMTMAHQAS), SEQ ID NO:289 (CI HSVHFAA), SEQ ID NO: 2985 (RVDAFNRGT), SEQ ID NO: 4508 (GSCLKIAQE), SEQ ID NO: 4292 (CAMLLQAVQ), SEQ ID NO: 4995 (CVGYRVHSP), SEQ ID NO: 4949 (CYHQVFSQG), SEQ ID NO: 5077 (CVGSQLHAM), SEQ ID NO: 2370 (NMNTFGKMN), SEQ ID NO: 5193 (CWSHLYFQT), SEQ ID NO: 4568 (KANEDLKQF), SEQ ID NO: 5206 (CFFYPMSMS), SEQ ID NO: 4215 (LYAFYMSSE), SEQ ID NO: 4841 (SSDQYEEMN),1 is a bar graph showing the relative accumulation of AAV capsid variants containing the 581-589 region of SEQ ID NO: 5092 (CISNYLKQG), SEQ ID NO: 4335 (CPMKHIQDR), SEQ ID NO: 5029 (CSFNIHKHT), SEQ ID NO: 3258 (SVRMFDAQY), SEQ ID NO: 4349 (CSSYLVTAN), SEQ ID NO: 348 (CTASWMSWD), or SEQ ID NO: 2729 (QQQQTNFQN), expressed as a log2 fold change in accumulation in muscle relative to other tissues. AAV variants generated using machine learning (ML) are indicated by arrows. Accumulation was compared to wild-type AAV capsids of AAV9, AAV PHP.B, AAV1, AAV2, and AAV5. [Figure 6] Figure 1 is a Circos plot showing AAV5 capsid variants identified in a primary screen performed as shown in Figure 1. The Venn diagram is not to scale. Over 1 million capsid variants were characterized as unique to heart tissue, over 100,000 variants were characterized as unique to skeletal muscle tissue, and over 1,000 variants were characterized as common to heart and skeletal muscle tissues. Variants identified in heart, skeletal muscle, or both heart and skeletal muscle tissues shared low identity with liver (approximately 0.7% overlap) and low identity with other tissues (e.g., non-muscle tissues). [Figure 7A] Normalized counts of plasmid library DNA are shown relative to assembled viral DNA of wild-type AAV control (shaded points) and AAV variant candidates (gray circles). Assembled virus levels in the AAV variant candidates were comparable to the wild-type AAV control at a spike-in frequency of 1x. [Figure 7B]The figures show a comparison of DNA levels in the liver and CNS for AAV variant candidates (gray circles), wild-type controls (shaded points), and AAV candidates selected for CNS tropism (open circles). The size of the circle for the selected AAV candidates corresponds to the amount of functional conversion in CNS tissue, with larger circles representing higher RNA expression in CNS tissue. AAV candidates with CNS tropism were more enriched in CNS tissue than in liver tissue. [Figure 7C] The figure shows a comparison of DNA levels in muscle and CNS for AAV variant candidates (gray circles), wild-type controls (shaded points), and AAV candidates selected for CNS tropism (open circles). The size of the circle for the selected AAV candidates corresponds to the amount of functional conversion in CNS tissue, with larger circles representing higher RNA expression in CNS tissue. AAV candidates with CNS tropism were more enriched in CNS tissue than in muscle tissue. [Figure 8A] A bar graph shows the proportion of candidates from various library subsets identified as muscle-specific in the secondary screen. Muscle-specific candidates generated using machine learning ("Muscle-specific ML synthesis results") contained a higher proportion of muscle-specific sequences than candidates identified in muscle in the primary screen ("Muscle observations"), CNS-targeted sequences, or negative control sequences. Machine learning-generated muscle-specific candidate sequences were 5-fold more likely to be cardiac- and / or skeletal muscle-specific than muscle-specific candidates identified in the primary screen, and 20-fold more likely to be cardiac- and / or skeletal muscle-specific than CNS-targeted variants. Candidates were classified as muscle-specific if they were more than two-fold enriched in cardiac and / or skeletal muscle over all other tissues and viral inputs (FDR < 0.1, considering consistency across multiple barcodes per capsid by permutation and α-RRA). [Figure 8B]Violin and boxplots are shown comparing the predicted likelihood of muscle specificity in the primary screen for candidates identified as muscle-specific in the secondary screen ("Yes") or not characterized ("No"). Candidates were classified as muscle-specific if they were more than 2-fold enriched in cardiac and / or skeletal muscle over all other tissues and viral inputs (FDR<0.1, considering consistency across multiple barcodes per capsid by permutation and α-RRA). [Figure 9] CNS prediction scores are shown for CNS target candidates identified across multiple non-human primates (NHPs), multiple samples, based on observational enrichment, enrichment frequency, or sequence similarity, or generated by machine learning. On average, CNS target candidates generated using machine learning had higher CNS prediction scores than candidates identified from other sources. [Figure 10] 1 is a plot showing the relative accumulation and functional conversion in various tissues after systemic administration of various concentrations of wild-type AAV9 capsid (top) and three identified CNS tissue-tropic AAV variants (SEQ ID NO: 18, SEQ ID NO: 424, and SEQ ID NO: 2028, bottom). RNA expression, representing functional conversion in each tissue, is shown on the x-axis. Circle size represents the relative accumulation of AAV virions in each tissue, as measured by DNA. These AAV variants are highly selective for CNS tissues. [Figure 11] 1 is a plot showing the relative accumulation and functional conversion of three identified CNS tissue-tropic AAV variants (SEQ ID NO: 18, SEQ ID NO: 424, and SEQ ID NO: 2028) in various CNS tissues after systemic administration. DNA quantification results for a given AAV variant are shown on the x-axis. Circle size corresponds to the amount of functional conversion of a given AAV variant in each tissue, with larger circles representing higher RNA expression in CNS tissues. The AAV variant exhibits widespread functional conversion in CNS tissues. [Figure 12]Relative functional transformation of RNA expression in various brain regions is shown for wild-type AAV9 (left) and the CNS tissue-tropic AAV variant of SEQ ID NO: 2028 (right). Brain regions sampled include the cortex (forebrain), cortex (occipital), cortex (temporal), thalamus, hypothalamus, hippocampus, cerebellum, caudate nucleus, putamen, pons, medulla oblongata, midbrain, and substantia nigra. Darker shading indicates greater transformation as measured by RNA expression. The AAV variant exhibits widespread functional transformation in CNS tissues. [Figure 13] Three AAV variants of the present disclosure (SEQ ID NO: 18, SEQ ID NO: 424, and SEQ ID NO: 2028, also shown in FIG. 11) have been shown to functionally convert neurons. CAG promoter-driven RNA expression revealed functional conversion of all cell types, while SYN promoter-driven RNA expression revealed functional conversion of neurons. [Figure 14] Several AAV variants of the present disclosure that target the CNS have been shown to also exhibit depletion in the dorsal root ganglia (DRG). [Figure 15] This indicates that promoter usage differentiates between CNS- and cardiac AAV variants. For example, certain CNS-specific AAV variants disclosed herein exhibit CAG promoter-driven and SYN promoter-driven RNA expression, while certain cardiac AAV variants exhibit only CAG promoter-driven RNA expression. [Figure 16A] Bar plot of cross-size of capsids enriched in myocardial tissue of non-human primates (NHPs), mice, or both NHPs and mice. [Figure 16B] Scatter plot showing the log2 fold change in enrichment of capsid variants or wild-type AAV capsids in NHP and mouse heart tissue. Seventeen variants enriched in both NHP and mouse heart tissue are indicated by dark circles. [Figure 17A] Bar plot of cross-size of capsids enriched in CNS tissues of non-human primates (NHPs) or mice. [Figure 17B] Scatter plot showing the log2 fold change in enrichment of capsid variants or wild-type AAV capsids in NHP CNS tissues versus mouse CNS tissues. [Figure 18] Scatter plot of mean z-scores of CNS tissue enrichment for screened AAV capsid variants, sorted by mean capsid variant rank across 12 differential expression analysis methods. High-scoring capsid variants, corresponding to open circles in the upper left quadrant, consistently ranked higher across multiple analysis strategies, and consistently ranked higher than wild-type AAV5 (wtAAV5) and wild-type AAV9 (wtAAV9). DETAILED DESCRIPTION OF THE INVENTION
[0079] Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.
[0080] Unless otherwise specified, whenever a range is recited, the range includes the recited endpoints. For example, the region from amino acid residue 581 to amino acid residue 589 of SEQ ID NO: 1 includes amino acid residues 581 and 589.
[0081] "Homology," "identity," or "similarity" can refer to sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing positions within each sequence that can be aligned for comparison purposes. If a position in the compared sequences can be occupied by the same base or amino acid, the molecules can be homologous at that position. The degree of homology between sequences can be a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or "non-homologous" sequence is less than 40% identical or less than 25% identical to one of the sequences of the present disclosure. Sequence homology can refer to the percent identity of a sequence relative to a reference sequence. Indeed, whether any particular sequence is at least 50%, 60%, 70%, 77.7%, 80%, 85%, 88.8%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any of the sequences described herein (which may correspond to the specific nucleic acid or amino acid sequences described herein) can be conventionally determined for such specific polypeptide sequences using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence, parameters can be set to calculate the percentage of identity over the entire length of the reference sequence and to allow for gaps in sequence homology of up to 5% across the entire reference sequence.The terms "percent identity" or "homology," in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that, when compared and aligned for maximum correspondence, have a predetermined percentage of the same nucleotides or amino acid residues, as determined using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN, or other algorithms available to those skilled in the art) or by visual inspection. Depending on the application, the percent "identity" can be over a region of the sequences being compared, such as a functional domain, or over the entire length of the two sequences being compared. In sequence comparison, typically, one sequence serves as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence based on the designated program parameters. For purposes herein, percent identity and sequence similarity determinations are performed using the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available at the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov / ). For example, when comparing a nine-residue amino acid sequence to another nine-residue amino acid sequence, if eight residues match, the sequences are 88.8% identical; if seven residues match, the sequences are 77.7% identical.
[0082] In some cases, identity (also referred to as global sequence alignment) between a reference sequence (query sequence, e.g., a sequence of the present disclosure) and a subject sequence can be determined using the computer program FASTDB. In some embodiments, parameters of certain embodiments that allow identity to be narrowly interpreted and that are used for amino acid alignment in FASTDB include Scoring Scheme=PAM (Percent Accepted Mutations) 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500, or the length of the subject sequence (which may be the shorter of these). According to this embodiment, if the subject sequence may be shorter than the query sequence due to N- or C-terminal deletions rather than internal deletions, the results can be manually corrected to account for the fact that the FASTDB program does not consider N- and C-terminal truncations of the subject sequence when calculating the global percent identity. For subject sequences that are N- and C-terminally truncated compared to the query sequence, the percent identity can be corrected by calculating the number of residues in the query sequence that are potentially flanking the N- and C-termini of the subject sequence that cannot be matched / aligned with the corresponding subject residues as a percentage of the total bases in the query sequence. Whether a residue can be matched / aligned can be determined by the results of a sequence alignment in FASTDB. This percentage can then be subtracted from the percent identity calculated by the FASTDB program using the specified parameters to obtain a final percent identity score. For purposes of this embodiment, this final percent identity score can be used.In some cases, for purposes of manually adjusting this percent identity score, only residues at the N- and C-termini of the subject sequence that cannot be matched / aligned with the query sequence can be considered. That is, only query residue positions outside the extreme N- and C-termini of the subject sequence can be considered for this manual correction. For example, a 90-residue subject sequence can be aligned with a 100-residue query sequence to determine percent identity. Because the subject sequence has a deletion at its N-terminus, the first 10 residues at the N-terminus are not matched / aligned in the FASTDB alignment. Since the 10 mismatched residues represent 10% of the sequence (number of unmatched residues at the N- and C-termini divided by the total number of residues in the query sequence), 10% can be subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues are perfectly matched, the final percent identity can be 90%. In another example, a 90-residue subject sequence can be compared with a 100-residue query sequence. This time, the deletion can be an internal deletion, so there can be no residues at the N- or C-termini of the subject sequence that cannot be matched / aligned with the query. In this case, the percent identity calculated by FASTDB cannot be manually corrected. Again, only residue positions outside the N- and C-termini of the subject sequence that cannot be matched / aligned with the query sequence in the FASTDB alignment can be manually corrected.
[0083] Peptide sequences for use in the present invention may contain one or more conservative amino acid substitutions, such that the resulting sequences have similar amino acid sequences and / or retain the same function. Those skilled in the art recognize that various amino acids are "conservative" because they have similar biochemical properties. Often, one or more of these amino acids in a protein, polypeptide, or peptide can be substituted with one or more other such amino acids without eliminating the desired activity of the protein, polypeptide, or peptide. That is, the amino acids glycine, alanine, valine, leucine, and isoleucine can often be substituted for each other (amino acids having aliphatic side chains). Of these possible substitutions, the use of glycine and alanine to substitute for each other (because glycine and alanine have relatively short side chains) and the use of valine, leucine, and isoleucine to substitute for each other (because valine, leucine, and isoleucine have longer aliphatic side chains that are hydrophobic) are preferred. Other amino acids that can often be substituted for one another include phenylalanine, tyrosine, and tryptophan (amino acids with aromatic side chains), lysine, arginine, and histidine (amino acids with basic side chains), aspartate and glutamate (amino acids with acidic side chains), asparagine and glutamine (amino acids with amide side chains), and cysteine and methionine (amino acids with sulfur-containing side chains). It is understood that natural or unnatural amino acids can be used to make amino acid substitutions within the scope of the present invention. For example, the methyl group of alanine may be replaced with an ethyl group, and / or minor modifications may be made to the peptide backbone. Whether natural or synthetic amino acids are used, preferably only L-amino acids are present. Substitutions of this nature are often referred to as "conservative substitutions."
[0084] As used herein, the "tropism" of an rAAV for a tissue may refer to the ability of a given rAAV to preferentially infect a given cell type or tissue. The degree of tropism may be determined by the ratio of the infection rate in the target tissue to the infection rate in a different non-target tissue. As used herein, improved tropism for a given cell type or tissue, for example, improved tropism achieved by the 581-589 region, is determined compared to wild-type AAV5 capsids. As used herein, "detargeting" of an rAAV for a tissue may refer to the ability of a given rAAV to avoid infection of the detargeted tissue or cell type while infecting one or more other tissues or cell types. The degree of detargeting may be determined by the ratio of the infection rate in the detargeted tissue to the infection rate in a different tissue that is not detargeted. As used herein, improved detargeting for a given cell type or tissue, for example, improved detargeting achieved by the 581-589 region, is determined compared to wild-type AAV5 capsids.
[0085] As used herein, "tissue tropism" refers to the preference of a virus having an engineered VP capsid polypeptide of the present disclosure to infect or be concentrated or accumulate in a given tissue. A "tissue-tropic" rAAV can specifically target or infect a first tissue or group of tissues and cannot target or infect a second tissue or group of tissues. For example, a "CNS-tropic" rAAV can specifically target or infect CNS tissue and cannot specifically target or infect muscle, skin, bone, or other tissue or group of tissues. A "tissue-detargeted" rAAV can specifically avoid targeting or infecting the detargeted tissue or group of tissues while infecting a second tissue or group of tissues. For example, a "liver-detargeted" rAAV is unable to target or infect liver tissue, but is able to infect one or more other tissues, such as nerve, muscle, skin, bone, and / or other tissues. Tissue tropism or tissue-detargeting, when used as a relative term and in the context in which it is described herein, refers to the increased or decreased tissue tropism of a given rAAV virion having a first capsid polypeptide in a first tissue compared to a second tissue, and / or refers to the increased or decreased tissue tropism of a given rAAV virion having a first capsid polypeptide compared to an rAAV virion having a second capsid polypeptide. In some embodiments, the first tissue can be a group of tissues. In some embodiments, the second tissue can be a group of tissues. For example, the first tissue may be a CNS tissue including the forebrain cortex, occipital cortex, temporal cortex, thalamus, hypothalamus, substantia nigra, hippocampus DG, hippocampus CA1, hippocampus CA3, and cerebellum, and the second tissue may be a non-CNS tissue collectively consisting of liver, skeletal muscle, heart, lung, spleen, lymph node, bone marrow, mammary gland, skin, adrenal gland, thyroid, colon, sciatic nerve, and spinal cord tissue.As another example, the first tissue may be liver tissue and the second tissue may be a non-liver tissue collectively consisting of CNS tissue, skeletal muscle, heart, lung, spleen, lymph node, bone marrow, mammary gland, skin, adrenal gland, thyroid, colon, sciatic nerve, and spinal cord tissue.
[0086] In some embodiments, the rAAV virions of the present disclosure may be referred to as preferentially targeting a certain tissue or as having tissue selectivity for a certain tissue. For example, an rAAV virion that preferentially targets CNS tissue may specifically target or infect CNS tissue, but may not target or infect skeletal muscle, cardiac muscle, or other tissues, or may target other tissues to a lesser extent than CNS tissue. As another example, an rAAV virion that has selectivity for retinal tissue may specifically target or infect CNS tissue, but may not target or infect skeletal muscle, cardiac muscle, or other tissues, or may target other tissues to a lesser extent than CNS tissue.
[0087]
[0088] As used herein, the "581-589 region" refers to a region or fragment of VP1 corresponding to amino acid residues 581 to 589 relative to the translation initiation site of the VP1 polypeptide. The 581-589 region is sometimes referred to as the "variant region." The 581-589 region corresponds to amino acid residues 445 to 453 of VP2 and amino acid residues 389 to 397 of VP3. The 581-589 region can confer tissue tropism to AAV, and defined variants (e.g., SEQ ID NO: 12 to SEQ ID NO: 3937, SEQ ID NO: 3938 to SEQ ID NO: 4237, SEQ ID NO: 4238 to SEQ ID NO: 4933, SEQ ID NO: 4934 to SEQ ID NO: 5233, SEQ ID NO: 5234 to SEQ ID NO: 5807, or SEQ ID NO: 5808 to SEQ ID NO: 5811) may be engineered to confer tissue tropism to rAAV formed from viral capsid polypeptides (VP1, VP2, and VP3) comprising the 581-589 region.VP1 with the generalized 581-589 region is shown in SEQ ID NO:2 (. 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 IVPGSVWMERDVYLQGPIWAKIPETGAHFHPSPAMGGFGLKHPPPMMLIKNTPVPGNITSFSDVPVSSFITQYSTGQVTVEMEWELKKENSKRWNPEIQYTNNYNDPQFVDFAPDSTGEYRTTRPIGTRYLTRPL), and the 581-589 region is 1 X 2 X 3 X 4 X 5 X 6 X 7 X8 X 9 wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 are each independently selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.
[0089] It is understood that the present disclosure includes polynucleotide sequences that encode any of the sequences disclosed herein, for example, where an amino acid sequence is provided, the present disclosure also includes the polynucleotide sequence that encodes said amino acid sequence.
[0090] It is understood that further embodiments include mutations in any of VP1, VP2, VP3, or combinations thereof, that do not alter desired properties (e.g., specific tissue tropism) or affect viral assembly, as described herein.
[0091] rAAV virions are made with capsids that may include engineered AAV5 VP capsid polypeptides (e.g., VP1, VP2, and VP3 capsid polypeptides) disclosed herein.
[0092] Capsids and capsid polypeptides engineered for tissue tropism Described herein are engineered capsids, engineered capsid polypeptides, and the 581-589 region of a capsid polypeptide that confer tissue tropism (e.g., tissue-specific accumulation, tissue-specific infectivity, or both) to a viral capsid. In some embodiments, an engineered capsid may comprise one or more engineered capsid polypeptides that assemble into a viral capsid of a recombinant adeno-associated virus (rAAV). In some embodiments, an engineered capsid polypeptide may comprise variation in its 581-589 region. The 581-589 region of a viral capsid polypeptide, which corresponds to amino acid residues 581-589 of the VP1 polypeptide, amino acid residues 445-453 of the VP2 polypeptide, and amino acid residues 389-397 of the VP3 polypeptide, is located at the AAV interface that interacts with host cells and tissues.
[0093] Also described herein are methods for using engineered capsids containing engineered capsid polypeptides having the 581-589 region for tissue-specific delivery of a payload (e.g., a polynucleotide, e.g., a transgene) encapsulated in the engineered capsid. Recombinant AAV containing a VP capsid polypeptide having the 581-589 region, engineered for tissue specificity, may be used to specifically infect target tissues. The use of tissue-tropic rAAV viral capsids for payload delivery offers numerous advantages over the use of adeno-associated virus (AAV) viral capsids, which lack tissue tropism, including reduced toxicity, a lower dose required to produce a therapeutic effect, a broader therapeutic window, and a reduced immune response. Furthermore, tissue-specific payload delivery may enable targeted therapy even when administered systemically. For example, for the treatment of neurological disorders, rAAV viral capsids with central nervous system (CNS) tissue tropism may be administered systemically to specifically deliver a payload to the CNS. In another example, for the treatment of muscle and vascular diseases, including myocardial, muscle-tropic rAAV viral capsids can be administered systemically to deliver payloads specifically to muscle.
[0094] In some embodiments, the tissue-tropic capsid of the present disclosure may be CNS tissue-tropic. For example, the CNS tissue-tropic capsid polypeptide may provide tropism to one or more CNS tissues (e.g., the hippocampus (dentate gyrus, CA1, or CA3), the cerebellum, the hypothalamus, the cortex (occipital, temporal, or forebrain), the substantia nigra, the thalamus, or a combination thereof). In some embodiments, the tissue-tropic capsid, engineered capsid polypeptide, or the 581-589 region of the capsid polypeptide may be muscle-tropic. For example, the muscle-targeting capsid polypeptide may confer targeting to one or more muscle tissues (e.g., aorta, esophagus, heart (including atria, ventricles, and valves), skeletal muscle (including biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, and quadriceps (including vastus lateralis)), or muscle fibers (e.g., type I (slow-twitch, oxidative) fibers, type IC fibers, type II fibers, type IIC fibers, type IIA (fast-twitch, oxidative / glycolytic) fibers, type IIAX fibers, type IIXA fibers, type IIX (fast-twitch, glycolytic) fibers, or combinations thereof).
[0095] The engineered capsid polypeptides of the present disclosure may include one or more amino acid substitutions relative to an AAV5 viral protein (VP) polypeptide (e.g., the VP1 polypeptide of SEQ ID NO: 1, the VP2 polypeptide of SEQ ID NO: 10, or the VP3 polypeptide of SEQ ID NO: 11). The engineered capsid polypeptide may include one or more amino acid substitutions relative to any or all of the VP1 polypeptides of SEQ ID NOs: 3-8. In some embodiments, the engineered capsid polypeptide may include a 581-589 region that includes one or more amino acid substitutions in a VP polypeptide region (e.g., the 581-589 region of VP1, VP2, VP3, or a combination thereof) corresponding to amino acid residues 581-589 of VP1 (e.g., SEQ ID NO: 1), amino acid residues 445-453 of VP2 (e.g., SEQ ID NO: 10), or amino acid residues 389-397 of VP3 (e.g., SEQ ID NO: 11). In some embodiments, the 581-589 region may be present in VP1, VP2, and VP3. An engineered viral capsid may be assembled from VP1, VP2, and VP3 polypeptides containing a 581-589 region with one or more amino acid substitutions. In some embodiments, the 581-589 region may confer CNS tissue tropism or improve the likelihood of achieving CNS tissue tropism. For example, a 581-589 region with an improved likelihood of achieving CNS tissue tropism may comprise any one of SEQ ID NOs: 12 to 3937, 3938 to 4237, or 5234 to 5807. In some embodiments, the 581-589 region may confer muscle tissue tropism or improve the likelihood of achieving muscle tissue tropism. For example, a 581-589 region with an improved likelihood of achieving muscle tissue tropism may comprise any one of SEQ ID NOs: 4238 to 4933, 4934 to 5233, or 5808 to 5811.
[0096] In some embodiments, the 581-589 region may confer CNS tissue tropism or improve the likelihood of achieving CNS tissue tropism. For example, a 581-589 region with an improved likelihood of achieving CNS tissue tropism may comprise any one of SEQ ID NOs: 12 to 3937 or 3938 to 4237. In some embodiments, the 581-589 region may confer muscle tissue tropism or improve the likelihood of achieving muscle tissue tropism. For example, a 581-589 region with an improved likelihood of achieving muscle tissue tropism may comprise any one of SEQ ID NOs: 4238 to 4933 or 4934 to 5233.
[0097] How to manipulate the capsid Disclosed herein is a high-throughput system for engineering engineered AAV capsids with altered function, including increased or decreased infectivity of a desired tissue relative to a wild-type AAV5 capsid (e.g., a capsid comprising the VP capsid polypeptide of SEQ ID NO: 1), e.g., improved targeting of the central nervous system (CNS), improved targeting of muscle, decreased targeting of non-CNS tissue, or decreased targeting of non-muscle tissue. A general overview of the process is shown in Figure 1. However, it should be understood that the present disclosure also encompasses reasonable variations or extensions of the method as would be understood by one of skill in the art. As shown in Figure 1, the method provides a theoretical diversity of 5x10 11 One may start by creating a capsid library with (5e11) unique sequence variants. Higher or lower theoretical diversity is also encompassed by the present invention. For example, a capsid library may have a theoretical diversity of about 1 x 10 3 (1e3) Approximately 1×10 from the street 20The library can then be cloned into plasmids and introduced into bacteria, after which the library plasmids are screened for productive assembly into virions in a producer cell line. The assembled virions are then intravenously administered to non-human primates (NHPs). After a period sufficient for distribution, infection, and stable transduction, the NHPs can be sacrificed, organs can be harvested, and the sequence of AAV capsids in each tissue can be determined by deep sequencing.
[0098] Figure 2A shows side (upper panel) and top (lower panel) views of the surface of a prototype AAV virion, identifying residues in known AAV capsids (including AAV2, AAV5, AAV6, and AAV9) that have been shown in the literature to interact with target cells. These target-interacting residues correspond to amino acids 581–589 of the AAV5 VP1 capsid protein.
[0099] Figure 2B shows the salient elements of the library plasmid, illustrating the rep and cap coding sequences between the AAV ITRs. In this illustrated embodiment (further described in Example 1), variations were introduced into each of residues 581-589 of the AAV5 cap protein, present in VP1, VP2, and VP3 (the "library variant region"). Each variation of 20 naturally occurring amino acids was introduced into each of the nine positions in the 581-589 region, resulting in 20 9 (20^9, approximately 5×10 11 This results in a theoretical library diversity of (5e11)) distinct sequence variants.
[0100] The engineered target region, 581-589, is most likely to interact with the target cell receptor and is relatively tolerant to alterations without impairing virion assembly. Unlike previous approaches that added unstructured peptides that protrude above the virion at the three-fold symmetry axis, the current approach introduces sequence diversity that alters the characteristics of the binding pocket. In addition, this approach may alter the overall structure of the receptor-bound trimer, allowing for altered allosteric interactions outside the binding pocket (e.g., AAVR PKD1). The non-random nature of the introduced diversity reduces missense and frameshift sequences in randomized libraries.
[0101] By cloning the polynucleotide encoding that capsid variant into the packaged virus genome (between the ITRs), recombinant virions with variant capsids will have polynucleotides with their cognate mutations, and by sequencing the packaged virus or infected cells, the unique variant that confers the desired function can be identified.
[0102] In some embodiments, the capsid is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV-DJ, AAV-DJ / 8, AAV-DJ / 9, AAV1 / 2, AAV.rh8, AAV.rh10, AAV .rh20, AAV.rh39, AAV.Rh43, AAV.Rh74, AAV.v66, AAV.Oligo001, AAV.SCH9, AAV.r3.45, AAV.RH M4-1, AAV.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PhP.eB, AAV.PhP.V1, AAV.PHP.B, AAV AAV.PhB.C1, AAV.PhB.C2, AAV.PhB.C3, AAV.PhB.C6, AAV.cy5, AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, AAV.HSC16, AAV.HSC17, or AAVhu68 (e.g., as described in WO2020 / 033842, which is incorporated by reference in its entirety). For example, the capsid can be an AAV5 capsid. The hu68 capsid is described in WO2018 / 160582, which is incorporated herein by reference in its entirety.
[0103] Such capsids can include the 581-589 region corresponding to amino acid residues 581 to 589 of AAV5 VP1, and thus similar engineered VP capsids with desired tissue tropism or preference, the ability to assemble, and various other desired traits are encompassed by the present invention. That is, any one of the engineered AAV5 VP capsid polypeptides disclosed herein having a mutation or substitution in its 581-589 region corresponding to the 581-589 region of AAV5 VP1 can be inserted into the corresponding region in any one of the other AAV capsids described herein, and the present disclosure includes such variants.
[0104] In some embodiments, the capsid is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV-DJ, AAV-DJ / 8, AAV-DJ / 9, AAV1 / 2, AAV.rh8, AAV.rh10, AAV.rh20, AAV.rh39, AAV.Rh43, AAV.Rh74, AAV.v66, AAV.Oligo001, AAV.SCH9, AAV.r3.45, AAV.RHM4-1, AAV.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PhP.eB, AAV.PhP.V1, AAV.PHP.B, AAV.PhB.C1, AAV.PhB.C2, AAV.PhB.C3, AAV.PhB.C6, AAV.cy5, AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5 , AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, AAV.HSC16, AAV.HSC17 or AAVhu68. For example, the capsid may be a derivative of AAV5.
[0105] In some embodiments, the capsid protein is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV-DJ, AAV-DJ / 8, AAV-DJ / 9, AAV1 / 2, AAV.rh8, AAV.rh10, AAV.rh 20, AAV.rh39, AAV.Rh43, AAV.Rh74, AAV.v66, AAV.Oligo001, AAV.SCH9, AAV.r3.45, AAV.RHM4-1, AA V.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PhP.eB, AAV.PhP.V1, AAV.PHP.B, AAV.PhB.C1, AA AAV.V.PhB.C2, AAV.PhB.C3, AAV.PhB.C6, AAV.cy5, AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, AAV.HSC16, AAV.HSC17, or AAVhu68 (e.g., as described in WO2020 / 033842, which is incorporated by reference in its entirety). In certain embodiments, the capsid is the rh32.33 capsid described in US Pat. No. 8,999,678, which is incorporated herein by reference in its entirety.
[0106] Such capsids may contain the 581-589 region corresponding to positions 581 to 589 of AAV5 VP1, and therefore similar engineered VP capsids with desired tissue tropism or preference, the ability to assemble, and various other desired traits are encompassed by the present invention.
[0107] Polynucleotides encoding VP, vectors and vector libraries Thus, in a first aspect, there is provided a polynucleotide encoding an adeno-associated virus (AAV) VP1 capsid polypeptide having the amino acid sequence of SEQ ID NO:2, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 are each independently selected from the 20 naturally occurring amino acids A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, and V, using the standard one-letter code. 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 91 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 In the sequence, X may be replaced by 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 are each independently selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V, and the VP1 capsid polypeptide does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.
[0108] In some embodiments, the polynucleotide encodes an AAV VP1 capsid polypeptide that further comprises one or more mutations at amino acid residues other than the 581-589 region of SEQ ID NO: 1, and the resulting recombinant capsid is capable of forming assembled virions that exhibit desired tissue targeting compared to wild-type AAV5 (SEQ ID NO: 1). The one or more mutations may confer improved tissue tropism (e.g., improved CNS tissue tropism or improved muscle tissue tropism) or improved tissue preference (e.g., improved CNS tissue preference or improved muscle tissue preference) to the assembled virions compared to the wild-type AAV5 capsid polypeptide.
[0109] In another aspect, a vector capable of replicating in a prokaryotic cell is provided, the vector comprising the polynucleotide described immediately above. In a typical embodiment, the vector is a plasmid encoding a replication-competent AAV genome.
[0110] In a further aspect, a library is provided. The library includes a plurality of vectors comprising polynucleotides encoding AAV capsids. In some embodiments, the vectors are plasmids, and the plurality of plasmids comprises a plurality of polynucleotides encoding different AAV VPs. The library may include a plurality of vectors encoding an AAV VP1 capsid polypeptide having the amino acid sequence of SEQ ID NO:2, wherein the polypeptide comprises one or more amino acid variations in the 581-589 region.
[0111] In various embodiments, the library comprises at least 1 x 10 9 (1e9) different AAV VP capsid polypeptides, at least 2.5 x 10 9 (2.5e9) different AAV VP capsid polypeptides, at least 5 x 10 9 (5e9) distinct AAV VP capsid polypeptides, at least 7.5 x 10 9 (7.5e9) different AAV VP capsid polypeptides, at least 1 x 10 10 (1e10) different AAV VP capsid polypeptides, at least 2.5 x 10 10 (2.5e10) different AAV VP capsid polypeptides, at least 5x10 10 (5e10) different AAV VP capsid polypeptides, at least 7.5 x 10 10 (7.5e10) different AAV VP capsid polypeptides, at least 1 x 10 11 (1e11) different AAV VP capsid polypeptides, at least 2.5 x 10 11 (2.5e11) different AAV VP capsid polypeptides or at least 5 x 10 11 The library encodes (5e11) different AAV VP capsid polypeptides. The library can encode VP capsid polypeptides containing 581-589 region variants.
[0112] In another aspect, a prokaryotic cell is provided comprising the vector, hi some embodiments, the prokaryotic cell is an E. coli cell and the vector is a plasmid.
[0113] In a related aspect, a library is provided, the library comprising a plurality of E. coli cells, the plurality of cells comprising a plurality of plasmids, the plurality of plasmids comprising a plurality of polynucleotides encoding different AAV VPs.
[0114] In some embodiments, the library comprises at least 1 x 10 9 (1e9) different AAV VP capsid polypeptides, at least 2.5 x 10 9 (2.5e9) different AAV VP capsid polypeptides, at least 5 x 10 9 (5e9) distinct AAV VP capsid polypeptides, at least 7.5 x 10 9 (7.5e9) different AAV VP capsid polypeptides, at least 1 x 10 10 (1e10) different AAV VP capsid polypeptides, at least 5 x 10 10 (5e10) different AAV VP capsid polypeptides, at least 7.5 x 10 10 (7.5e10) different AAV VP capsid polypeptides, at least 1 x 10 11 (1e11) different AAV VP capsid polypeptides, at least 2.5 x 10 11 (2.5e11) different AAV VP capsid polypeptides or at least 5 x 10 11 The library encodes (5e11) different AAV VP capsid polypeptides. The library can encode VP capsid polypeptides containing 581-589 region variants.
[0115] VP polypeptide and peptide library In another aspect, an AAV VP1 capsid polypeptide is provided, the polypeptide having the amino acid sequence of SEQ ID NO:2, wherein X 1 , X2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 are each independently selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, and V. The polypeptide contains at least one mutation compared to native AAV VP1 and therefore does not have the sequence of SEQ ID NO: 1. In addition, the polypeptide does not have the sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8.
[0116] In some embodiments, the polypeptide further comprises one or more mutations at amino acid residues other than the 581-589 region of SEQ ID NO: 1, and the resulting recombinant capsid is capable of forming assembled virions that exhibit desired tissue targeting compared to wild-type AAV5 (SEQ ID NO: 1).
[0117] In a further aspect, a library is provided, the library comprising a plurality of polypeptides as described immediately above, the plurality having different primary amino acid sequences. The library may comprise a plurality of polypeptides of SEQ ID NO: 2 comprising one or more amino acid variations in the 581-589 region thereof.
[0118] In some embodiments, the library comprises at least 1 x 10 9 (1e9) different AAV VP capsid polypeptides, at least 2.5 x 10 9 (2.5e9) different AAV VP capsid polypeptides, at least 5 x 10 9 (5e9) distinct AAV VP capsid polypeptides, at least 7.5 x 10 9 (7.5e9) different AAV VP capsid polypeptides, at least 1 x 10 10 (1e10) different AAV VP capsid polypeptides, at least 2.5 x 10 10(2.5e10) different AAV VP capsid polypeptides, at least 5x10 10 (5e10) different AAV VP capsid polypeptides, at least 7.5 x 10 10 (7.5e10) different AAV VP capsid polypeptides, at least 1 x 10 11 (1e11) different AAV VP capsid polypeptides, at least 2.5 x 10 11 (2.5e11) different AAV VP capsid polypeptides or at least 5 x 10 11 (5e11) different AAV VP capsid polypeptides. The library may include VP capsid polypeptides that include 581-589 region variants.
[0119] In certain embodiments, the library comprises at least about 1 x 10 5 (1e5) ~ at least about 5 × 10 11 (5e11) different AAV VP capsid polypeptides. In certain embodiments, the library comprises at least about 1 x 10 AAV VP capsid polypeptides. 5 (1e5) pieces, at least about 2×10 5 (2e5) pieces, at least about 3×10 5 (3e5) pieces, at least about 4×10 5 (4e5) pieces, at least about 5×10 5 (5e5) pieces, at least about 6×10 5 (6e5) pieces, at least about 7×10 5 (7e5) pieces, at least about 8×10 5 (8e5) pieces, at least about 9×10 5 (9e5) pieces, at least about 1×10 6 (1e6) pieces, at least about 2×10 6 (2e6) pieces, at least about 3×10 6 (3e6) pieces, at least about 4×10 6 (4e6) pieces, at least about 5×10 6 (5e6) pieces, at least about 6×10 6 (6e6) pieces, at least about 7×10 6(7e6) pieces, at least about 8×10 6 (8e6) pieces, at least about 9×10 6 (9e6) pieces, at least about 1×10 7 (1e7) pieces, at least about 2×10 7 (2e7) pieces, at least about 3×10 7 (3e7) pieces, at least about 4×10 7 (4e7) pieces, at least about 5×10 7 (5e7) pieces, at least about 6×10 7 (6e7) pieces, at least about 7×10 7 (7e7) pieces, at least about 8×10 7 (8e7) pieces, at least about 9×10 7 (9e7) pieces, at least about 1×10 8 (1e8) pieces, at least about 2×10 8 (2e8) pieces, at least about 3×10 8 (3e8) pieces, at least about 4×10 8 (4e8) pieces, at least about 5×10 8 (5e8) pieces, at least about 6×10 8 (6e8) pieces, at least about 7×10 8 (7e8) pieces, at least about 8×10 8 (8e8) pieces, at least about 9×10 8 (9e8) pieces, at least about 1×10 9 (1e9) pieces, at least about 2×10 9 (2e9) pieces, at least about 3×10 9 (3e9) pieces, at least about 4×10 9 (4e9) pieces, at least about 5×10 9 (5e9) pieces, at least about 6×10 9 (6e9) pieces, at least about 7×10 9 (7e9) pieces, at least about 8×10 9 (8e9) pieces, at least about 9×10 9 (9e9) pieces, at least about 1×10 10 (1e10) pieces, at least about 2×10 10 (2e10) pieces, at least about 3×10 10 (3e10) pieces, at least about 4×10 10(4e10) pieces, at least about 5×10 10 (5e10) pieces, at least about 6×10 10 (6e10) pieces, at least about 7×10 10 (7e10) pieces, at least about 8×10 10 (8e10) pieces, at least about 9×10 10 (9e10) pieces, at least about 1×10 11 (1e11) pieces, at least about 2×10 11 (2e11) pieces, at least about 3×10 11 (3e11) pieces, at least about 4×10 11 (4e11) or at least about 5×10 11 Contains (5e11) pieces.
[0120] In certain embodiments, the present invention provides a recombinant adeno-associated virus AAV VP1 capsid polypeptide having at least one mutation in a region of residues 581 to 589 (inclusive) of SEQ ID NO:1, wherein the mutation is such that the accumulation of AAV virions having the AAV VP1 capsid polypeptide in a target tissue (e.g., CNS tissue or muscle tissue) compared to a non-target tissue is increased relative to wild-type AAV5. at least about 1.1-fold, at least about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at least about 2-fold, at least about 2.2-fold, at least about 2.4-fold, at least about 2.6-fold, at least about 2.8-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about The AAVVP1 capsid polypeptide may have a 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, or at least about 500-fold improvement, wherein the AAVVP1 capsid polypeptide does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. In some embodiments, the VP1 capsid polypeptide comprises a variation in the 581-589 region thereof. For example, a VP1 capsid polypeptide comprising the 581-589 region comprises a VP1 capsid polypeptide in which residues 581 through 589 in SEQ ID NO:1 are X. 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 In the sequence, X may be replaced by 1 , X 2 , X 3 , X 4 , X 5 , X 6, X 7 , X 8 and X 9 are each independently selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V, and the VP1 capsid polypeptide does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.
[0121] rAAV virions, virion library In another aspect, a recombinant AAV virion (rAAV) is provided. The virion comprises an AAV VP capsid polypeptide as described above. In some embodiments, the rAAV has improved tropism for primate and human CNS tissue compared to rAAVs having the native AAV5 VP1 capsid polypeptide (SEQ ID NO: 1). In some embodiments, the rAAV has improved tropism for primate and human muscle tissue compared to rAAVs having the native AAV5 VP1 capsid polypeptide (SEQ ID NO: 1). In some embodiments, the rAAV has improved assembly ability or exhibits increased virion stability compared to rAAVs having the native AAV5 VP1 capsid polypeptide (SEQ ID NO: 1).
[0122] In some embodiments, the rAAV has an improved ability to cross the blood-brain barrier following intravenous administration compared to an rAAV having the native AAV5 VP1 capsid polypeptide (SEQ ID NO: 1).
[0123] In certain of these embodiments, the rAAV has an improved ability to infect one or more brain regions selected from the hippocampus, dentate gyrus, cerebral cortex, temporal cortex, occipital cortex, thalamus, forebrain, substantia nigra, hypothalamus, cerebellum, and combinations thereof following systemic administration compared to an rAAV having a native AAV5 VP1 capsid polypeptide (SEQ ID NO: 1).
[0124] In some embodiments, the rAAV has an improved ability to infect one or more brain regions selected from the hippocampus, dentate gyrus, cerebral cortex, temporal cortex, occipital cortex, thalamus, forebrain, substantia nigra, hypothalamus, cerebellum, and combinations thereof following systemic administration, and also has reduced tropism for non-CNS tissues, compared to an rAAV having a native AAV5 VP1 capsid polypeptide (SEQ ID NO: 1).
[0125] In some embodiments, the rAAV has an improved ability to infect muscle tissue (including the aorta, esophagus, heart (e.g., atrium, ventricle, valves), skeletal muscle (e.g., biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, quadriceps (including vastus lateralis)), or muscle fibers (including type I (slow-twitch, oxidative) fibers, type IC fibers, type II fibers, type IIC fibers, type IIA (fast-twitch, oxidative / glycolytic) fibers, type IIAX fibers, type IIXA fibers, type IIX (fast-twitch, glycolytic) fibers), or combinations thereof) following systemic administration compared to an rAAV having a native AAV5 VP1 capsid polypeptide (SEQ ID NO: 1).
[0126] In some embodiments, the rAAV has an improved ability to infect muscle tissue (including the aorta, esophagus, heart (e.g., atrium, ventricle, valves), skeletal muscle (e.g., biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, quadriceps (including vastus lateralis)), or muscle fibers (including type I (slow-twitch, oxidative) fibers, type IC fibers, type II fibers, type IIC fibers, type IIA (fast-twitch, oxidative / glycolytic) fibers, type IIAX fibers, type IIXA fibers, type IIX (fast-twitch, glycolytic) fibers), or combinations thereof) following systemic administration, and also has a reduced tropism for non-muscle tissues, compared to an rAAV having a native AAV5 VP1 capsid polypeptide (SEQ ID NO: 1).
[0127] Additionally, provided are polynucleotide sequences encoding the rAAV capsid VP proteins described herein.
[0128] In a further aspect, a library is provided comprising a plurality of rAAVs as described above, wherein the plurality of rAAVs comprises a plurality of VP capsid polypeptides having different primary amino acid sequences, and wherein an rAAV of the plurality of rAAVs can comprise the polypeptide of SEQ ID NO: 2 comprising one or more amino acid variations in the 581-589 region thereof.
[0129] In some embodiments, the library comprises at least 1 x 10 9 (1e5) different AAV VP capsid polypeptides, at least 2.5 x 10 9 (2.5e9) different AAV VP capsid polypeptides, at least 5 x 10 9 (5e9) distinct AAV VP capsid polypeptides, at least 7.5 x 10 9 (7.5e9) different AAV VP capsid polypeptides, at least 1 x 10 10 (1e10) different AAV VP capsid polypeptides, at least 2.5 x 10 10 (2.5e10) different AAV VP capsid polypeptides, at least 5x10 10 (5e10) different AAV VP capsid polypeptides, at least 7.5 x 10 10 (7.5e10) different AAV VP capsid polypeptides, at least 1 x 10 11 (1e11) different AAV VP capsid polypeptides, at least 2.5 x 10 11 (2.5e11) different AAV VP capsid polypeptides or at least 5 x 10 11 The library may contain (5e11) different AAV VP capsid polypeptides. The library may also contain AAV VP capsid polypeptides containing variants of the 581-589 region. For example, a VP1 capsid polypeptide containing the 581-589 region has residues 581 to 589 of SEQ ID NO: 1 as X. 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X9 In the sequence, X may be replaced by 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 are each independently selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V, and the VP1 capsid polypeptide does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.
[0130] Pharmaceutical Composition In another aspect, a pharmaceutical composition is provided, which comprises an rAAV as described above and a pharmaceutically acceptable carrier.
[0131] The pharmaceutical composition can include a first active ingredient. The first active ingredient can include a viral vector as described herein and / or any payload as described herein. The pharmaceutical composition can be formulated in unit dosage form. The pharmaceutical composition can include a pharmaceutically acceptable excipient, diluent, or carrier. The pharmaceutical composition can include a second, third, or fourth active ingredient, such as to facilitate gene replacement, RNA editing, DNA editing, or enhanced imaging.
[0132] The pharmaceutical compositions described herein may include an excipient. The excipient may include a cryopreservative such as DMSO, glycerol, polyvinylpyrrolidone (PVP), or a combination thereof. The excipient may include a cryopreservative such as sucrose, trehalose, starch, a salt of any of these, a derivative of any of these, or a combination thereof. The excipient may include a pH agent (to minimize oxidation or degradation of the components of the composition), a stabilizer (to prevent denaturation or degradation of the components of the composition), a buffer (to increase temperature stability), a solubilizer (to increase protein solubility), or a combination thereof. The excipient may include a surfactant, a sugar, an amino acid, an antioxidant, a salt, a nonionic surfactant, a solubilizer, a triglyceride, an alcohol, or a combination thereof. The excipients can include sodium carbonate, acetate, citrate, phosphate, polyethylene glycol (PEG), human serum albumin (HSA), sorbitol, sucrose, trehalose, polysorbate 80, sodium phosphate, sucrose, disodium phosphate, mannitol, polysorbate 20, histidine, citrate, albumin, sodium hydroxide, glycine, sodium citrate, trehalose, arginine, sodium acetate, acetate, HCl, disodium edetate, lecithin, glycerol, xanthan gum, soy isoflavones, polysorbate 80, ethyl alcohol, water, teprenone, or any combination thereof.
[0133] The compositions and methods provided herein can be used as pharmaceutical compositions. The compositions described throughout this specification can be formulated into medicaments, and the compositions can be used to treat a human or mammal diagnosed with a disease and in need thereof. In some cases, the pharmaceutical compositions can be used prophylactically.
[0134] The compositions provided herein can be used in the methods provided herein. Any of the compositions provided herein can be used in the methods provided herein. In some cases, the methods include at least partially preventing, alleviating, ameliorating, and / or treating a disease or condition, or a symptom of a disease or condition. The subject can be a human or non-human. The subject can be a mammal (e.g., rat, mouse, cow, dog, pig, sheep, horse). The subject can be a vertebrate or an invertebrate. The subject can be a laboratory animal. The subject can be a patient. The subject can be suffering from a disease. The subject can exhibit symptoms of a disease. The subject can be asymptomatic of a disease but still suffer from a disease. The subject can be receiving medical care from a caregiver (e.g., the subject is hospitalized and receiving treatment from a physician).
[0135] Methods of treatment or detection In some embodiments, the present disclosure provides methods of treatment using rAAV virions having any one of the engineered AAV VP capsid polypeptide sequences disclosed herein. In some embodiments, the present disclosure provides methods of detection using rAAV virions having any one of the engineered AAV VP capsid polypeptide sequences disclosed herein. The treatment method can include administering to a subject an effective amount of a pharmaceutical composition comprising an rAAV virion assembled from a VP polypeptide comprising a 581-589 region that confers tissue tropism (e.g., CNS tissue tropism or muscle tropism) to the rAAV. The rAAV virion can comprise the 581-589 region of a VP polypeptide described herein (e.g., comprising a 581-589 region variant that confers tissue tropism or tissue preference). In some embodiments, the rAAV may be assembled from a VP capsid polypeptide comprising the 581-589 region of any one of SEQ ID NOs: 12 through 3937, 3938 through 4237, 4238 through 4933, 4934 through 5233, 5234 through 5807, or 5808 through 5811. The rAAV virion may encapsidate any payload, including those disclosed herein.
[0136] Therapeutic methods may include administering an rAAV containing a DNA molecule encapsulated in its capsid and concentrating the DNA in a target tissue (e.g., CNS tissue, muscle tissue, cardiac tissue, or skeletal muscle tissue) to a DNA concentration that is at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 300-fold, at least 500-fold, or at least 1000-fold greater than the DNA concentration of wild-type AAV9.
[0137] Therapeutic methods may include administering an rAAV containing a DNA molecule encapsulated in a capsid, and concentrating the DNA in a target tissue (e.g., CNS tissue, muscle tissue, cardiac tissue, or skeletal muscle tissue) to a DNA concentration that is at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 300-fold, at least 500-fold, or at least 1000-fold greater than the DNA concentration of wild-type AAV5.
[0138] Therapeutic methods may include administering an rAAV containing a DNA molecule encapsulated in its capsid and expressing the RNA encoded by that DNA in a target tissue (e.g., CNS tissue, muscle tissue, cardiac muscle tissue, or skeletal muscle tissue) at an RNA enrichment that is at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 300-fold, at least 500-fold, or at least 1000-fold greater than the RNA enrichment of wild-type AAV9.
[0139] Therapeutic methods may include administering an rAAV containing a DNA molecule encapsulated in its capsid and expressing the RNA encoded by that DNA in a target tissue (e.g., CNS tissue, muscle tissue, cardiac muscle tissue, or skeletal muscle tissue) at an RNA enrichment that is at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 300-fold, at least 500-fold, or at least 1000-fold greater than the RNA enrichment of wild-type AAV5.
[0140] In some embodiments, the effective amount is at least 1 x 10 per dose. 8(1e8) viral genomes. In some embodiments, the effective amount is at least 5 x 10 per dose. 8 (5e8) viral genomes, 7.5 × 10 per dose 8 (7.5e8) viral genomes, at least 1 × 10 per dose 9 (1e9) viral genomes, at least 2.5 × 10 per dose 9 (2.5e9) viral genomes, at least 5x10 per dose 9 In some embodiments, an effective amount of rAAV assembled from VP polypeptides comprising the 581-589 region of any one of SEQ ID NOs: 12 to 3937, 3938 to 4237, 4238 to 4933, 4934 to 5233, 5234 to 5807, or 5808 to 5811 may be less than an effective amount of AAV assembled from the VP1 polypeptide of SEQ ID NO: 1, the VP2 polypeptide of SEQ ID NO: 10, and the VP3 polypeptide of SEQ ID NO: 11.
[0141] In some embodiments, the effective amount is at least 1×10 / kg of patient body weight. 11 (1e11) viral genomes, at least 5 × 10 per kg 11 (5e11) viral genomes, at least 1 × 10 per kg 12 (1e12) viral genomes, at least 5 × 10 per kg 12 (5e12) viral genomes, at least 1 × 10 per kg 13 (1e13) viral genomes, at least 1 × 10 per kg 14 (1e14) viral genomes or at least 5 × 10 14In some embodiments, the effective amount of an rAAV assembled from VP polypeptides comprising the 581-589 region of any one of SEQ ID NOs: 12 to 3937, 3938 to 4237, 4238 to 4933, 4934 to 5233, 5234 to 5807, or 5808 to 5811 may be less than the effective amount of an AAV assembled from the VP1 polypeptide of SEQ ID NO: 1, the VP2 polypeptide of SEQ ID NO: 10, and the VP3 polypeptide of SEQ ID NO: 11.
[0142] In some embodiments, the rAAV virion is administered by a systemic route, including enteral and parenteral routes. The rAAV virion may be administered intravenously. In some embodiments, the rAAV may be administered intramuscularly. In some embodiments, the rAAV may be administered intraperitoneally. In some embodiments, the rAAV may be administered topically. In some embodiments, the rAAV may be administered orally. In certain embodiments, the rAAV virion is administered intravenously. In some embodiments, the rAAV is administered intrathecally. In some embodiments, the rAAV is administered by intracerebroventricular injection. In some embodiments, the rAAV is administered by intracerebral ventricular injection. In some embodiments, the rAAV is administered by intracisternal administration. In some embodiments, the rAAV is administered by intravitreal injection. In some embodiments, the rAAV is administered by parenchymal injection. In some embodiments, the rAAV is administered by intraparenchymal injection. In some embodiments, the rAAV is administered by intramyocardial injection. In some embodiments, the rAAV is administered by intracoronary injection. In some embodiments, the rAAV is administered by intrapericardial injection. For example, rAAV virions with CNS tissue tropism may be administered by intrathecal injection, intracisternal injection, intraventricular injection, intraparenchymal injection, or intravenous injection. In another example, rAAV virions with muscle tissue tropism may be administered by intramuscular injection, intracoronary injection, intrapericardial injection, intramyocardial injection, or intravenous injection. In another example, rAAV virions with cardiac tissue tropism may be administered by intramyocardial injection, intrapericardial injection, intracoronary injection, or intravenous injection.
[0143] In various embodiments, the patient is afflicted with one of the conditions listed in Table 1 below. In certain embodiments, the patient is afflicted with one of the conditions listed in Table 1, and the rAAV comprises a payload containing a transgene product associated with a condition in Table 1. In some embodiments, the rAAV may be selected to specifically target a primary gene delivery target (e.g., the CNS or muscle). For example, an rAAV selected to target the CNS may comprise a VP capsid polypeptide comprising the 581-589 region (e.g., any one of SEQ ID NOs: 12 to 3937, 3938 to 4237, or 5234 to 5807), which improves the likelihood of achieving CNS tissue tropism. In another example, an rAAV selected for muscle targeting may contain a VP capsid polypeptide containing the 581-589 region (e.g., any one of SEQ ID NOs: 4238 to 4933, 4934 to 5233, or 5808 to 5811), which improves the likelihood of achieving muscle tropism.
[0144] In some embodiments, an rAAV virion of the present disclosure, having any of the engineered AAV VP capsid polypeptide sequences disclosed herein, comprises a vector genome, which vector genome comprises a therapeutic polynucleotide or payload. In further embodiments, the payload may be under the control of a regulatory sequence that directs expression in infected human cells. In some embodiments, the payload comprises any genetically encodable payload, such as a therapeutic polynucleotide encoding an RNA (e.g., a guide RNA), a suppressor tRNA, a transgene, or a genomic variant. In some embodiments, the payload may be under the control of a promoter. The promoter may be a ubiquitous promoter, or the promoter may be cell-specific or tissue-specific. For example, the payload may be under the control of a neuronal promoter for expression in neurons. In another example, the payload may be under the control of a muscle promoter for expression in muscle cells.
[0145] In some embodiments, the therapeutic polynucleotide encodes a guide RNA, tRNA, suppressor tRNA, siRNA, miRNA, mRNA, shRNA, circular RNA, antisense oligonucleotide (ASO), ribozyme, DNAzyme, aptamer, or a combination thereof. In some embodiments, the therapeutic polynucleotide encodes a linear therapeutic polynucleotide or a circular therapeutic polynucleotide.
[0146] In some embodiments, the therapeutic polynucleotide is a transgene encoding a therapeutic protein. In certain embodiments, the transgene encodes a protein selected from the targets suitable for modification or transgene production in Table 1. In some embodiments, a transgene encoding a CNS target is packaged in an rAAV capsid comprising a VP capsid polypeptide comprising a 581-589 region (e.g., any one of SEQ ID NOs: 12 to 3937, 3938 to 4237, or 5234 to 5807) with improved aspiration or preference for CNS tissue. In some embodiments, a transgene encoding a muscle target is packaged in an rAAV capsid comprising a VP capsid polypeptide comprising a 581-589 region (e.g., any one of SEQ ID NOs: 4238 to 4933, 4934 to 5233, or 5808 to 5811) with improved aspiration or preference for muscle tissue. [Table 1-1] [Table 1-2]
[0147] In some embodiments, the therapeutic polynucleotide encodes a therapeutic RNA. In some embodiments, the therapeutic polynucleotide encodes an RNA, such as a guide RNA (including engineered guide RNA or synthetic guide RNA), for genome editing or RNA editing. The guide RNA may target a gene such as those set forth in Table 1, or a gene encoding a protein nucleotide set forth in Table 1, to facilitate editing of the target gene. In some embodiments, editing of the target gene may treat a condition in a subject, such as a condition set forth in Table 1.
[0148] In some embodiments, the therapeutic polynucleotide encodes a tRNA or modified tRNA (engineered tRNA or synthetic tRNA). For example, the tRNA or modified tRNA can be a suppressor tRNA. The suppressor tRNA can be engineered to have an anticodon region that recognizes a stop codon, such as any premature stop codon (opal, ochre, or amber). The suppressor tRNA can target a premature stop codon in a gene such as those listed in Table 1 or in a gene encoding a protein nucleotide listed in Table 1, to promote readthrough of the gene. In some embodiments, inhibition of the premature stop codon can treat a condition in a subject, such as a condition listed in Table 1.
[0149] In some embodiments, the therapeutic polynucleotide (e.g., therapeutic RNA, tRNA, or genomic variant) can target a gene listed in Table 1 or any gene associated with a neurological disease, Parkinson's disease, Alzheimer's disease, tauopathy, Stargardt's disease, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Rett syndrome, cystic fibrosis, or any genetic disease. In some embodiments, the target gene can be any of ABCA4, AAT, SERPINA1, SERPINA1 E342K, HEXA, LRRK2, SNCA, DMD, APP, Tau, GBA, PINK1, RAB7A, CFTR, ALAS1, ATP7B, ATP7B G1226R, HFE C282Y, LIPA c.894 G>A, PCSK9 start site, SCNN1A start site, a fragment of any of these, or a combination thereof. In some embodiments, the therapeutic polynucleotide is a gene therapy payload (e.g., a transgene), i.e., it may itself be one of the genes listed in Table 1 or any gene associated with a neurological disease, Parkinson's disease, Alzheimer's disease, tauopathy, Stargardt's disease, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Rett syndrome, cystic fibrosis, or any genetic disease. In some embodiments, the transgene may be any of ABCA4, AAT, SERPINA1, SERPINA1 E342K, HEXA, LRRK2, SNCA, DMD, APP, Tau, GBA, PINK1, RAB7A, CFTR, ALAS1, ATP7B, ATP7B G1226R, HFE C282Y, LIPA c.894 G>A, PCSK9 start site, or SCNN1A start site, a fragment of any of these, or a combination thereof.
[0150] Engineered AAVs containing a VP capsid polypeptide comprising the CNS tissue-tropic 581-589 region may be used to deliver a payload for treating a neurological or central nervous system condition. For example, engineered AAVs containing a VP capsid polypeptide comprising the 581-589 region of any one of SEQ ID NOs: 12 to 3937 or 3938 to 4237 may be used to treat a neurological condition (e.g., aromatic L-amino acid decarboxylase (AADC) deficiency, Alzheimer's disease, tauopathy, synucleinopathy, Batten disease, mucopolysaccharidosis type III, frontotemporal dementia, Parkinson's disease, Gaucher disease, Canavan disease, Tay-Sachs disease, Huntington's disease, Potocki-Lupski syndrome, amyotrophic lateral sclerosis, Down syndrome, Sanfilippo disease type A, Sanfilippo disease type B, or Rett syndrome). In some embodiments, engineered AAVs comprising a VP capsid polypeptide comprising the CNS tissue-tropic 581-589 region are used to target proteins associated with neurological conditions (e.g., aromatic L-amino acid decarboxylase (AADC), amyloid precursor protein (APP), α-synuclein, microtubule-associated protein tau (MAPT), ApoE, nerve growth factor (NGF), telomerase reverse transcriptase (TERT), CLN2, CLN3, CLN6, N-acetyl-α-glucosaminidase (NAGLU), granulin, glucosylceramidase β (GBA), aspartoacylase, GDNF, neurturin (NTN), glutamic acid decarboxylase (GDNF ... Transgenes encoding acid enzyme (GAD), FOXG1, Kv7.2, laforin, leucine-rich repeat kinase 2 (LRRK2), hexosaminidase A (HEXA), hexosaminidase B (HEXB), huntingtin, cholesterol 24-hydroxylase, C9orf72, superoxide dismutase 1 (SOD1), dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRKA1), N-sulfoglucosamine sulfohydrolase (SGSH), surfeit locus protein 1 (SURF1), GABA transporter 1 (GAT1), and methyl-CpG binding protein 2 (MECP2) may be delivered.In some embodiments, engineered AAVs comprising a VP capsid polypeptide comprising the CNS tissue-tropic 581-589 region are used to target proteins associated with neurological conditions (e.g., aromatic L-amino acid decarboxylase (AADC), amyloid precursor protein (APP), α-synuclein, microtubule-associated protein tau (MAPT), ApoE, nerve growth factor (NGF), telomerase reverse transcriptase (TERT), CLN2, CLN3, CLN6, N-acetyl-α-glucosaminidase (NAGLU), granulin, glucosylceramidase β (GBA), aspartoacylase, GDNF, neurturin (NTN), glutamic acid decarboxylase (GAD), FOXG1, Therapeutic polynucleotides may be delivered that alter expression or promote editing of genes encoding Kv7.2, laforin, leucine-rich repeat kinase 2 (LRRK2), hexosaminidase A (HEXA), hexosaminidase B (HEXB), huntingtin, cholesterol 24-hydroxylase, C9orf72, superoxide dismutase 1 (SOD1), dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRKA1), N-sulfoglucosamine sulfohydrolase (SGSH), surfeit locus protein 1 (SURF1), GABA transporter 1 (GAT1), and methyl-CpG binding protein 2 (MECP2).
[0151] An engineered AAV containing a VP capsid polypeptide comprising the muscle-tropic 581-589 region may be used to deliver a payload for treating a muscle condition. For example, an engineered AAV containing a VP capsid polypeptide comprising the 581-589 region of any one of SEQ ID NOs: 4238 to 4933 or 4934 to 5233 may be used to treat a muscle condition (e.g., Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, dysferlinopathy, Pompe disease, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, glycogen storage disease, X-linked myotubular myopathy, or euchromatin histone-lysine N-methyltransferase 2). In some embodiments, engineered AAVs containing a VP capsid polypeptide comprising the muscle-tropic 581-589 region may be used to deliver transgenes encoding proteins associated with muscle conditions (e.g., neurotrophin 3 (NFT3), dystrophin, mini-dystrophin, micro-dystrophin, dysferlin, acid alpha-glucosidase (GAA), fukutin-related protein (FKRP), double homeobox 4 (DUX4), glycogen synthase 1 (GYS1), myotubularin, or euchromatin histone-lysine N-methyltransferase 2 (EHMT2)). In some embodiments, engineered AAVs containing a VP capsid polypeptide comprising the muscle-tropic 581-589 region may be used to deliver therapeutic polynucleotides that alter expression or promote editing of genes encoding proteins associated with muscle conditions (e.g., neurotrophin 3 (NFT3), dystrophin, mini-dystrophin, micro-dystrophin, dysferlin, acid alpha-glucosidase (GAA), fukutin-related protein (FKRP), double homeobox 4 (DUX4), glycogen synthase 1 (GYS1), myotubularin, or euchromatin histone-lysine N-methyltransferase 2 (EHMT2)).
[0152] In some embodiments, the therapeutic polynucleotide encodes a genomic variant. For example, the genomic variant may be a DNA editing enzyme, an RNA editing enzyme, a transcriptional activator, or a transcriptional repressor. The DNA editing enzyme may be any DNA editing enzyme, including any CRISPR / Cas system, meganuclease, zinc finger nuclease (ZFN), or TALE nuclease (TALEN and megaTALEN). The CRISPR / Cas system may be Cas3, Cas8, Cas10, Cas9, Cas4, Cas12, or Cas13. The RNA editing enzyme may be an ADAR. In some embodiments, the ADAR is human ADAR1 or human ADAR2. The transcriptional activator may be VP64. The transcriptional repressor may be KRAB. Such genomic variants may target any gene listed in Table 1 for editing.
[0153] In some embodiments, the present disclosure provides AAV virions having an engineered AAV VP capsid polypeptide (e.g., comprising a 581-589 region variant), which encapsidate any one or any combination of the therapeutic payloads disclosed herein, in some embodiments, multiple copies of the therapeutic payload are encapsidated.
[0154] In some embodiments, the therapeutic polynucleotide is a polynucleotide that can serve as a homologous template for homologous recombination repair.In some embodiments, the therapeutic polynucleotide can be a guide polynucleotide for CRISPR / Cas system or ADAR enzyme.For example, the therapeutic polynucleotide can be a guide RNA for CRISPR / Cas or a guide RNA for ADAR.
[0155] In some embodiments, the rAAV virions of the present disclosure having any of the engineered AAV VP capsid polypeptide sequences disclosed herein comprise a vector genome, which comprises a detectable polynucleotide or payload. In further embodiments, the payload may be under the control of a regulatory sequence that directs expression in infected human cells. Examples of detectable polynucleotides include, but are not limited to, any genetically encodable detectable moiety. For example, the genetically encodable detectable moiety may be a fluorescent protein, such as EGFP, GFP, YFP, RFP, CFP, or any of their variants. In some embodiments, the present disclosure provides rAAV virions having an engineered AAV VP capsid polypeptide, which encapsulate any one or any combination of the detectable payloads disclosed herein. In some embodiments, the capsid encapsulates multiple copies of the detectable payload.
[0156] In some embodiments, the present disclosure provides rAAV virions having an engineered AAV VP capsid polypeptide, which virions encapsulate any one or any combination of therapeutic and detectable payloads disclosed herein. For example, rAAVs of the present disclosure having an engineered AAV VP capsid polypeptide may encapsulate a transgene and a fluorescent protein. As another example, rAAVs of the present disclosure having an engineered AAV VP capsid polypeptide may encapsulate a therapeutic RNA (e.g., a guide RNA) and a fluorescent protein.
[0157] Using the CNS-specific or muscle-specific AAVs described herein to deliver a payload (e.g., a payload encoding a therapeutic polypeptide or therapeutic polynucleotide) may cause lower toxicity in a subject compared to non-specific AAVs (e.g., an AAV comprising the VP1 polypeptide of SEQ ID NO: 1). Tissue-specific AAVs (e.g., CNS-specific or muscle-specific AAVs) can be effective at lower doses compared to non-specific AAVs because the administered AAV infects a greater proportion of the relevant tissue (e.g., CNS tissue or muscle tissue) than non-specific AAVs. As a result, the therapeutically effective dose of tissue-specific AAVs can be lower than the therapeutically effective dose of non-specific AAVs, thereby allowing for the administration of lower doses and therefore lower toxicity. For example, administration of a therapeutically effective dose of tissue-specific AAVs may result in lower hepatotoxicity than administration of a therapeutically effective dose of non-specific AAVs. Administration of a lower dose than non-specific AAVs may also result in less production of neutralizing antibodies in the subject. Neutralizing antibodies may reduce the effectiveness of AAV therapy by inhibiting infection of target tissues, or may cause serious side effects in the subject due to immune response.In addition, tissue-specific AAV (for example, CNS-specific AAV or muscle-specific AAV) may cause fewer off-target effects when administered at the same dose compared with non-specific AAV.This is because less AAV infects off-target tissues (for example, non-CNS tissues or non-muscle tissues) than non-specific AAV.Off-target effects may include increased gene expression in off-target tissues, decreased gene expression in off-target tissues, gene editing in off-target tissues, immune response or liver toxicity.
[0158] In vivo selected VP polypeptides In a further aspect, there are provided engineered (also referred to as recombinant) adeno-associated virus (AAV) VP capsid polypeptides identified using the methods described herein.
[0159] In some embodiments, the engineered adeno-associated virus (AAV) viral protein (VP) capsid polypeptide has an amino acid sequence at least 70% identical to SEQ ID NO:1, the engineered AAV VP capsid polypeptide has at least one substitution relative to SEQ ID NO:1 in the 581-589 region corresponding to residues 581 to 589 (inclusive) of SEQ ID NO:1, the capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), and the VP capsid polypeptide does not have the sequence of any of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. In some embodiments, the VP capsid polypeptide comprises a 581-589 region variant (e.g., one or more amino acid substitutions relative to SEQ ID NO:1 in the region from residue 581 to residue 589 (inclusive)). The VP capsid polypeptide may comprise the sequence of SEQ ID NO: 2, and the 581-589 region thereof has any one of the sequences of SEQ ID NO: 12 to SEQ ID NO: 3937, SEQ ID NO: 3938 to SEQ ID NO: 4237, SEQ ID NO: 4238 to SEQ ID NO: 4933, SEQ ID NO: 4934 to SEQ ID NO: 5233, SEQ ID NO: 5234 to SEQ ID NO: 5807, or SEQ ID NO: 5808 to SEQ ID NO: 5811.
[0160] In some embodiments, the engineered adeno-associated virus (AAV) viral protein (VP) capsid polypeptide has CNS tissue tropism and has an amino acid sequence at least 70% identical to SEQ ID NO:1, the engineered AAV VP capsid polypeptide has at least one substitution relative to SEQ ID NO:1 in the 581-589 region corresponding to residues 581 to 589 (inclusive) of SEQ ID NO:1, the capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), the at least one substitution confers increased central nervous system (CNS) tissue tropism to an rAAV virion having the AAV5 VP capsid polypeptide of SEQ ID NO:1, and the VP capsid polypeptide does not have the sequence of any of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. In some embodiments, the CNS-tropic VP capsid polypeptide comprises a 581-589 region variant (e.g., comprising one or more amino acid substitutions in the region from residue 581 to residue 589 (inclusive) relative to SEQ ID NO: 1). The CNS-tropic VP capsid polypeptide may comprise the sequence of SEQ ID NO: 2, with the 581-589 region having any one of the sequences of SEQ ID NOs: 12 to 3937, 3938 to 4237, or 5234 to 5807.
[0161] In some embodiments, the engineered adeno-associated virus (AAV) viral protein (VP) capsid polypeptide is muscle-tropic and has an amino acid sequence at least 70% identical to SEQ ID NO:1, the engineered AAV VP capsid polypeptide has at least one substitution relative to SEQ ID NO:1 in a 581-589 region corresponding to residues 581 to 589 (inclusive) of SEQ ID NO:1, the capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), the at least one substitution confers increased tropism on muscle tissue relative to an rAAV virion having the AAV5 VP capsid polypeptide of SEQ ID NO:1, and the VP capsid polypeptide does not have the sequence of any of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. In some embodiments, the muscle-tropic VP capsid polypeptide comprises a 581-589 region variant (e.g., comprising one or more amino acid substitutions in the region from residue 581 to residue 589 (inclusive) compared to SEQ ID NO: 1). The muscle-tropic VP capsid polypeptide may comprise the sequence of SEQ ID NO: 2, with the 581-589 region having any one of the sequences of SEQ ID NOs: 4238 to 4933, 4934 to 5233, or 5808 to 5811.
[0162] In certain embodiments, the engineered adeno-associated virus (AAV) viral protein (VP) capsid polypeptide (e.g., a CNS tissue-tropic VP capsid polypeptide or a muscle-tropic VP capsid polypeptide) has an amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% identical to the sequence of SEQ ID NO:1.
[0163] In some embodiments, the AAV VP capsid polypeptide has the amino acid sequence of SEQ ID NO:2, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6, X 7 , X 8 and X 9 are each independently selected from any amino acid, and the capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), wherein the VP capsid polypeptide does not have the sequence of any of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8, and optionally has an additional mutation at any other position in the VP capsid polypeptide. 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 The portion corresponds to a sequence selected from any one of SEQ ID NOs: 12 to 3937, 3938 to 4237, 4238 to 4933, 4934 to 5233, 5234 to 5807, and 5808 to 5811.
[0164] In some embodiments, the AAV VP capsid polypeptide is a CNS tissue-tropic capsid polypeptide and has the amino acid sequence of SEQ ID NO:2, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9are each independently selected from any amino acid, and the capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), wherein the at least one substitution confers increased tropism for central nervous system (CNS) tissue in the rAAV relative to an rAAV virion having an AAV5 VP capsid polypeptide of SEQ ID NO: 1, wherein the VP capsid polypeptide does not have the sequence of any of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8, and optionally has an additional mutation at any other position in the VP capsid polypeptide. In some embodiments, X of the CNS tissue-tropic VP capsid polypeptide 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 corresponds to any one of SEQ ID NOs: 12 to 3937, SEQ ID NOs: 3938 to 4237, and SEQ ID NOs: 5234 to 5807.
[0165] In some embodiments, the AAV VP capsid polypeptide is a muscle-tropic capsid polypeptide and has the amino acid sequence of SEQ ID NO:2, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9are each independently selected from any amino acid, and the capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), wherein the at least one substitution confers increased tropism on the rAAV for muscle tissue relative to an rAAV virion having an AAV5 VP capsid polypeptide of SEQ ID NO: 1, wherein the VP capsid polypeptide does not have the sequence of any of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8, and optionally has an additional mutation at any other position in the VP capsid polypeptide. In some embodiments, X of the muscle-tropic VP capsid polypeptide 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 corresponds to any one of SEQ ID NOs: 4238 to 4933, SEQ ID NOs: 4934 to 5233, and SEQ ID NOs: 5808 to 5811.
[0166] In some embodiments, the engineered adeno-associated virus (AAV) viral protein (VP) capsid polypeptide (e.g., a CNS tissue-tropic VP capsid polypeptide or a muscle-tropic VP capsid polypeptide) has the amino acid sequence of SEQ ID NO:2, wherein the amino acid residues X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 are each independently selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V, and the engineered AAV VP capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), wherein the rAAV VP capsid polypeptide does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.
[0167] In some embodiments, the 581-589 region of the engineered VP capsid polypeptide, which corresponds to residues 581 to 589 (inclusive) of SEQ ID NO:1, has a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs:12 to 3937, SEQ ID NOs:3938 to 4237, SEQ ID NOs:4238 to 4933, SEQ ID NOs:4934 to 5233, SEQ ID NOs:5234 to 5807, or SEQ ID NOs:5808 to 5811. In some embodiments, the 581-589 region of the engineered VP capsid polypeptide comprises one amino acid substitution compared to any one of SEQ ID NOs: 12 through 3937, 3938 through 4237, 4238 through 4933, 4934 through 5233, 5234 through 5807, or 5808 through 5811. In some embodiments, the 581-589 region of the engineered VP capsid polypeptide comprises two amino acid substitutions compared to any one of SEQ ID NOs: 12 through 3937, 3938 through 4237, 4238 through 4933, 4934 through 5233, 5234 through 5807, or 5808 through 5811. In certain embodiments, the 581-589 region of the engineered VP capsid polypeptide has a sequence identical to any one of SEQ ID NO: 12 through SEQ ID NO: 3937, SEQ ID NO: 3938 through SEQ ID NO: 4237, SEQ ID NO: 4238 through SEQ ID NO: 4933, SEQ ID NO: 4934 through SEQ ID NO: 5233, SEQ ID NO: 5234 through SEQ ID NO: 5807, or SEQ ID NO: 5808 through SEQ ID NO: 5811.
[0168] In some embodiments, the engineered adeno-associated virus (AAV) viral protein (VP) capsid polypeptide is an engineered AAV5 viral capsid protein, wherein the engineered AAV VP5 capsid polypeptide has at least one substitution in a 581-589 region corresponding to residues 581 to 589 (inclusive) of SEQ ID NO:1 relative to SEQ ID NO:1, wherein the capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), wherein the at least one substitution confers increased tropism on central nervous system (CNS) tissue relative to an rAAV virion having the AAV5 VP capsid polypeptide of SEQ ID NO:1, and wherein the VP capsid polypeptide does not have the sequence of any of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8, and optionally has additional mutations at any other positions of the VP protein.
[0169] In some embodiments, the AAV VP capsid polypeptide has the amino acid sequence of SEQ ID NO:2, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 are each independently selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V, and the polypeptide does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.
[0170] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), and (X) is amino acid residue X of SEQ ID NO:2. 1 , X 2 , X 3 , X4 , X 5 , X 6 , X 7 , X 8 and X 9 (B) is a 581-589 region having a polypeptide sequence comprising: 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 are each independently selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V, and the capsid polypeptide is capable of assembling into a recombinant AAV virion (rAAV), and the polypeptide does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
[0171] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 9 that are predicted to confer tropism or preference for CNS tissue to a recombinant AAV virion (rAAV) based on a secondary screen, and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), wherein the capsid polypeptide is capable of assembling into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The present invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide comprising a 581-589 region having a sequence selected from the list of polypeptides in Table 9 in the region corresponding to amino acid residues 445 to 453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide comprising a 581-589 region having a sequence selected from the list of polypeptides in Table 9 in the region corresponding to amino acid residues 389 to 397 of AAV5 VP3.
[0172] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to a sequence set forth in Table 9. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 18. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3472. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 262. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3306. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2028. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2791. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 424. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2536.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 1971. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 415. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3846. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3283. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 1956. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3297. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4545. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2661. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 1576.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 425. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 709. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2168. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 54. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 429. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 708. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 428. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4119. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3906.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2456. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2278. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5006. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO:426.
[0173] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 18. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3472. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 262. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3306. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2028. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2791. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 424. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1971. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 415. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3846. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3283. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1956. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3297. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4545. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1576.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 425. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 709. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2168. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 54. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 429. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 708. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 428. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4119. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3906. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2456. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2278. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5006. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 426.
[0174] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 18. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2028. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 424. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3306. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3472. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 415. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 709. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1971. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2791. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1956. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 262. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 425. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 708. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 54. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3283. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 430.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3297. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 428. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 885. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 429. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 569. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 724. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1576. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4545. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 426. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1887. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3906. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3935.
[0175] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 18 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3472 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 262 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3306 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2028 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2791 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 424 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1971 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 415 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3846, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3283, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1956, with one or two conservative substitutions.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3297 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4545 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1576 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 425 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 709 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2168 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 54 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 429 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 708 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 428 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4119 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3906 with one or two conservative substitutions.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2456 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2278 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5006 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 426 with one or two conservative substitutions. The conservative substitutions may be at any position in the 581-589 region.
[0176] In some embodiments, the AAV VP capsid polypeptide preferentially targets CNS tissue with at least 100-fold greater DNA enrichment than wild-type AAV9. For example, an AAV comprising the 581-589 region of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3846, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:2168, SEQ ID NO:54, SEQ ID NO:429, SEQ ID NO:708, SEQ ID NO:428, SEQ ID NO:4119, SEQ ID NO:3906, SEQ ID NO:2456, SEQ ID NO:2278, SEQ ID NO:5006, SEQ ID NO:426, SEQ ID NO:307, SEQ ID NO:5155, SEQ ID NO:2640, SEQ ID NO:4317, SEQ ID NO:1145, SEQ ID NO:430, or SEQ ID NO:885 The VP capsid polypeptide can preferentially target CNS tissues with at least 100-fold higher DNA enrichment than wild-type AAV9.
[0177] In some embodiments, the AAV VP capsid polypeptide preferentially targets CNS tissue with at least 200-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 3306, SEQ ID NO: 2028, SEQ ID NO: 2791, SEQ ID NO: 424, SEQ ID NO: 2536, SEQ ID NO: 1971, SEQ ID NO: 415, SEQ ID NO: 3846, SEQ ID NO: 3283, SEQ ID NO: 1956, or SEQ ID NO: 3297 can preferentially target CNS tissue with at least 200-fold greater DNA enrichment than wild-type AAV9.
[0178] In some embodiments, the AAV VP capsid polypeptide preferentially targets CNS tissue with at least 1000-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 18 may preferentially target CNS tissue with at least 1000-fold greater DNA enrichment than wild-type AAV9.
[0179] In some embodiments, an AAV VP capsid polypeptide preferentially targets CNS tissue with at least 100-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 3306, SEQ ID NO: 2028, SEQ ID NO: 2791, SEQ ID NO: 424, SEQ ID NO: 2536, SEQ ID NO: 1971, SEQ ID NO: 415, SEQ ID NO: 3283, SEQ ID NO: 1956, SEQ ID NO: 3297, SEQ ID NO: 4545, SEQ ID NO: 2661, SEQ ID NO: 1576, SEQ ID NO: 425, SEQ ID NO: 709, SEQ ID NO: 54, SEQ ID NO: 429, SEQ ID NO: 428, SEQ ID NO: 426, or SEQ ID NO: 430 may preferentially target CNS tissue with at least 100-fold greater RNA enrichment than wild-type AAV9.
[0180] In some embodiments, AAV VP capsid polypeptides preferentially target CNS tissue with at least 200-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 regions of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:430, SEQ ID NO:569, and SEQ ID NO:719 can preferentially target CNS tissue with at least 200-fold greater RNA enrichment than wild-type AAV9.
[0181] In some embodiments, the AAV VP capsid polypeptide preferentially targets CNS tissue with at least 500-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 regions of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, and SEQ ID NO: 2028 may preferentially target CNS tissue with at least 500-fold greater RNA enrichment than wild-type AAV9.
[0182] In some embodiments, the AAV VP capsid polypeptide preferentially targets CNS tissue with at least 5-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3846, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, or SEQ ID NO:1576 can preferentially target CNS tissue with at least 5-fold greater DNA enrichment than wild-type AAV5.
[0183] In some embodiments, the AAV VP capsid polypeptide preferentially targets CNS tissue with at least 10-fold greater DNA enrichment than wild-type AAV 9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 18, SEQ ID NO: 3472, SEQ ID NO: 262, SEQ ID NO: 3306, SEQ ID NO: 2028, SEQ ID NO: 2791, or SEQ ID NO: 424 can preferentially target CNS tissue with at least 10-fold greater DNA enrichment than wild-type AAV 5.
[0184] In some embodiments, an AAV VP capsid polypeptide preferentially targets CNS tissue with at least 5-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:429, SEQ ID NO:708, SEQ ID NO:428, SEQ ID NO:426, SEQ ID NO:307, SEQ ID NO:4317, SEQ ID NO:430, or SEQ ID NO:885 may preferentially target CNS tissue with at least 5-fold greater RNA enrichment than wild-type AAV5.
[0185] In some embodiments, AAV VP capsid polypeptides preferentially target CNS tissue with at least 20-fold greater RNA enrichment than wild-type AAV9. For example, AAV VP capsid polypeptides comprising the 581-589 regions of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:430, SEQ ID NO:569, and SEQ ID NO:719 can preferentially target CNS tissue with at least 20-fold greater RNA enrichment than wild-type AAV5.
[0186] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 2 (SEQ ID NOs:12-3937) predicted to confer tropism or preference for CNS tissue to a recombinant AAV virion (rAAV) based on a primary screen, and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), wherein the capsid polypeptide is capable of assembling into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The present invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 2 (SEQ ID NO: 12 to SEQ ID NO: 3937) in a region corresponding to amino acid residues 445 to 453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 2 (SEQ ID NO: 12 to SEQ ID NO: 3937) in a region corresponding to amino acid residues 389 to 397 of AAV5 VP3. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6]
Table 2-7
Table 2-8
Table 2-9
Table 2-10
Table 2-11
Table 2-12
Table 2-13
Table 2-14
Table 2-15
Table 2-16
Table 2-17
Table 2-18
Table 2-19
Table 2-20
Table 2-21
Table 2-22
Table 2-23
Table 2-24
Table 2-25
Table 2-26
Table 2-27
Table 2-28
Table 2-29
Table 2-30
Table 2-31
Table 2-32
[0187] In some embodiments, the engineered AAV The VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 3 (SEQ ID NOs:3938-4237) predicted to confer tropism or preference for CNS tissue to recombinant AAV virions (rAAV) based on a primary screen, and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), which capsid polypeptide can assemble into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The present invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 3 (SEQ ID NO: 3938 to SEQ ID NO: 4237) in the region corresponding to amino acid residues 445 to 453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 3 (SEQ ID NO: 3938 to SEQ ID NO: 4237) in the region corresponding to amino acid residues 389 to 397 of AAV5 VP3. [Table 3-1] [Table 3-2] [Table 3-3]
[0188] In some embodiments, the engineered AAV The VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 4 (SEQ ID NOs:5234-5807) predicted to confer tropism or preference for CNS tissue to recombinant AAV virions (rAAV) based on a primary screen, and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), which capsid polypeptide can assemble into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The present invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 4 (SEQ ID NO: 5234 to SEQ ID NO: 5807) in a region corresponding to amino acid residues 445 to 453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 4 (SEQ ID NO: 5234 to SEQ ID NO: 5807) in a region corresponding to amino acid residues 389 to 397 of AAV5 VP3. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6]
[0189] In some embodiments, the engineered AAV VP capsid polypeptide confers tropism or preference for a CNS tissue, wherein the CNS tissue is selected from the group consisting of the hippocampus (dentate gyrus, CA1 and CA3), cerebellum, hypothalamus, cortex (occipital, temporal and forebrain), substantia nigra, thalamus, and any combination thereof.
[0190] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 10 that are predicted to confer tropism or preference for myocardial tissue to a recombinant AAV virion (rAAV) based on a secondary screen, and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), wherein the capsid polypeptide is capable of assembling into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 10 in a region corresponding to amino acid residues 445-453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 10 in a region corresponding to amino acid residues 389-397 of AAV5 VP3.
[0191] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to a sequence set forth in Table 10. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 348. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2536. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5607. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 1576. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4955. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5017. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4349. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4964.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 293. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4314. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4995. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4366. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4961. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4952. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5075. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4354. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5060.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5138. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5206. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4288. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5092. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4059. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4295. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5030. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4938. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2661.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5215. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4960. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4969. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO:5023.
[0192] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 348. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5607. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1576. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4955. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5017. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4349. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4964. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 293. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4314. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4995. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4366. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4961. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4952. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5075. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4354. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5060.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5138. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5206. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4288. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5092. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4059. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4295. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5030. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4938. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5215. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4960. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4969. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5023. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO:4934.
[0193] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 348 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5607 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1576 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4955 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5017 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4349 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4964 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 293 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4314 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4995, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4366, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4961, with one or two conservative substitutions.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4952 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5075 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4354 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5060 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5138 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5206 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4288 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5092 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4059 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4295 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5030, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4938, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661, with one or two conservative substitutions.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5215 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4960 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4969 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5023 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4934 with one or two conservative substitutions. The conservative substitutions may be at any position in the 581-589 region.
[0194] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 25-fold higher DNA enrichment than wild-type AAV9. For example, an AAV comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:1576, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:4964, SEQ ID NO:293, SEQ ID NO:4314, SEQ ID NO:4995, SEQ ID NO:4366, SEQ ID NO:4961, SEQ ID NO:4952, SEQ ID NO:5075, SEQ ID NO:4354, SEQ ID NO:5060, SEQ ID NO:5138, SEQ ID NO:5206, SEQ ID NO:4288, SEQ ID NO:5092, SEQ ID NO:4059, SEQ ID NO:4295, SEQ ID NO:5030, SEQ ID NO:4938, SEQ ID NO:2661, SEQ ID NO:5215, SEQ ID NO:4960, SEQ ID NO:4969, SEQ ID NO:5023, SEQ ID NO:4934, SEQ ID NO:4545, SEQ ID NO:4963, SEQ ID NO:4363, SEQ ID NO:5159, or SEQ ID NO:4973 The VP capsid polypeptide can preferentially target myocardial tissue with at least 25-fold higher DNA condensation than wild-type AAV9.
[0195] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 30-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:1576, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:4964, SEQ ID NO:293, SEQ ID NO:4314, SEQ ID NO:4995, or SEQ ID NO:4366 can preferentially target myocardial tissue with at least 30-fold greater DNA enrichment than wild-type AAV9.
[0196] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 50-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 348 or SEQ ID NO: 2536 can preferentially target myocardial tissue with at least 50-fold greater DNA enrichment than wild-type AAV9.
[0197] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 10-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:5052, SEQ ID NO:5193, SEQ ID NO:5138, SEQ ID NO:5163, SEQ ID NO:4952, SEQ ID NO:293, SEQ ID NO:4317, SEQ ID NO:5075, SEQ ID NO:386, SEQ ID NO:4288, SEQ ID NO:4995, SEQ ID NO:5030, SEQ ID NO:4986, SEQ ID NO:5206, SEQ ID NO:4338, SEQ ID NO:5159, SEQ ID NO:4346, SEQ ID NO:5060, SEQ ID NO:4949, SEQ ID NO:5017, SEQ ID NO:5215, SEQ ID NO:4314, SEQ ID NO:5080, SEQ ID NO:4964, SEQ ID NO:4379, SEQ ID NO:4304, SEQ ID NO:18, SEQ ID NO:4363, SEQ ID NO:5027, SEQ ID NO:4349, SEQ ID NO:5208, or SEQ ID NO:4938 may preferentially target myocardial tissue with at least 10-fold greater RNA enrichment than wild-type AAV9.
[0198] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 20-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:5052, SEQ ID NO:5193, SEQ ID NO:5138, or SEQ ID NO:5163 may preferentially target myocardial tissue with at least 20-fold greater RNA enrichment than wild-type AAV9.
[0199] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 40-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 348 may preferentially target myocardial tissue with at least 40-fold greater RNA enrichment than wild-type AAV9.
[0200] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 5-fold higher DNA enrichment than wild-type AAV5. For example, an AAV comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:1576, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:4964, SEQ ID NO:293, SEQ ID NO:4314, SEQ ID NO:4995, SEQ ID NO:4366, SEQ ID NO:4961, SEQ ID NO:4952, SEQ ID NO:5075, SEQ ID NO:4354, SEQ ID NO:5060, SEQ ID NO:5138, SEQ ID NO:5206, SEQ ID NO:4288, SEQ ID NO:5092, SEQ ID NO:4059, SEQ ID NO:4295, SEQ ID NO:5030, SEQ ID NO:4938, SEQ ID NO:2661, SEQ ID NO:5215, SEQ ID NO:4960, SEQ ID NO:4969, SEQ ID NO:5023, SEQ ID NO:4934, SEQ ID NO:4545, SEQ ID NO:4963, SEQ ID NO:4363, SEQ ID NO:5159, or SEQ ID NO:4973 The VP capsid polypeptide can preferentially target myocardial tissue with at least 5-fold higher DNA enrichment than wild-type AAV5.
[0201] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 10-fold greater DNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 348 or SEQ ID NO: 2536 can preferentially target myocardial tissue with at least 10-fold greater DNA enrichment than wild-type AAV5.
[0202] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 5-fold greater RNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:5052, SEQ ID NO:5193, SEQ ID NO:5138, SEQ ID NO:5163, SEQ ID NO:4952, SEQ ID NO:293, or SEQ ID NO:4317 may preferentially target myocardial tissue with at least 5-fold greater RNA enrichment than wild-type AAV5.
[0203] In some embodiments, the AAV VP capsid polypeptide preferentially targets myocardial tissue with at least 10-fold greater RNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 348 may preferentially target myocardial tissue with at least 10-fold greater RNA enrichment than wild-type AAV5.
[0204] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 11 that are predicted to confer tropism or preference for skeletal muscle tissue to a recombinant AAV virion (rAAV) based on a secondary screen, and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), wherein the capsid polypeptide is capable of assembling into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 11 in a region corresponding to amino acid residues 445-453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 11 in a region corresponding to amino acid residues 389-397 of AAV5 VP3.
[0205] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to a sequence set forth in Table 11. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3472. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3297. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2661. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4545. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 348. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 18. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4349. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 293.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5017. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4955. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4366. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5092. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 210. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4059. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2536. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5206. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 1971.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 262. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4343. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4995. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4009. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5190. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 724. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4288. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4973. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4314.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 1561. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5147. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4238. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO:4961.
[0206] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3472. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3297. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4545. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 348. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 18. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4349. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 293. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5017. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4955. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4366. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5092. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 210. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4059. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5206. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1971.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 262. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4343. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4995. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4009. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5190. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 724. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4288. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4973. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4314. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1561. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5147. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4238. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4961.
[0207] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3472 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3297 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4545 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 348 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 18 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4349 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 293 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5017 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4955 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4366, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5092, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 210, with one or two conservative substitutions.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4059 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5206 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1971 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 262 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4343 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4995 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4009 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5190 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 724 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4288, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4973, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4314, with one or two conservative substitutions.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1561 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5147 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4238 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4961 with one or two conservative substitutions. The conservative substitutions may be at any position in the 581-589 region.
[0208] In some embodiments, an AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least 15-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:3472, SEQ ID NO:3297, SEQ ID NO:2661, SEQ ID NO:4545, SEQ ID NO:348, SEQ ID NO:18, SEQ ID NO:4349, SEQ ID NO:293, SEQ ID NO:5017, SEQ ID NO:4955, SEQ ID NO:4366, SEQ ID NO:5092, SEQ ID NO:210, SEQ ID NO:4059, SEQ ID NO:2536, SEQ ID NO:5206, or SEQ ID NO:1971 can preferentially target skeletal muscle tissue with at least 15-fold greater DNA enrichment than wild-type AAV9.
[0209] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least 20-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:3472, SEQ ID NO:3297, SEQ ID NO:2661, SEQ ID NO:4545, or SEQ ID NO:348 can preferentially target skeletal muscle tissue with at least 20-fold greater DNA enrichment than wild-type AAV9.
[0210] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least 30-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 3472 or SEQ ID NO: 3297 can preferentially target skeletal muscle tissue with at least 30-fold greater DNA enrichment than wild-type AAV9.
[0211] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least two-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:1934, SEQ ID NO:3283, SEQ ID NO:5817 (KTGTRDSAR), SEQ ID NO:278, SEQ ID NO:1634, SEQ ID NO:1391, or SEQ ID NO:1537 may preferentially target skeletal muscle tissue with at least two-fold greater RNA enrichment than wild-type AAV9.
[0212] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least 10-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:1934, SEQ ID NO:3283, SEQ ID NO:5817, or SEQ ID NO:278 can preferentially target skeletal muscle tissue with at least 10-fold greater RNA enrichment than wild-type AAV9.
[0213] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least 25-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:1934, or SEQ ID NO:3283 can preferentially target skeletal muscle tissue with at least 25-fold greater RNA enrichment than wild-type AAV9.
[0214] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least four-fold greater DNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:3472, SEQ ID NO:3297, SEQ ID NO:2661, SEQ ID NO:4545, SEQ ID NO:348, SEQ ID NO:18, SEQ ID NO:4349, SEQ ID NO:293, SEQ ID NO:5017, SEQ ID NO:4955, or SEQ ID NO:4366 can preferentially target skeletal muscle tissue with at least four-fold greater DNA enrichment than wild-type AAV5.
[0215] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least 5-fold greater DNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:3472, SEQ ID NO:3297, SEQ ID NO:2661, SEQ ID NO:4545, or SEQ ID NO:348 can preferentially target skeletal muscle tissue with at least 5-fold greater DNA enrichment than wild-type AAV5.
[0216] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with an RNA enrichment at least equal to that of wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:1934, SEQ ID NO:3283, SEQ ID NO:5817, or SEQ ID NO:278 can preferentially target skeletal muscle tissue with an RNA enrichment at least equal to that of wild-type AAV5.
[0217] In some embodiments, the AAV VP capsid polypeptide preferentially targets skeletal muscle tissue with at least three-fold greater RNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:1934, or SEQ ID NO:3283 can preferentially target skeletal muscle tissue with at least three-fold greater RNA enrichment than wild-type AAV5.
[0218] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 12 that are predicted to confer tropism or preference for muscle tissue to a recombinant AAV virion (rAAV) based on a secondary screen, and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), wherein the capsid polypeptide is capable of assembling into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 12 in a region corresponding to amino acid residues 445-453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 12 in a region corresponding to amino acid residues 389-397 of AAV5 VP3.
[0219] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to a sequence set forth in Table 12. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 348. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2536. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4955. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5017. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4349. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 293. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 1576. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 2661.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4964. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4314. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4995. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4366. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4545. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4961. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5206. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5092. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3472.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5075. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4059. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4354. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5060. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4288. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4952. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5138. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 18. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 5030.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 3297. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4295. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO: 4363. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has a sequence that is at least 75%, at least 77.7%, at least 85%, at least 88.8%, or 100% identical to SEQ ID NO:4963.
[0220] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 348. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4955. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5017. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4349. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 293. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1576. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4964. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4314. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4995. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4366. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4545. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4961. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5206. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5092. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3472.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5075. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4059. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4354. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5060. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4288. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4952. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5138. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 18. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5030. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3297. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4295. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4363. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4963.
[0221] In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 348 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2536 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4955 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5017 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4349 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 293 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 1576 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 2661 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4964 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4314 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4995, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4366, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4545, with one or two conservative substitutions.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4961 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5206 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5092 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3472 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5075 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4059 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4354 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5060 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4288 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4952 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5138, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 18, with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 5030, with one or two conservative substitutions.In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 3297 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4295 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4363 with one or two conservative substitutions. In some embodiments, the 581-589 region of the AAV5 VP capsid polypeptide has the sequence of SEQ ID NO: 4963 with one or two conservative substitutions. The conservative substitutions may be at any position in the 581-589 region.
[0222] In some embodiments, the AAV VP capsid polypeptide preferentially targets muscle tissue with at least 20-fold higher DNA enrichment than wild-type AAV9. For example, an AAV comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:293, SEQ ID NO:1576, SEQ ID NO:2661, SEQ ID NO:4964, SEQ ID NO:4314, SEQ ID NO:4995, SEQ ID NO:4366, SEQ ID NO:4545, SEQ ID NO:4961, SEQ ID NO:5206, SEQ ID NO:5092, SEQ ID NO:3472, SEQ ID NO:5075, SEQ ID NO:4059, SEQ ID NO:4354, SEQ ID NO:5060, SEQ ID NO:4288, SEQ ID NO:4952, SEQ ID NO:5138, SEQ ID NO:18, SEQ ID NO:5030, SEQ ID NO:3297, SEQ ID NO:4295, SEQ ID NO:4363, SEQ ID NO:4963, SEQ ID NO:4973, SEQ ID NO:5159, SEQ ID NO:4960, SEQ ID NO:4938, SEQ ID NO:5157, SEQ ID NO:5023, or SEQ ID NO:4969 The VP capsid polypeptide can preferentially target muscle tissue with at least 20-fold higher DNA enrichment than wild-type AAV9.
[0223] In some embodiments, an AAV VP capsid polypeptide preferentially targets muscle tissue with at least 25-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:293, SEQ ID NO:1576, SEQ ID NO:2661, SEQ ID NO:4964, SEQ ID NO:4314, SEQ ID NO:4995, or SEQ ID NO:4366 may preferentially target muscle tissue with at least 25-fold greater DNA enrichment than wild-type AAV9.
[0224] In some embodiments, the AAV VP capsid polypeptide preferentially targets muscle tissue with at least 30-fold greater DNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 348 or SEQ ID NO: 2536 can preferentially target muscle tissue with at least 30-fold greater DNA enrichment than wild-type AAV9.
[0225] In some embodiments, the AAV VP capsid polypeptide preferentially targets muscle tissue with at least 5-fold greater RNA enrichment than wild-type AAV9. For example, an AAV comprising the 581-589 region of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:348, SEQ ID NO:5052, SEQ ID NO:5193, SEQ ID NO:5026, SEQ ID NO:278, SEQ ID NO:5163, SEQ ID NO:293, SEQ ID NO:4943, SEQ ID NO:4952, SEQ ID NO:4317, SEQ ID NO:5075, SEQ ID NO:386, SEQ ID NO:4986, SEQ ID NO:4995, SEQ ID NO:4288, SEQ ID NO:5030, SEQ ID NO:5206, SEQ ID NO:5159, SEQ ID NO:4949, SEQ ID NO:4338, SEQ ID NO:5060, SEQ ID NO:4346, SEQ ID NO:5215, SEQ ID NO:5017, SEQ ID NO:4314, SEQ ID NO:5080, SEQ ID NO:4964, SEQ ID NO:4363, SEQ ID NO:4379, SEQ ID NO:5027, SEQ ID NO:4304, SEQ ID NO:18, SEQ ID NO:4349, SEQ ID NO:4938, or SEQ ID NO:2536 The VP capsid polypeptide can preferentially target muscle tissue with at least 5-fold higher RNA enrichment than wild-type AAV9.
[0226] In some embodiments, the AAV VP capsid polypeptide preferentially targets muscle tissue with at least 10-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:348, SEQ ID NO:5052, SEQ ID NO:5193, SEQ ID NO:5026, SEQ ID NO:278, or SEQ ID NO:5163 may preferentially target muscle tissue with at least 10-fold greater RNA enrichment than wild-type AAV9.
[0227] In some embodiments, the AAV VP capsid polypeptide preferentially targets muscle tissue with at least 100-fold greater RNA enrichment than wild-type AAV9. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 5138 may preferentially target muscle tissue with at least 100-fold greater RNA enrichment than wild-type AAV9.
[0228] In some embodiments, an AAV VP capsid polypeptide preferentially targets muscle tissue with at least 5-fold greater DNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:293, SEQ ID NO:1576, SEQ ID NO:2661, SEQ ID NO:4964, SEQ ID NO:4314, SEQ ID NO:4995, SEQ ID NO:4366, SEQ ID NO:4545, SEQ ID NO:4961, SEQ ID NO:5206, SEQ ID NO:5092, SEQ ID NO:3472, SEQ ID NO:5075, SEQ ID NO:4059, SEQ ID NO:4354, or SEQ ID NO:5060 may preferentially target muscle tissue with at least 5-fold greater DNA enrichment than wild-type AAV5.
[0229] In some embodiments, the AAV VP capsid polypeptide preferentially targets muscle tissue with at least 10-fold greater DNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO: 348 may preferentially target muscle tissue with at least 10-fold greater DNA enrichment than wild-type AAV5.
[0230] In some embodiments, an AAV VP capsid polypeptide preferentially targets muscle tissue with an RNA enrichment at least equal to that of wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 region of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:348, SEQ ID NO:5052, SEQ ID NO:5193, SEQ ID NO:5026, SEQ ID NO:278, SEQ ID NO:5163, SEQ ID NO:293, SEQ ID NO:4943, SEQ ID NO:4952, SEQ ID NO:4317, SEQ ID NO:5075, SEQ ID NO:386, SEQ ID NO:4986, or SEQ ID NO:4995 may preferentially target muscle tissue with an RNA enrichment at least equal to that of wild-type AAV5.
[0231] In some embodiments, the AAV VP capsid polypeptide preferentially targets muscle tissue with at least two-fold greater RNA enrichment than wild-type AAV5. For example, an AAV VP capsid polypeptide comprising the 581-589 regions of SEQ ID NO:5138, SEQ ID NO:3472, SEQ ID NO:348, and SEQ ID NO:5052 may preferentially target muscle tissue with at least two-fold greater RNA enrichment than wild-type AAV5.
[0232] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 5 that are predicted to confer tropism or preference for muscle tissue to recombinant AAV virions (rAAV) based on a primary screen (SEQ ID NOs:4238-4933), and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), wherein the capsid polypeptide is capable of assembling into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The present invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 5 (SEQ ID NOs: 4238 to 4933) in the region corresponding to amino acid residues 445 to 453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 5 (SEQ ID NOs: 4238 to 4933) in the region corresponding to amino acid residues 389 to 397 of AAV5 VP3. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 5-7]
[0233] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 6 that have an improved potential for conferring tropism or preference for muscle tissue to a recombinant AAV virion (rAAV) (SEQ ID NOs:4934-5233), and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), wherein the capsid polypeptide is capable of assembly into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The present invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 6 (SEQ ID NO: 4934 to SEQ ID NO: 5233) in a region corresponding to amino acid residues 445 to 453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 6 (SEQ ID NO: 4934 to SEQ ID NO: 5233) in a region corresponding to amino acid residues 389 to 397 of AAV5 VP3. [Table 6-1] [Table 6-2] [Table 6-3]
[0234] In some embodiments, the engineered AAV VP capsid polypeptide comprises a polypeptide sequence represented by the formula (A)-(X)-(B), where (A) is the polypeptide sequence of SEQ ID NO:5812 (VAYNVGGQMATNNQSSTTAP, corresponding to residues 561-580 of SEQ ID NO:2), (X) is a 581-589 region having a polypeptide sequence selected from the list of polypeptides in Table 7 that have an improved potential for conferring tropism or preference to a recombinant AAV virion (rAAV) for CNS tissue (SEQ ID NOs:5808-5811), and (B) is the polypeptide sequence of SEQ ID NO:5813 (IVPGSVWMERDVYLQGPIWA, corresponding to residues 590-609 of SEQ ID NO:2), wherein the capsid polypeptide is capable of assembly into the rAAV, and the capsid does not have the sequence of any of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. The present invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 7 (SEQ ID NOs: 5808 to 5811) in a region corresponding to amino acid residues 445 to 453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 7 (SEQ ID NOs: 5808 to 5811) in a region corresponding to amino acid residues 389 to 397 of AAV5 VP3. [Table 7]
[0235] In some embodiments, the engineered AAV VP capsid polypeptide confers tropism or preference for muscle tissue, wherein the muscle tissue is selected from the group consisting of aorta, esophagus, heart (e.g., atrium, ventricle, valves), skeletal muscle (e.g., biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, quadriceps (including vastus lateralis)), muscle fibers (including Type I (slow-twitch, oxidative) fibers, Type IC fibers, Type II fibers, Type IIC fibers, Type IIA (fast-twitch, oxidative / glycolytic) fibers, Type IIAX fibers, Type IIXA fibers, Type IIX (fast-twitch, glycolytic) fibers), and combinations thereof.
[0236] Described below are engineered mutant AAV5 VP1 polypeptide sequences that stabilize or improve virion assembly, tissue tropism, or both. In some embodiments, the disclosure provides an AAV5 VP1 capsid polypeptide that shares 98.7% or less sequence identity with SEQ ID NO:1, where the AAV5 capsid polypeptide sequence contains at least one mutation in the region from position 581 to position 589 of SEQ ID NO:1. In some embodiments, the engineered AAV5 polypeptide contains a 581-589 region variant (e.g., containing at least one amino acid substitution compared to residues 561-580 of SEQ ID NO:1).
[0237] The present invention also includes rAAVs composed of engineered AAV5 VP2 capsid polypeptides that contain a 581-589 region having a sequence selected from the list of polypeptides in Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7 (SEQ ID NO: 12 to SEQ ID NO: 3937, SEQ ID NO: 3938 to SEQ ID NO: 4237, SEQ ID NO: 4238 to SEQ ID NO: 4933, SEQ ID NO: 4934 to SEQ ID NO: 5233, SEQ ID NO: 5234 to SEQ ID NO: 5807, or SEQ ID NO: 5808 to SEQ ID NO: 5811) in the region corresponding to amino acid residues 445 to 453 of AAV5 VP2, and engineered AAV5 VP3 capsid polypeptides that contain a 581-589 region having a sequence selected from the list of polypeptides in Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7 in the region corresponding to amino acid residues 389 to 397 of AAV5 VP3. The present invention also includes rAAVs composed of an engineered AAV5 VP2 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 9, Table 10, Table 11, or Table 10 in a region corresponding to amino acid residues 445-453 of AAV5 VP2, and an engineered AAV5 VP3 capsid polypeptide that contains a 581-589 region having a sequence selected from the list of polypeptides in Table 9, Table 10, Table 11, or Table 10 in a region corresponding to amino acid residues 389-397 of AAV5 VP3.
[0238] Engineered VP polypeptides suitable for assembly of rAAV In various preferred embodiments, the mutated (engineered, recombinant) VP capsid polypeptides of the present disclosure (e.g., including 581-589 region variants) are capable of forming assembled virions, in some cases virions that have similar or improved stability compared to virions comprising the AAV5 VP1 capsid polypeptide of SEQ ID NO:1.
[0239] In the assembled purified virus, X corresponds to positions 581 to 589 of SEQ ID NO: 1, or as generalized in SEQ ID NO: 2. 1 ~X 9 The frequency of a given amino acid residue at a given position in the 581-589 region corresponding to the sequence of the 581-589 region was analyzed to determine whether it was greater than the frequency of that given amino acid residue at that position in the entire plasmid library. Based on the determined amino acid residue frequencies, the degree to which each amino acid at each position in the 581-589 region contributes to capsid assembly was determined, and the sequence of the 581-589 region (X in SEQ ID NO: 2) was determined. 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 ) and identified sequences that favor capsid assembly and rules for selecting sequences that favor capsid assembly.
[0240] Disclosed herein are engineered AAV5 VP capsid polypeptides capable of forming assembled viral capsids that may have comparable or improved stability compared to wild-type AAV5 VP capsid polypeptides, wherein the engineered AAV5 VP capsid polypeptide variant sequence has one or more mutations, wherein the VP1 polypeptide sequence has the one or more mutations in the 581-589 region (corresponding to positions 581 to 589 of SEQ ID NO:2), and wherein the sequence includes X 1is selected from A, D, E, G, L, M, N, Q, S, T or V, or X 1 is selected from A, D, E, M, or T. In some embodiments, X 1 is E or X 2 is selected from A, C, D, E, G, H, I, N, P, Q, S, T or V, or X 2 is selected from A, S, T or V, or X 2 is A or X 3 is selected from A, D, E, G, H, M, N, Q, S, T or V, or X 3 is selected from D, E, N, Q or T, or X 3 is D or T, or X 4 is selected from A, D, E, G, H, N, P, Q, S or T, or X 4 is selected from D, E, P or Q, or X 4 is E or X 5 is selected from A, C, D, E, G, H, N, Q, S, T or Y, or X 5 is selected from D, E, N, Q or T, or X 5 is N or X 6 is selected from A, D, E, G, H, N, P, Q, S or T, or X 6 is selected from D, N or Q, or X 6 is D or X 7 is selected from A, C, D, E, G, H, N, Q, S or T, or X 7 is selected from A, D, E or G, or X 7 is A or X 8 is selected from A, C, D, E, G, H, N, Q, S or T, or X 8 contains A, D, G or S, or X 8 is G or X 9 is selected from A, D, E, G, H, N, P, Q, S or T, or X 9is selected from A, D, G or P, or X 9 is G.
[0241] In various embodiments, the VP polypeptide is capable of forming an assembled viral capsid, in some cases with similar or improved stability compared to virions comprising the AAV5 VP1 capsid polypeptide of SEQ ID NO:1.
[0242] Examples of amino acid substitutions within the 581-589 region that may be favorable for viral capsid assembly are shown in Table 8. In some embodiments, the following amino acids are independently selected from the group consisting of X, XB, XC, XD, XE, XF, XH, XI, XJ ... 1 ~X 9 can be mutated at one or more positions in any combination to result in an AAV VP1 capsid that can assemble. In addition, X can be mutated at any one or more positions in any combination to result in an AAV VP1 capsid that can assemble, so long as the capsid remains assembleable. 1 ~X 9 One or more mutations outside this region can be tolerated. [Table 8-1] [Table 8-2]
[0243] CNS tissue-tropic 581-589 region variants The present disclosure provides AAV5 virions having a VP capsid polypeptide with at least one mutation in a region containing residues that interact with target cells (e.g., target CNS cells within a target CNS tissue of interest), which mutation enhances tropism or preference for CNS tissue compared to a wild-type VP capsid polypeptide (e.g., a VP capsid polypeptide of SEQ ID NO: 1, SEQ ID NO: 10, or SEQ ID NO: 11). In some embodiments, the invention provides an AAV5 VP1 capsid polypeptide that shares at least 80% sequence identity with SEQ ID NO: 1, wherein the AAV5 VP1 capsid polypeptide has at least one mutation in the 581-589 region corresponding to residues 581-589 of SEQ ID NO: 1, wherein the at least one mutation enhances tropism or preference for the central nervous system (CNS) compared to the wild-type VP capsid polypeptide (SEQ ID NO: 1). The following sequence rules and sequences also apply to the 581-589 region of AAV5 VP2 (amino acid residues 445-453 of the VP2 sequence set forth in SEQ ID NO: 10) and the 581-589 region of AAV5 VP3 (amino acid residues 389-397 of the VP3 sequence set forth in SEQ ID NO: 11). That is, the present disclosure includes AAV5 VP2 capsid polypeptides and AAV5 VP3 capsid polypeptides with one or more amino acid substitutions in the 581-589 regions of VP2 and VP3 corresponding to amino acid residues 581-589 of AAV5 VP1, where the one or more mutations are consistent with the rules or sequences in the sections below.
[0244] A VP capsid polypeptide (e.g., a V1 capsid polypeptide, a VP2 capsid polypeptide, or a VP3 capsid polypeptide, or a combination thereof) comprising a CNS tissue-tropic 581-589 region (e.g., any one of SEQ ID NOs: 12 to 3937 or 3938 to 4237, or any 581-589 region conforming to the rules set forth herein) can be assembled to form an rAAV with altered surface properties compared to a wild-type AAV (e.g., comprising the VP1 polypeptide of SEQ ID NO: 1). The surface can form an interface that interacts with the target tissue, and the altered surface properties of the rAAV can promote tissue-specific interaction (e.g., CNS tissue-specific interaction) between the rAAV and its target tissue. In some embodiments, the altered surface properties can be a change in charge distribution, an increase or decrease in hydrophobicity, a change in the availability or distribution of hydrogen bond donors or acceptors, or the formation or shape of a binding pocket. Such changes in surface properties may favor the interaction of the rAAV with CNS tissue, but may also be unfavorable for the interaction of the rAAV with non-CNS tissue.
[0245] CNS-tropic rAAVs assembled from VP capsid polypeptides (e.g., V1 capsid polypeptide, VP2 capsid polypeptide, VP3 capsid polypeptide, or combinations thereof) comprising the 581-589 region (e.g., any one of SEQ ID NOs: 12 to 3937 or 3938 to 4237, or any 581-589 region according to the rules set forth herein) can preferentially infect CNS tissues (e.g., forebrain cortex, occipital cortex, temporal cortex, thalamus, hypothalamus, substantia nigra, hippocampal DG, hippocampal CA1, hippocampal CA3, cerebellum, or combinations thereof) at higher levels than wild-type AAV5, and can preferentially infect non-CNS tissues (e.g., liver, skeletal muscle, heart, lung, spleen, lymph nodes, bone marrow, mammary gland, skin, adrenal gland, thyroid gland, colon, sciatic nerve, spinal cord, or combinations thereof). The CNS-tropic AAV can infect the CNS tissue at an infection rate that is at least about 1.1 times, at least about 1.2 times, at least about 1.3 times, at least about 1.4 times, at least about 1.5 times, at least about 1.6 times, at least about 1.7 times, at least about 1.8 times, at least about 1.9 times, at least about 2 times, at least about 2.2 times, at least about 2.4 times, at least about 2.6 times, at least about 2.8 times, at least about 3 times, at least about 3.5 times, at least about 4 times, at least about 4.5 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 20 times, at least about 30 times, at least about 40 times, at least about 50 times, at least about 100 times, at least about 200 times, at least about 300 times, at least about 400 times, or at least about 500 times that of wild-type AAV5 infecting non-CNS tissue. In some embodiments, the non-CNS tissue is liver tissue.
[0246] In some embodiments, a CNS-tropic rAAV assembled from VP capsid polypeptides (e.g., V1 capsid polypeptide, VP2 capsid polypeptide, or VP3 capsid polypeptide, or a combination thereof) containing the 581-589 region (e.g., any one of SEQ ID NOs: 12 to 3937 or 3938 to 4237, or any 581-589 region according to the rules set forth herein) can deliver a payload (e.g., a payload encoding a therapeutic peptide or therapeutic polynucleotide) to a tissue infected with the rAAV, where it can be expressed. In some embodiments, the expression level of the payload in CNS tissue may be at least about 2.5-fold, at least about 2.8-fold, at least about 3-fold, at least about 3.2-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or at least about 1000-fold greater than the expression level in non-CNS tissue (e.g., liver tissue). In some embodiments, when a CNS-tropic AAV is used to deliver a payload to a CNS tissue, the specificity for the CNS tissue may be at least about 1.1-fold, at least about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at least about 2-fold, at least about 2.2-fold, at least about 2.4-fold, at least about 2.6-fold, at least about 2.8-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, or at least about 500-fold greater than wild-type AAV5.
[0247] CNS directional array Capsids of recombinant AAV viruses with specificity for central nervous system (CNS) tissues (CNS-tropic rAAVs) can be identified by screening an rAAV library containing a VP capsid polypeptide having the 581-589 region as described herein. The library can be screened by systemically administering the rAAV library to non-human primates (NHPs) and identifying sequences within the 581-589 region of the VP capsid polypeptide that result in tissue-tropic accumulation in or infection of CNS tissues (e.g., forebrain cortex, occipital cortex, temporal cortex, thalamus, hypothalamus, substantia nigra, hippocampal DG, hippocampal CA1, hippocampal CA3, cerebellum, or a combination thereof). The CNS-tropic rAAVs can preferentially accumulate in or infect CNS tissues over non-CNS tissues (e.g., liver, skeletal muscle, heart, lung, spleen, lymph nodes, bone marrow, mammary gland, skin, adrenal gland, thyroid, colon, sciatic nerve, spinal cord, or a combination thereof). Exemplary 581-589 region sequences identified in primary screening as conferring CNS tissue tropism to rAAV are shown in Tables 2 and 4. Exemplary 581-589 region sequences identified in secondary screening as conferring CNS tissue tropism to rAAV are shown in Table 9.
[0248] A CNS-tropic rAAV assembled from a VP capsid polypeptide (e.g., a V1 capsid polypeptide, a VP2 capsid polypeptide, or a VP3 capsid polypeptide, or a combination thereof) comprising the 581-589 region (e.g., any one of SEQ ID NOs: 12 to 3937) can preferentially infect CNS tissues (e.g., the forebrain cortex, occipital cortex, temporal cortex, thalamus, hypothalamus, substantia nigra, hippocampal DG, hippocampal CA1, hippocampal CA3, cerebellum, or a combination thereof) over non-CNS tissues (e.g., the liver, skeletal muscle, heart, lung, spleen, lymph nodes, bone marrow, mammary gland, skin, adrenal gland, thyroid gland, colon, sciatic nerve, spinal cord, or a combination thereof).
[0249] Disclosed herein are engineered AAV5 VP capsid polypeptides capable of forming assembled virions that have improved central nervous system tissue tropism compared to wild-type AAV5 VP capsid polypeptides (e.g., VP1 of SEQ ID NO: 1, VP2 of SEQ ID NO: 10, or VP3 of SEQ ID NO: 11), wherein the engineered AAV5 VP capsid polypeptide variant sequence is a 581-589 region of the VP capsid polypeptide, comprising a sequence at positions 581 to 589 (X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 ) in the region corresponding to X 1 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 2 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 3 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 4 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 5 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 6 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 7 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 8is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 9 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0250] In some embodiments, the 581-589 region of the CNS tissue-tropic VP capsid polypeptide may comprise any one of the sequences of SEQ ID NO:12 to SEQ ID NO:3937.
[0251] In some embodiments, the present invention provides an AAV5 VP capsid polypeptide having at least one mutation in the 581-589 region corresponding to residues 581 to 589 of AAV5 VP1 (e.g., SEQ ID NO: 1), which region has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to any sequence selected from SEQ ID NOs: 12 to 3937, wherein the at least one mutation enhances central nervous system tissue tropism compared to a wild-type AAV5 capsid polypeptide.
[0252] CNS-directed sequences generated by machine learning Additional 581-589 regions that confer CNS tissue tropism may be generated using machine learning algorithms trained on sequences identified in in vivo screening in CNS tissues. These patterns may be used to generate new 581-589 regions of sequence that improve the likelihood of CNS tissue tropism for VP capsid polypeptides and rAAVs assembled from those VP capsid polypeptides. In some embodiments, new 581-589 regions of sequence may be generated by randomly sampling amino acid residues at each position in the 581-589 region that favored CNS tissue tropism in in vivo screening. The resulting sequences may then be tested using classifiers such as random forests or gradient boosting to predict the CNS tissue specificity of each 581-589 region. The 581-589 region with the highest predicted CNS tissue specificity may be selected as the CNS tissue-tropic sequence. For example, the 581-589 region of any one of SEQ ID NOs: 3938 to 4237 may be selected. To improve the potential for CNS tissue tropism in rAAV, the 581-589 region sequences generated using machine learning are shown in Table 3.
[0253] Favorable and unfavorable amino acid residues at each position in the 581-589 region of an engineered AAV5 capsid polypeptide that improve the likelihood of CNS tissue tropism compared to a wild-type AAV5 capsid polypeptide may be determined using in vivo data, machine learning (ML) models, or a combination thereof. A recombinant AAV viral capsid library may be screened by systemically administering the rAAV library to non-human primates (NHPs) and identifying sequences in the 581-589 region of the VP capsid polypeptide that achieve tissue-tropic accumulation in or improve the likelihood of infecting CNS tissues (e.g., forebrain cortex, occipital cortex, temporal cortex, thalamus, hypothalamus, substantia nigra, hippocampal DG, hippocampal CA1, hippocampal CA3, cerebellum, or a combination thereof).
[0254] A CNS-tropic rAAV assembled from a VP capsid polypeptide comprising the 581-589 region (e.g., a V1 capsid polypeptide, a VP2 capsid polypeptide, or a VP3 capsid polypeptide, or a combination thereof) can preferentially infect CNS tissues (e.g., the forebrain cortex, the occipital cortex, the temporal cortex, the thalamus, the hypothalamus, the substantia nigra, the hippocampal DG, the hippocampal CA1, the hippocampal CA3, the cerebellum, or a combination thereof) over non-CNS tissues (e.g., the liver, skeletal muscle, the heart, the lung, the spleen, the lymph nodes, the bone marrow, the mammary gland, the skin, the adrenal gland, the thyroid gland, the colon, the sciatic nerve, the spinal cord, or a combination thereof) compared to wild-type AAV5 capsid polypeptides.
[0255] Disclosed herein are engineered AAV5 VP capsid polypeptides capable of forming assembled virions that have improved tropism or preference for central nervous system tissues compared to wild-type AAV5 VP capsid polypeptides (e.g., VP1 of SEQ ID NO: 1, VP2 of SEQ ID NO: 10, or VP3 of SEQ ID NO: 11), wherein the engineered AAV5 VP capsid polypeptide variant sequence is a 581-589 region of the VP capsid polypeptide, comprising a sequence at positions 581 to 589 (X 11) of SEQ ID NO: 2. 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 ) in the region corresponding to X 1 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 2 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 3 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 4is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 5 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 6 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 7 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 8 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 9 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0256] In some embodiments, the 581-589 region of the CNS tissue-tropic VP capsid polypeptide may comprise any one of the sequences set forth in SEQ ID NO:3938 through SEQ ID NO:4237.
[0257] In some embodiments, the present invention provides an AAV5 VP capsid polypeptide having at least one mutation in the 581-589 region corresponding to residues 581 to 589 of AAV5 VP1 (e.g., SEQ ID NO: 1), which region has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to any sequence selected from SEQ ID NOs: 3938 to 4237, wherein the at least one mutation enhances central nervous system tissue tropism compared to a wild-type AAV5 capsid polypeptide.
[0258] The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 18 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 54 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 2028 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 424 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 3306 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 3472 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 415 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 709 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1971 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2791 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 1956 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 262 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 425 relative to WT AAV5.The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2536 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 708 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 3283 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 430 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 3297 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 2661 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 428 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 885 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 429 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 569 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 724 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 1576 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 4545 relative to WT AAV5.The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 426 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1887 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 3906 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 3935 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 3846 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2168 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4119 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2456 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2278 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 5006 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 307 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 5155 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 2640 relative to WT AAV5.The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4317 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1145 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 23 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 103 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 22 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4031 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1008 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4790 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2522 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1432 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 2914 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 5042 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 2865 relative to WT AAV5.The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4264 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 964 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1268 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 5065 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 706 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4704 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2994 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 829 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1171 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1041 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 5070 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 139 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 3304 relative to WT AAV5.The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2431 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4288 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 5795 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1300 relative to WT AAV5. The present disclosure provides a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1770 relative to WT AAV5. Tissue-tropic rAAVs are provided. The present disclosure provides tissue-tropic rAAVs comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2830 relative to WT AAV5. The present disclosure provides tissue-tropic rAAVs comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1972 relative to WT AAV5. The present disclosure provides tissue-tropic rAAVs comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1649 relative to WT AAV5. The present disclosure provides tissue-tropic rAAVs comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2515 relative to WT AAV5. The present disclosure provides tissue-tropic rAAVs comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2849 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 3796 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 5815 (SYKMIHNTA) relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 118 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4766 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 770 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 1069 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 3061 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 4290 relative to WT AAV5.The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4261 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4239 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 3478 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 2671 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 256 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1256 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 719 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 1448 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 280 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a 581-589 region variant of SEQ ID NO: 4338 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 5037 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 1901 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 438 relative to WT AAV5.The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 2834 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 5491 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 4591 relative to WT AAV5. The present disclosure provides a tissue-tropic rAAV comprising a VP capsid polypeptide having a variant of the 581-589 region of SEQ ID NO: 4936 relative to WT AAV5.
[0259] 581-589 region variants for CNS targeting In some embodiments, the present invention provides an AAV5 VP capsid polypeptide comprising at least one mutation in the 581-589 region corresponding to residues 581 to 589 of AAV5 VP1, the region having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to any sequence selected from SEQ ID NO: 12 to SEQ ID NO: 3937, SEQ ID NO: 3938 to SEQ ID NO: 4237, or SEQ ID NO: 5234 to SEQ ID NO: 5807, wherein the at least one mutation enhances CNS tissue tropism compared to a wild-type AAV5 capsid polypeptide.
[0260] Muscle tissue-targeting variants in the 581-589 region The present disclosure provides AAV5 virions having a VP capsid polypeptide with at least one mutation in a region containing residues that interact with target cells (e.g., target muscle cells within a target muscle tissue of interest), wherein the at least one mutation enhances tropism or preference for muscle tissue compared to a wild-type VP capsid polypeptide (e.g., a VP capsid polypeptide of SEQ ID NO: 1, SEQ ID NO: 10, or SEQ ID NO: 11). In some embodiments, the invention provides an AAV5 VP1 capsid polypeptide that shares at least 80% sequence identity with SEQ ID NO: 1, wherein the AAV5 VP1 capsid polypeptide has at least one mutation in the 581-589 region corresponding to residues 581-589 of SEQ ID NO: 1, wherein the at least one mutation enhances tropism or preference for muscle tissue compared to a wild-type VP capsid polypeptide of SEQ ID NO: 1. The sequence rules and sequences below also apply to the 581-589 region of AAV5 VP2 (amino acid residues 445-453 of the VP2 sequence set forth in SEQ ID NO: 10) and the 581-589 region of AAV5 VP3 (amino acid residues 389-397 of the VP3 sequence set forth in SEQ ID NO: 11). That is, the present disclosure includes AAV5 VP2 capsid polypeptides and AAV5 VP3 capsid polypeptides with one or more amino acid substitutions in the 581-589 regions of VP2 and VP3 corresponding to amino acid residues 581-589 of AAV5 VP1, where the one or more mutations are consistent with the rules or sequences in the sections below.
[0261] A VP capsid polypeptide (e.g., a V1 capsid polypeptide, a VP2 capsid polypeptide, or a VP3 capsid polypeptide, or a combination thereof) comprising a muscle-tropic 581-589 region (e.g., any one of SEQ ID NOs: 4238 to 4933 or 4934 to 5233, or any 581-589 region conforming to the rules set forth herein) can be assembled to form an rAAV with altered surface properties compared to a wild-type AAV (e.g., comprising the VP1 polypeptide of SEQ ID NO: 1). The surface can form an interface that interacts with a target tissue, and the altered surface properties of the rAAV can promote tissue-specific interaction (e.g., muscle-specific interaction) between the rAAV and its target tissue.
[0262] A muscle-tropic rAAV assembled from a VP capsid polypeptide (e.g., a V1 capsid polypeptide, a VP2 capsid polypeptide, or a VP3 capsid polypeptide, or a combination thereof) comprising the 581-589 region (e.g., any one of SEQ ID NOs: 4238 to 4933 or SEQ ID NOs: 4934 to 5233, or any 581-589 region according to the rules set forth herein) is expressed in muscle tissue (e.g., aorta, esophagus) at a higher level than wild-type AAV5. , heart (including atria, ventricles, and valves), skeletal muscle (including biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, and quadriceps (including vastus lateralis)), or muscle fibers (e.g., type I (slow-twitch, oxidative) fibers, type IC fibers, type II fibers, type IIC fibers, type IIA (fast-twitch, oxidative / glycolytic) fibers, type IIAX fibers, type IIXA fibers, type IIX (fast-twitch, glycolytic) fibers, or combinations thereof), and non-muscle tissues (e.g., liver, CNS, heart, lung, spleen, lymph nodes, bone marrow, mammary gland, skin, adrenal gland, thyroid gland, colon, ischial nerve, etc.). The muscle-tropic AAV may infect muscle tissue preferentially over non-muscle tissue (transverse, spinal, or a combination thereof) at least about 1.1-fold, at least about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at least about 2-fold, at least about 2.2-fold, at least about 2.4-fold, at least about 2.6-fold, at least about 2.8-fold, or at least about 1.8-fold less than wild-type AAV5. In some embodiments, the non-muscle tissue can be infected with at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, or at least about 500-fold higher infection rates. In some embodiments, the non-muscle tissue is liver tissue.
[0263] In some embodiments, a muscle-tropic rAAV assembled from a VP capsid polypeptide (e.g., a V1 capsid polypeptide, a VP2 capsid polypeptide, or a VP3 capsid polypeptide, or a combination thereof) containing the 581-589 region (e.g., any one of SEQ ID NOs: 4238 to 4933 or SEQ ID NOs: 4934 to 5233, or any 581-589 region according to the rules set forth herein) can deliver a payload (e.g., a payload encoding a therapeutic peptide or therapeutic polynucleotide) to a tissue infected with the rAAV, where the payload can be expressed. In some embodiments, the expression level of the payload in muscle tissue may be at least about 2.5-fold, at least about 2.8-fold, at least about 3-fold, at least about 3.2-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, at least about 75-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or at least about 1000-fold higher than the expression level in non-muscle tissue (e.g., liver tissue). In some embodiments, when a CNS-tropic AAV is used to deliver a payload to muscle tissue, the specificity for muscle tissue may be at least about 1.1-fold, at least about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at least about 2-fold, at least about 2.2-fold, at least about 2.4-fold, at least about 2.6-fold, at least about 2.8-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, or at least about 500-fold greater than wild-type AAV5.
[0264] muscle directional array Capsids of recombinant AAV viruses with specificity for muscle tissue (muscle-tropic rAAV) can be identified by screening rAAV libraries containing VP capsid polypeptides with 581-589 region variants as described herein. The library can be screened by systemically administering the rAAV library to non-human primates (NHPs) and identifying sequences in the 581-589 region of the VP capsid polypeptide that result in tissue-targeted accumulation in muscle tissue (e.g., aorta, esophagus, heart (including atria, ventricles, and valves), skeletal muscle (including biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, and quadriceps (including vastus lateralis)), or muscle fibers (e.g., type I (slow-twitch, oxidative) fibers, type IC fibers, type II fibers, type IIC fibers, type IIA (fast-twitch, oxidative / glycolytic) fibers, type IIAX fibers, type IIXA fibers, type IIX (fast-twitch, glycolytic) fibers), or a combination thereof) or that allow the rAAV to infect muscle tissue. Muscle-tropic rAAVs may preferentially accumulate in or infect muscle tissue compared to non-muscle tissue (e.g., liver, CNS, heart, lung, spleen, lymph nodes, bone marrow, mammary gland, skin, adrenal gland, thyroid gland, colon, sciatic nerve, spinal cord, or a combination thereof). Exemplary region sequences identified in primary screening to confer muscle tropism to rAAVs are shown in Tables 5 and 7. Exemplary region sequences identified in secondary screening to confer cardiac muscle tropism to rAAVs are shown in Table 10. Exemplary region sequences identified in secondary screening to confer skeletal muscle tropism to rAAVs are shown in Table 11. Exemplary region sequences identified in secondary screening to confer muscle tropism to rAAVs are shown in Table 12.
[0265] Muscle-tropic rAAVs assembled from VP capsid polypeptides (e.g., V1 capsid polypeptide, VP2 capsid polypeptide, or VP3 capsid polypeptide, or a combination thereof) comprising the 581-589 region (e.g., any one of SEQ ID NOs: 4238 to 4933) can be delivered to non-muscle tissues (e.g., liver, CNS, heart, lung, spleen, lymph node, bone marrow, mammary gland, skin, adrenal gland, thyroid, colon, sciatic nerve, spinal cord, or a combination thereof). In comparison with the skeletal muscle, the virus may preferentially infect muscle tissue (e.g., the aorta, esophagus, heart (including atria, ventricles, and valves), skeletal muscle (including biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, and quadriceps (including vastus lateralis)), or muscle fibers (e.g., type I (slow-twitch, oxidative) fibers, type IC fibers, type II fibers, type IIC fibers, type IIA (fast-twitch, oxidative / glycolytic) fibers, type IIAX fibers, type IIXA fibers, type IIX (fast-twitch, glycolytic) fibers), or combinations thereof).
[0266] The present invention discloses an engineered AAV5 VP capsid polypeptide capable of forming assembled virions that have improved muscle tropism compared to a wild-type AAV5 VP capsid polypeptide (e.g., VP1 of SEQ ID NO: 1, VP2 of SEQ ID NO: 10, or VP3 of SEQ ID NO: 11), wherein the engineered AAV5 VP capsid polypeptide variant sequence is a 581-589 region of the VP capsid polypeptide, comprising positions 581 to 589 (X 11) of SEQ ID NO: 2. 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 ) in the region corresponding to X 1 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 2 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 3is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 4 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 5 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 6 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 7 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 8 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, X 9 is selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y or V.
[0267] In some embodiments, the 581-589 region of the muscle-tropic VP capsid polypeptide may comprise any one of the sequences set forth in SEQ ID NO:4238 to SEQ ID NO:4933.
[0268] In some embodiments, the present invention provides an AAV5 VP capsid polypeptide having at least one mutation in the 581-589 region corresponding to residues 581 to 589 of AAV5 VP1 (e.g., SEQ ID NO: 1), which region has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99%, or 100% sequence identity to any sequence selected from SEQ ID NOs: 4238 to 4933, wherein the at least one mutation enhances muscle tissue tropism compared to a wild-type AAV5 capsid polypeptide.
[0269] CNS-directed sequences generated by machine learning Additional 581-589 regions that confer tropism or preference for muscle tissue may be generated using machine learning algorithms trained on sequences identified in in vivo screening in muscle tissue. These patterns may be used to generate new 581-589 regions of sequence that improve the likelihood that VP capsid polypeptides and rAAVs assembled from those VP capsid polypeptides will confer muscle tissue tropism. In some embodiments, new 581-589 regions of sequence may be generated by randomly sampling amino acid residues at each position in the 581-589 region that favored muscle tissue tropism in in vivo screening. The resulting sequences may then be tested using classifiers such as random forests or gradient boosting to predict muscle specificity for each 581-589 region. The 581-589 region with the highest predicted muscle specificity may be selected as the muscle-tropic sequence. For example, the 581-589 region of any one of SEQ ID NOs: 4934 to 5233 may be selected. To improve the potential for conferring muscle tropism to rAAV, the 581-589 region sequences generated using machine learning are shown in Table 6.
[0270] Recombinant AAV viral capsid libraries can be screened in non-human primates (NHPs) by systemically administering the rAAV library and identifying sequences in the 581-589 region of the VP capsid polypeptide that confer tissue-targeted accumulation in or enhance the potential to infect muscle tissue (e.g., aorta, esophagus, heart (including atria, ventricles, and valves), skeletal muscle (including biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, and quadriceps (including vastus lateralis)), or muscle fibers (e.g., type I (slow-twitch, oxidative) fibers, type IC fibers, type II fibers, type IIC fibers, type IIA (fast-twitch, oxidative / glycolytic) fibers, type IIAX fibers, type IIXA fibers, type IIX (fast-twitch, glycolytic) fibers), or combinations thereof).
[0271] A muscle-tropic rAAV assembled from a VP capsid polypeptide comprising the 581-589 region (e.g., a V1 capsid polypeptide, a VP2 capsid polypeptide, or a VP3 capsid polypeptide, or a combination thereof) exhibits superior virulence in muscle tissues (e.g., aorta, esophagus, heart (including atria, ventricles, and valves)), skeletal muscles (biceps, brachialis, thigh, diaphragm, gastrocnemius, tibialis anterior, triceps, and quadriceps (vastus lateralis)) compared to a wild-type AAV5 capsid polypeptide. The virus may preferentially infect muscle tissues (e.g., muscle fibers, including muscle fibers) or muscle fibers (e.g., type I (slow-twitch, oxidative) fibers, type IC fibers, type II fibers, type IIC fibers, type IIA (fast-twitch, oxidative / glycolytic) fibers, type IIAX fibers, type IIXA fibers, type IIX (fast-twitch, glycolytic) fibers), or combinations thereof) over non-muscle tissues (e.g., liver, CNS, heart, lung, spleen, lymph nodes, bone marrow, mammary gland, skin, adrenal gland, thyroid, colon, sciatic nerve, spinal cord, or combinations thereof).
[0272] The present invention discloses an engineered AAV5 VP capsid polypeptide capable of forming assembled virions that have improved muscle tissue tropism compared to a wild-type AAV5 VP capsid polypeptide (e.g., VP1 of SEQ ID NO: 1, VP2 of SEQ ID NO: 10, or VP3 ...
Claims
1. 1. A viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, wherein a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system (CNS) tissue with at least 100-fold greater DNA enrichment than wild-type AAV9.
2. 2. The VP capsid polypeptide of claim 1, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3846, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:2168, SEQ ID NO:54, SEQ ID NO:429, SEQ ID NO:708, SEQ ID NO:428, SEQ ID NO:4119, SEQ ID NO:3906, SEQ ID NO:2456, SEQ ID NO:2278, SEQ ID NO:5006, SEQ ID NO:426, SEQ ID NO:307, SEQ ID NO:5155, SEQ ID NO:2640, SEQ ID NO:4317, SEQ ID NO:1145, SEQ ID NO:430, and SEQ ID NO:
885.
3. 3. The VP capsid polypeptide of any one of claims 1 to 2, wherein the recombinant viral capsid is capable of preferentially targeting the CNS tissue with at least 200-fold higher DNA enrichment than the wild-type AAV9.
4. 4. The VP capsid polypeptide of claim 3, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3846, SEQ ID NO:3283, SEQ ID NO:1956 and SEQ ID NO:3297.
5. 5. The VP capsid polypeptide of any one of claims 1 to 4, wherein the recombinant viral capsid is capable of preferentially targeting the CNS tissue with at least 1000-fold higher DNA enrichment than the wild-type AAV9.
6. The VP capsid polypeptide of claim 5, wherein the 581-589 region has the sequence of SEQ ID NO:
18.
7. 1. A viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, wherein a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system (CNS) tissue with at least 100-fold greater RNA enrichment than wild-type AAV9.
8. 8. The VP capsid polypeptide of claim 7, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:429, SEQ ID NO:428, SEQ ID NO:426, and SEQ ID NO:
430.
9. The VP capsid polypeptide of any one of claims 7 to 8, wherein the recombinant viral capsid is capable of preferentially targeting the CNS tissue with at least 200-fold higher RNA enrichment than the wild-type AAV9.
10. 10. The VP capsid polypeptide of claim 9, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:430, SEQ ID NO:569 and SEQ ID NO:
719.
11. The VP capsid polypeptide of any one of claims 7 to 8, wherein the recombinant viral capsid is capable of preferentially targeting the CNS tissue with at least 500-fold higher RNA enrichment than the wild-type AAV9.
12. 12. The VP capsid polypeptide of claim 11, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262 and SEQ ID NO:2028.
13. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, wherein a recombinant viral capsid comprising said VP capsid polypeptide is capable of preferentially targeting central nervous system (CNS) tissue with at least 5-fold greater DNA enrichment than wild-type AAV5.
14. 14. The VP capsid polypeptide of claim 13, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3846, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, and SEQ ID NO:1576.
15. 15. The VP capsid polypeptide of any one of claims 13 to 14, wherein the recombinant viral capsid is capable of preferentially targeting the CNS tissue with at least 10-fold higher DNA enrichment than the wild-type AAV5.
16. 16. The VP capsid polypeptide of claim 15, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791 and SEQ ID NO:
424.
17. A viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, wherein a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system (CNS) tissue with at least 5-fold greater RNA enrichment than wild-type AAV5.
18. 18. The VP capsid polypeptide of claim 17, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:429, SEQ ID NO:708, SEQ ID NO:428, SEQ ID NO:426, SEQ ID NO:307, SEQ ID NO:4317, SEQ ID NO:430, and SEQ ID NO:
885.
19. 18. The VP capsid polypeptide of any one of claims 16 to 17, wherein the recombinant viral capsid is capable of preferentially targeting the CNS tissue with at least 20-fold higher RNA enrichment than the wild-type AAV5.
20. 20. The VP capsid polypeptide of claim 19, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2028, SEQ ID NO:2791, SEQ ID NO:424, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:415, SEQ ID NO:3283, SEQ ID NO:1956, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:425, SEQ ID NO:709, SEQ ID NO:54, SEQ ID NO:430, SEQ ID NO:569 and SEQ ID NO:
719.
21. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising: (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006 or (dd) SEQ ID NO: 426, The VP capsid polypeptide having a sequence which is at least 85% identical to
22. The 581-589 region is (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006 or (dd) SEQ ID NO: 426, 22. The VP capsid polypeptide of claim 21 having the sequence:
23. 1. A viral protein (VP) capsid polypeptide, 581-589, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region having a sequence at least 85% identical to any one of SEQ ID NOs:12 through 3937 or SEQ ID NOs:3938 through 4237.
24. 24. The VP capsid polypeptide of claim 23, wherein the 581-589 region has a sequence as set forth in any one of SEQ ID NOs: 12 to 3937 or SEQ ID NOs: 3938 to 4237.
25. 25. The VP capsid polypeptide of any one of claims 1 to 24, wherein the VP capsid polypeptide is capable of assembling into a recombinant viral capsid.
26. A viral protein (VP) capsid polypeptide capable of assembling into a recombinant viral capsid, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising: Contains at least one amino acid substitution compared to SEQ ID NO:9, the recombinant viral capsid has a CNS tissue tropism that is at least three times higher than the wild-type VP capsid polypeptide of SEQ ID NO:1; The VP capsid polypeptide comprises at least one amino acid substitution compared to each of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:
8.
27. The 581-589 area is 1 X 2X 3 X 4 X 5 X 6 X 7 X 8 X 9 In the sequence, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 and X 9 27. The VP capsid polypeptide of claim 26, wherein each of is individually selected from A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.
28. The VP capsid polypeptide has the sequence of SEQ ID NO:2, and is selected from residues 581 to 589 of SEQ ID NO:2 (X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 28. The VP capsid polypeptide of claim 26 or claim 27, wherein the 581-589 region corresponds to the 581-589 region.
29. 29. The VP capsid polypeptide of any one of claims 26 to 28, wherein the 581-589 region has a sequence that is at least 70%, at least 77%, at least 80%, at least 88%, at least 90%, or at least 95% identical to any one of SEQ ID NOs: 12 to 3937.
30. VP capsid polypeptide according to any one of claims 26 to 28, wherein the 581-589 region has a sequence as set forth in any one of SEQ ID NOs: 12 to 3937.
31. 29. The VP capsid polypeptide of any one of claims 26 to 28, wherein the 581-589 region has a sequence that is at least 70%, at least 77%, at least 80%, at least 88%, at least 90%, or at least 95% identical to any one of SEQ ID NOs: 3938 to 4237.
32. VP capsid polypeptide according to any one of claims 26 to 28, wherein the 581-589 region has a sequence as set forth in any one of SEQ ID NOs: 3938 to 4237.
33. 33. The VP capsid polypeptide of any one of claims 1 to 32, wherein the VP capsid polypeptide comprises an amino acid sequence that is at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 98.5%, at least 99%, or at least 99.5% identical to SEQ ID NO:
1.
34. A VP capsid polypeptide described in any one of claims 1 to 33, having an infection rate for CNS tissue that is at least 2.5 times, at least 3 times, at least 3.5 times, at least 4 times, at least 5 times, at least 10 times, at least 20 times, at least 50 times, at least 75 times, at least 100 times, at least 200 times, at least 500 times, or at least 1000 times higher than the infection rate for CNS tissue of the wild-type VP capsid polypeptide.
35. A VP capsid polypeptide described in any one of claims 1 to 34, wherein the 581-589 region improves the stability of a recombinant viral capsid assembled from the VP capsid polypeptide compared to a wild-type AAV5 capsid comprising the peptide of SEQ ID NO:
1.
36. 36. The VP capsid polypeptide of any one of claims 1 to 35, wherein the 581-589 region reduces toxicity when administered to a subject compared to the wild-type VP capsid polypeptide of SEQ ID NO:
1.
37. 37. The VP capsid polypeptide of any one of claims 1 to 36, wherein the CNS tissue is selected from the forebrain cortex, occipital cortex, temporal cortex, thalamus, hypothalamus, substantia nigra, hippocampal DG, hippocampal CA1, hippocampal CA3, cerebellum, and combinations thereof.
38. A pharmaceutical composition comprising a VP capsid polypeptide according to any one of claims 1 to 37.
39. 39. The pharmaceutical composition of claim 38, wherein the VP capsid polypeptide is assembled into a recombinant viral capsid.
40. 40. The pharmaceutical composition of claim 38 or claim 39, further comprising a payload encapsulated in the recombinant viral capsid.
41. The pharmaceutical composition of claim 40, wherein the payload encodes a therapeutic polynucleotide or a therapeutic peptide.
42. 41. The pharmaceutical composition of claim 40, wherein the payload encodes any of a guide RNA, a tRNA, a suppressor tRNA, an siRNA, a miRNA, an mRNA, an shRNA, a circular RNA, or an antisense oligonucleotide (ASO), a ribozyme, a DNAzyme, an aptamer, or a combination thereof.
43. 41. The pharmaceutical composition of claim 40, wherein the payload encodes a component of the CRISPR / Cas system, an adenosine deaminase acting on RNA (ADAR) enzyme, a transcriptional activator or a transcriptional repressor.
44. A recombinant adeno-associated virus (rAAV) comprising a VP capsid polypeptide described in any one of claims 1 to 37 assembled into a recombinant viral capsid and a payload encapsulated in the recombinant viral capsid.
45. The rAAV of claim 44, further comprising a VP2 polypeptide comprising the 581-589 region and a VP3 polypeptide comprising the 581-589 region.
46. The rAAV of claim 44 or claim 45, wherein the payload encodes a therapeutic polynucleotide or a therapeutic peptide.
47. 47. The rAAV of claim 46, wherein the payload encodes any of a guide RNA, a tRNA, a suppressor tRNA, an siRNA, a miRNA, an mRNA, an shRNA, a circular RNA, or an antisense oligonucleotide (ASO), a ribozyme, a DNAzyme, an aptamer, or a combination thereof.
48. The rAAV of claim 46, wherein the payload encodes a component of the CRISPR / Cas system, an adenosine deaminase acting on RNA (ADAR) enzyme, a transcriptional activator or a transcriptional repressor.
49. 1. A method for delivering a payload to central nervous system (CNS) tissue of a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV encapsulating the payload in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting the CNS tissue with the rAAV; preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 100-fold higher than wild-type AAV9; The method comprising:
50. 50. The method of claim 49, wherein the DNA enrichment is at least 200-fold higher than the wild-type AAV9.
51. 51. The method of claim 49 or claim 50, wherein the DNA enrichment is at least 1000-fold higher than the wild-type AAV9.
52. 1. A method for transcribing a payload in central nervous system (CNS) tissue of a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV encapsulating the payload in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting the CNS tissue with the rAAV; preferentially transcribe said payload into said CNS tissue infected with said rAAV with RNA enrichment at least 100-fold higher than wild-type AAV9; The method comprising:
53. 53. The method of claim 52, wherein the DNA enrichment is at least 200-fold higher than the wild-type AAV9.
54. 54. The method of claim 49 or claim 53, wherein the DNA enrichment is at least 500-fold higher than the wild-type AAV9.
55. 1. A method for delivering a payload to central nervous system (CNS) tissue of a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV encapsulating the payload in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting the CNS tissue with the rAAV; preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 5-fold higher than wild-type AAV5; The method comprising:
56. 56. The method of claim 55, wherein the DNA enrichment is at least 10-fold higher than the wild-type AAV5.
57. 1. A method for transcribing a payload in central nervous system (CNS) tissue of a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV encapsulating the payload in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting the CNS tissue with the rAAV; preferentially transcribe said payload into said CNS tissue infected with said rAAV with RNA enrichment at least 5-fold higher than wild-type AAV5; The method comprising:
58. 58. The method of claim 57, wherein the DNA enrichment is at least 20-fold higher than the wild-type AAV5.
59. 1. A method for delivering a payload to central nervous system (CNS) tissue of a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV encapsulating the payload in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006 or (dd) SEQ ID NO: 426, having a sequence that is at least 85% identical to infecting CNS tissue with said rAAV with at least 3-fold increased CNS tissue tropism compared to a wild-type AAV5 capsid comprising a peptide of SEQ ID NO:1; delivering the payload to the CNS tissue infected with the rAAV; The method comprising:
60. 1. A method for delivering a payload to central nervous system (CNS) tissue of a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV comprising a VP capsid polypeptide that includes a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide; the 581-589 region comprises at least one amino acid substitution compared to residues 581 to 589 of SEQ ID NO:1; the VP capsid polypeptide comprises at least one amino acid substitution compared to each of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8; infecting CNS tissue with said rAAV with at least 3-fold increased CNS tissue tropism compared to a wild-type AAV5 capsid comprising a peptide of SEQ ID NO:1; delivering the payload to the CNS tissue infected with the rAAV; The method comprising:
61. 1. A method for delivering a payload to central nervous system (CNS) tissue of a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV encapsulating the payload in a capsid, the rAAV comprising a VP capsid polypeptide according to any one of claims 1 to 37; infecting the CNS tissue with the rAAV; delivering the payload to the CNS tissue infected with the rAAV; The method comprising:
62. 62. The method of any one of claims 49-61, further comprising expressing a therapeutic polypeptide or therapeutic polynucleotide encoded by the payload in the CNS tissue infected with the rAAV.
63. 63. The method of any one of claims 49 to 62, further comprising producing a therapeutic effect in CNS tissue of the subject.
64. 1 x 10 per kg of subject's body weight 5 ~5×10 14 The method of claim 63, wherein administration of an rAAV provides the therapeutic effect.
65. The method of claim 63 or claim 64, comprising administering the rAAV in an amount sufficient to provide the therapeutic effect without causing toxicity in the subject.
66. 66. The method of any one of claims 49-65, wherein the CNS tissue comprises any of the forebrain cortex, occipital cortex, temporal cortex, thalamus, hypothalamus, substantia nigra, hippocampus DG, hippocampus CA1, hippocampus CA3, cerebellum, or combinations thereof.
67. 1. A method of treating a condition in a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV comprising a VP capsid polypeptide that includes a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting a central nervous system (CNS) tissue of the subject with the rAAV; preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 100-fold higher than wild-type AAV9; treating said condition by producing a therapeutic effect in said CNS tissue; The method comprising:
68. 68. The method of claim 67, wherein the DNA enrichment is at least 200-fold higher than the wild-type AAV9.
69. 69. The method of claim 67 or claim 68, wherein the DNA enrichment is at least 1000-fold higher than the wild-type AAV9.
70. 1. A method of treating a condition in a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV comprising a VP capsid polypeptide that includes a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting a central nervous system (CNS) tissue of the subject with the rAAV; preferentially transcribe said payload into said CNS tissue infected with said rAAV with RNA enrichment at least 100-fold higher than wild-type AAV9; treating said condition by producing a therapeutic effect in said CNS tissue; The method comprising:
71. 71. The method of claim 70, wherein the DNA enrichment is at least 200-fold higher than the wild-type AAV9.
72. 72. The method of claim 70 or claim 71, wherein the DNA enrichment is at least 500-fold higher than the wild-type AAV9.
73. 1. A method of treating a condition in a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV comprising a VP capsid polypeptide that includes a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting a central nervous system (CNS) tissue of the subject with the rAAV; preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 5-fold higher than wild-type AAV5; treating said condition by producing a therapeutic effect in said CNS tissue; The method comprising:
74. 74. The method of claim 73, wherein the DNA enrichment is at least 10-fold higher than the wild-type AAV5.
75. 1. A method of treating a condition in a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV comprising a VP capsid polypeptide that includes a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting a central nervous system (CNS) tissue of the subject with the rAAV; preferentially transcribe said payload into said CNS tissue infected with said rAAV with RNA enrichment at least 5-fold higher than wild-type AAV5; treating said condition by producing a therapeutic effect in said CNS tissue; The method comprising:
76. 76. The method of claim 75, wherein the DNA enrichment is at least 20-fold higher than the wild-type AAV5.
77. 1. A method of treating a condition in a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV comprising a VP capsid polypeptide that includes a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006 or (dd) having a sequence at least 85% identical to SEQ ID NO: 426; infecting CNS tissue of the subject with the rAAV; delivering the payload to the CNS tissue infected with the rAAV; treating said condition by producing a therapeutic effect in said CNS tissue; The method comprising:
78. 1. A method of treating a condition in a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV comprising a VP capsid polypeptide that includes a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide; the 581-589 region comprises at least one amino acid substitution compared to residues 581 to 589 of SEQ ID NO:1; the VP capsid polypeptide does not have any of the sequences of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8; infecting a CNS tissue of the subject with the rAAV with at least 3-fold increased CNS tissue tropism relative to a wild-type AAV5 capsid comprising a peptide of SEQ ID NO:1; delivering the payload to the CNS tissue infected with the rAAV; treating said condition by producing a therapeutic effect in said CNS tissue; The method comprising:
79. 1. A method of treating a condition in a subject, comprising: administering to the subject a recombinant adeno-associated virus (rAAV), the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide according to any one of claims 1 to 37; infecting CNS tissue of the subject with the rAAV; delivering the payload to the CNS tissue infected with the rAAV; treating said condition by producing a therapeutic effect in said CNS tissue; The method comprising:
80. 80. The method of any one of claims 67 to 79, wherein the condition is a neurological condition.
81. 81. The method of claim 80, wherein the neurological condition is aromatic L-amino acid decarboxylase (AADC) deficiency, Alzheimer's disease, tauopathy, synucleinopathy, Batten disease, mucopolysaccharidosis type III, frontotemporal dementia, Parkinson's disease, corticobasal degeneration, progressive supranuclear palsy, chronic traumatic encephalopathy, Gaucher disease, Canavan disease, Tay-Sachs disease, Huntington's disease, Potocki-Lupski syndrome, amyotrophic lateral sclerosis, Down syndrome, Sanfilippo disease type A, Sanfilippo disease type B, or Rett syndrome.
82. 82. The method of any one of claims 67 to 81, wherein the condition is Rett Syndrome.
83. 83. The method of Claim 82, wherein the payload encodes a guide RNA that targets an mRNA encoded by MECP2, or a tRNA that targets a premature stop codon within MECP2.
84. 84. The method of any one of claims 67 to 83, wherein the condition is Parkinson's disease.
85. The payload is selected from the group consisting of LRRK2, GBA, α-synuclein, AADC, GDNF, neurturin, GAD, FOXG1, K v 7.2, the method of claim 84, encoding a guide RNA that targets an mRNA encoding fragile X mental retardation protein, tau, or laforin.
86. 86. The method of any one of claims 67 to 85, wherein the condition is Alzheimer's disease.
87. 87. The method of claim 86, wherein the payload encodes a guide RNA that targets an mRNA encoding amyloid precursor protein (APP), alpha-synuclein (SNCA), tau protein (MAPT), or apolipoprotein E (ApoE).
88. 87. The method of claim 86, wherein the payload encodes a transgene encoding amyloid precursor protein (APP), alpha-synuclein (SNCA), tau protein (MAPT), or apolipoprotein E (ApoE).
89. 1 x 10 per kg of subject's body weight 5 ~5×10 14 89. The method of any one of claims 67 to 88, comprising administering a single rAAV.
90. 90. The method of any one of claims 49-89, comprising infecting the CNS tissue with at least 2.5 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 50 fold, at least 75 fold, at least 100 fold, at least 200 fold, at least 500 fold, or at least 1000 fold greater tissue tropism than a wild-type AAV5 capsid comprising a peptide of SEQ ID NO:
1.
91. 91. The method of any one of claims 49-90, wherein the payload encodes a therapeutic protein, a therapeutic polynucleotide, a guide RNA, a tRNA, a suppressor tRNA, an siRNA, a miRNA, an mRNA, an shRNA, a circular RNA, an antisense oligonucleotide (ASO), a ribozyme, a DNAzyme, an aptamer, or a combination thereof.
92. 92. The method of claim 91, wherein the guide RNA is a CRISPR / Cas guide RNA or an ADAR guide RNA.
93. The therapeutic protein is selected from the group consisting of aromatic L-amino acid decarboxylase (AADC), amyloid precursor protein (APP), α-synuclein, microtubule-associated protein tau (MAPT), ApoE, nerve growth factor (NGF), telomerase reverse transcriptase (TERT), CLN2, CLN3, CLN6, N-acetylglucosaminidase (NAGLU), granulin, glucosylceramidase β (GBA), aspartoacylase, GDNF, neurturin (NTN), glutamic acid decarboxylase (GAD), FOXG1, K v7.2, laforin, leucine-rich repeat kinase 2 (LRRK2), hexosaminidase A (HEXA), hexosaminidase B (HEXB), huntingtin, cholesterol 24-hydroxylase, C9orf72, superoxide dismutase 1 (SOD1), dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRKA1), N-sulfoglucosamine sulfohydrolase (SGSH), surfeit locus protein 1 (SURF1), GABA transporter 1 (GAT1), and methyl-CpG binding protein 2 (MECP2).
94. The therapeutic polynucleotide is selected from the group consisting of aromatic L-amino acid decarboxylase (AADC), amyloid precursor protein (APP), α-synuclein, microtubule-associated protein tau (MAPT), ApoE, nerve growth factor (NGF), telomerase reverse transcriptase (TERT), CLN2, CLN3, CLN6, N-acetyl-α-glucosaminidase (NAGLU), granulin, glucosylceramidase β (GBA), aspartoacylase, GDNF, neurturin (NTN), glutamic acid decarboxylase (GAD), FOXG1, K v 7.2, laforin, leucine-rich repeat kinase 2 (LRRK2), hexosaminidase A (HEXA), hexosaminidase B (HEXB), huntingtin, cholesterol 24-hydroxylase, C9orf72, superoxide dismutase 1 (SOD1), dual specificity tyrosine phosphorylation regulated kinase 1A (DYRKA1), N-sulfoglucosamine sulfohydrolase (SGSH), surfeit locus protein 1 (SURF1), GABA transporter 1 (GAT1), and methyl-CpG binding protein 2 (MECP2).
95. 95. The method of any one of claims 49 to 94, wherein the payload encodes a component of a CRISPR / Cas system, an adenosine deaminase acting on RNA (ADAR) enzyme, a transcriptional activator or a transcriptional repressor.
96. 96. The method of claim 95, wherein the components of the CRISPR / Cas system include Cas3, Cas8, Cas10, Cas9, Cas4, Cas12, Cas13, guide RNA, or a combination thereof.
97. 96. The method of claim 95, wherein the ADAR enzyme is ADAR1 or ADAR2.
98. 96. The method of claim 95, wherein the transcriptional activator is VP64.
99. 96. The method of claim 95, wherein the transcriptional repressor is KRAB.
100. 100. The method of any one of claims 49-99, comprising systemically administering the rAAV to the subject.
101. 101. The method of any one of claims 49-100, comprising administering the rAAV by intravenous, intramuscular, intraperitoneal or oral administration.
102. The method of any one of claims 49-101, further comprising expressing a therapeutic polypeptide or therapeutic polynucleotide encoded by the payload in the CNS tissue infected with the rAAV.
103. The method of claim 102, comprising expressing the therapeutic polypeptide or therapeutic polynucleotide with increased CNS tissue tropism compared to a wild-type AAV5 capsid comprising the peptide of SEQ ID NO:
1.
104. The method of claim 103, comprising expressing the therapeutic polypeptide or therapeutic polynucleotide with a directionality that is at least 3-fold, at least 3.5-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 75-fold, at least 100-fold, at least 200-fold, at least 500-fold, or at least 1000-fold greater than that of the wild-type AAV5 capsid.
105. 105. The method of any one of claims 49 to 104, comprising causing less toxicity in the subject than would be caused by systemic administration of comparable numbers of wild-type AAV5 capsids comprising the VP capsid polypeptide of SEQ ID NO:
1.
106. The method of any one of claims 49-105, comprising causing less toxicity in the subject than would be caused by systemic administration of a wild-type AAV5 capsid comprising a VP capsid polypeptide of SEQ ID NO:1 in sufficient numbers to deliver a comparable number of payloads to the CNS tissue.
107. 107. The method of any one of claims 49-106, comprising generating a lower concentration of neutralizing antibodies in the subject than would be generated by systemic administration of comparable numbers of wild-type AAV5 capsids comprising the VP capsid polypeptide of SEQ ID NO:
1.
108. The method of any one of claims 49 to 107, comprising producing a concentration of neutralizing antibodies in the subject that is lower than the concentration of neutralizing antibodies produced by intravitreal administration of a comparable number of wild-type AAV2 capsids.
109. The method of any one of claims 49 to 108, comprising producing a concentration of neutralizing antibodies in the subject that is lower than the concentration of neutralizing antibodies produced by intravitreal administration of a comparable number of wild-type AAV8 capsids.
110. The method of any one of claims 49 to 109, comprising producing a concentration of neutralizing antibodies in the subject that is lower than the concentration of neutralizing antibodies produced by intravitreal administration of a comparable number of wild-type AAV9 capsids.
111. 111. The method of any one of claims 49-110, wherein the VP capsid polypeptide further comprises one or more mutations outside of the 581-589 region that contribute to reduced production of neutralizing antibodies against wild-type AAV capsid.
112. 112. The method of any one of claims 49-111, comprising generating a concentration of neutralizing antibodies in said subject that is lower than the concentration of neutralizing antibodies generated upon systemic administration of a wild-type AAV5 capsid comprising a VP capsid polypeptide of SEQ ID NO:1 in sufficient numbers to deliver a comparable number of payloads to said CNS tissue.
113. 1. A viral protein (VP) capsid polypeptide, comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, wherein the 581-589 region comprises at least one amino acid substitution compared to SEQ ID NO:9, and wherein a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting central nervous system tissue and myocardial tissue.
114. 114. The VP capsid polypeptide of claim 113, wherein the 581-589 region has a sequence that has at least 85% sequence identity with a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:2536, SEQ ID NO:3846, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:4317, SEQ ID NO:23, SEQ ID NO:22, SEQ ID NO:964, SEQ ID NO:4288, SEQ ID NO:4338, SEQ ID NO:5037 and SEQ ID NO:4936.
115. The VP capsid polypeptide of claim 113 or claim 114, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:2536, SEQ ID NO:3846, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:4317, SEQ ID NO:23, SEQ ID NO:22, SEQ ID NO:964, SEQ ID NO:4288, SEQ ID NO:4338, SEQ ID NO:5037 and SEQ ID NO:4936.
116. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, and wherein a recombinant viral capsid comprising said VP capsid polypeptide is capable of preferentially targeting central nervous system tissue and skeletal muscle tissue.
117. 116. The VP capsid polypeptide of claim 115, wherein the 581-589 region has a sequence that has at least 85% sequence identity with a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:3283, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:307, SEQ ID NO:4317, SEQ ID NO:1268, SEQ ID NO:4288, SEQ ID NO:724, and SEQ ID NO:5037.
118. The VP capsid polypeptide of claim 115 or claim 116, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:3306, SEQ ID NO:2536, SEQ ID NO:1971, SEQ ID NO:3283, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:307, SEQ ID NO:4317, SEQ ID NO:1268, SEQ ID NO:4288, SEQ ID NO:724 and SEQ ID NO:5037.
119. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, and wherein a recombinant viral capsid comprising said VP capsid polypeptide is capable of preferentially targeting central nervous system tissue and muscle tissue.
120. 120. The VP capsid polypeptide of claim 119, wherein the 581-589 region has a sequence that has at least 85% sequence identity with a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:2536, SEQ ID NO:3846, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:4317, SEQ ID NO:23, SEQ ID NO:22, SEQ ID NO:964, SEQ ID NO:4288, SEQ ID NO:4290, SEQ ID NO:4338 and SEQ ID NO:5037.
121. The VP capsid polypeptide of claim 119 or claim 120, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:3472, SEQ ID NO:262, SEQ ID NO:2536, SEQ ID NO:3846, SEQ ID NO:3297, SEQ ID NO:4545, SEQ ID NO:2661, SEQ ID NO:1576, SEQ ID NO:4317, SEQ ID NO:23, SEQ ID NO:22, SEQ ID NO:964, SEQ ID NO:4288, SEQ ID NO:4290, SEQ ID NO:4338 and SEQ ID NO:5037.
122. 1. A recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising: administering to the subject a rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting a central nervous system (CNS) tissue of the subject with the rAAV; preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 100-fold higher than wild-type AAV9; The rAAV comprising:
123. 1. A recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising: administering to the subject a rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting a central nervous system (CNS) tissue of the subject with the rAAV; preferentially transcribe said payload into said CNS tissue infected with said rAAV with RNA enrichment at least 100-fold higher than wild-type AAV9; The rAAV comprising:
124. 1. A recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising: administering to the subject a rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting a central nervous system (CNS) tissue of the subject with the rAAV; preferentially delivering the payload to the CNS tissue infected with the rAAV at a DNA enrichment at least 5-fold higher than wild-type AAV5; The rAAV comprising:
125. 1. A recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising: administering to the subject a rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9; infecting a central nervous system (CNS) tissue of the subject with the rAAV; preferentially transcribe said payload into said CNS tissue infected with said rAAV with RNA enrichment at least 5-fold higher than wild-type AAV5; The rAAV comprising:
126. 1. A recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising: administering to the subject a rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising (a) SEQ ID NO: 18, (b) SEQ ID NO: 3472, (c) SEQ ID NO: 262, (d) SEQ ID NO: 3306, (e) SEQ ID NO: 2028, (f) SEQ ID NO: 2791, (g) SEQ ID NO: 424, (h) SEQ ID NO: 2536, (i) SEQ ID NO: 1971, (j) SEQ ID NO: 415, (k) SEQ ID NO: 3846, (l) SEQ ID NO: 3283, (m) SEQ ID NO: 1956, (n) SEQ ID NO: 3297, (o) SEQ ID NO: 4545, (p) SEQ ID NO: 2661, (q) SEQ ID NO: 1576, (r) SEQ ID NO: 425, (s) SEQ ID NO: 709, (t) SEQ ID NO: 2168, (u) SEQ ID NO: 54, (v) SEQ ID NO: 429, (w) SEQ ID NO: 708, (x) SEQ ID NO: 428, (y) SEQ ID NO: 4119, (z) SEQ ID NO: 3906, (aa) SEQ ID NO: 2456, (bb) SEQ ID NO: 2278, (cc) SEQ ID NO: 5006 or (dd) SEQ ID NO: 426, having a sequence that is at least 85% identical to infecting CNS tissue of the subject with the rAAV; delivering the payload to the CNS tissue infected with the rAAV; The rAAV comprising:
127. 1. A recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising: administering to the subject a rAAV, the rAAV comprising a VP capsid polypeptide including a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide; the 581-589 region comprises at least one amino acid substitution compared to residues 581 to 589 of SEQ ID NO:1; the VP capsid polypeptide does not have any of the sequences of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8; infecting a CNS tissue of the subject with the rAAV with at least 3-fold increased CNS tissue tropism relative to a wild-type AAV5 capsid comprising a peptide of SEQ ID NO:1; delivering the payload to the CNS tissue infected with the rAAV; The rAAV comprising:
128. 1. A recombinant adeno-associated virus (rAAV) for use in a method of treating a condition in a subject, the method comprising: administering to the subject a rAAV, the rAAV having a payload encapsulated in a capsid, the rAAV comprising a VP capsid polypeptide according to any one of claims 1 to 37; infecting CNS tissue of the subject with the rAAV; delivering the payload to the CNS tissue infected with the rAAV; The rAAV comprising:
129. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, wherein a recombinant viral capsid comprising said VP capsid polypeptide is capable of preferentially targeting myocardial tissue with at least 25-fold greater DNA enrichment than wild-type AAV9.
130. 130. The VP capsid polypeptide of claim 129, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:348, SEQ ID NO:2536, SEQ ID NO:1576, SEQ ID NO:4955, SEQ ID NO:5017, SEQ ID NO:4349, SEQ ID NO:4964, SEQ ID NO:293, SEQ ID NO:4314, SEQ ID NO:4995, SEQ ID NO:4366, SEQ ID NO:4961, SEQ ID NO:4952, SEQ ID NO:5075, SEQ ID NO:4354, SEQ ID NO:5060, SEQ ID NO:5138, SEQ ID NO:5206, SEQ ID NO:4288, SEQ ID NO:5092, SEQ ID NO:4059, SEQ ID NO:4295, SEQ ID NO:5030, SEQ ID NO:4938, SEQ ID NO:2661, SEQ ID NO:5215, SEQ ID NO:4960, SEQ ID NO:4969, SEQ ID NO:5023, SEQ ID NO:4934, SEQ ID NO:4545, SEQ ID NO:4963, SEQ ID NO:4363, SEQ ID NO:5159, and SEQ ID NO:4973.
131. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising: (a) SEQ ID NO: 348, (b) SEQ ID NO: 2536, (c) SEQ ID NO: 1576, (d) SEQ ID NO: 4955, (e) SEQ ID NO: 5017, (f) SEQ ID NO: 4349, (g) SEQ ID NO: 4964, (h) SEQ ID NO: 293, (i) SEQ ID NO: 4314, (j) SEQ ID NO: 4995, (k) SEQ ID NO: 4366, (l) SEQ ID NO: 4961, (m) SEQ ID NO: 4952, (n) SEQ ID NO: 5075, (o) SEQ ID NO: 4354, (p) SEQ ID NO: 5060, (q) SEQ ID NO: 5138, (r) SEQ ID NO: 5206, (s) SEQ ID NO: 4288, (t) SEQ ID NO: 5092, (u) SEQ ID NO: 4059, (v) SEQ ID NO: 4295, (w) SEQ ID NO: 5030, (x) SEQ ID NO: 4938, (y) SEQ ID NO: 2661, (z) SEQ ID NO: 5215, (aa) SEQ ID NO: 4960, (bb) SEQ ID NO: 4969, (cc) SEQ ID NO: 5023 or (dd) SEQ ID NO: 4934, The VP capsid polypeptide having a sequence which is at least 85% identical to
132. A viral protein (VP) capsid polypeptide, the VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, the 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, wherein a recombinant viral capsid comprising the VP capsid polypeptide is capable of preferentially targeting skeletal muscle tissue with at least 15-fold greater DNA enrichment than wild-type AAV9.
133. 133. The VP capsid polypeptide of claim 132, wherein the 581-589 region has a sequence selected from the group consisting of SEQ ID NO:3472, SEQ ID NO:3297, SEQ ID NO:2661, SEQ ID NO:4545, SEQ ID NO:348, SEQ ID NO:18, SEQ ID NO:4349, SEQ ID NO:293, SEQ ID NO:5017, SEQ ID NO:4955, SEQ ID NO:4366, SEQ ID NO:5092, SEQ ID NO:210, SEQ ID NO:4059, SEQ ID NO:2536, SEQ ID NO:5206, and SEQ ID NO:1971.
134. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising: (a) SEQ ID NO: 3472, (b) SEQ ID NO: 3297, (c) SEQ ID NO: 2661, (d) SEQ ID NO: 4545, (e) SEQ ID NO: 348, (f) SEQ ID NO: 18, (g) SEQ ID NO: 4349, (h) SEQ ID NO: 293, (i) SEQ ID NO: 5017, (j) SEQ ID NO: 4955, (k) SEQ ID NO: 4366, (l) SEQ ID NO: 5092, (m) SEQ ID NO: 210, (n) SEQ ID NO: 4059, (o) SEQ ID NO: 2536, (p) SEQ ID NO: 5206, (q) SEQ ID NO: 1971, (r) SEQ ID NO: 262, (s) SEQ ID NO: 4343, (t) SEQ ID NO: 4995, (u) SEQ ID NO: 4009, (v) SEQ ID NO: 5190, (w) SEQ ID NO: 724, (x) SEQ ID NO: 4288, (y) SEQ ID NO: 4973, (z) SEQ ID NO: 4314, (aa) SEQ ID NO: 1561, (bb) SEQ ID NO: 5147, (cc) SEQ ID NO: 4238 or (dd) SEQ ID NO: 4961, The VP capsid polypeptide having a sequence which is at least 85% identical to
135. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising at least one amino acid substitution compared to SEQ ID NO:9, wherein a recombinant viral capsid comprising said VP capsid polypeptide is capable of preferentially targeting muscle tissue with at least 20-fold greater DNA enrichment than wild-type AAV9.
136. The 581-589 region is SEQ ID NO: 348, SEQ ID NO: 2536, SEQ ID NO: 4955, SEQ ID NO: 5017, SEQ ID NO: 4349, SEQ ID NO: 293, SEQ ID NO: 1576, SEQ ID NO: 2661, SEQ ID NO: 4964, SEQ ID NO: 4314, SEQ ID NO: 4995, SEQ ID NO: 4366, SEQ ID NO: 4545, SEQ ID NO: 4961, SEQ ID NO: 5206, SEQ ID NO: 5092, SEQ ID NO: 3472, SEQ ID NO: 5075, SEQ ID NO: 4059, SEQ ID NO: 4354, 46. The VP capsid polypeptide of claim 45 having a sequence selected from the group consisting of SEQ ID NO:5060, SEQ ID NO:4288, SEQ ID NO:4952, SEQ ID NO:5138, SEQ ID NO:18, SEQ ID NO:5030, SEQ ID NO:3297, SEQ ID NO:4295, SEQ ID NO:4363, SEQ ID NO:4963, SEQ ID NO:4973, SEQ ID NO:5159, SEQ ID NO:4960, SEQ ID NO:4938, SEQ ID NO:5157, SEQ ID NO:5023 and SEQ ID NO:4969.
137. A viral protein (VP) capsid polypeptide, said VP capsid polypeptide comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, said 581-589 region comprising: (a) SEQ ID NO: 348, (b) SEQ ID NO: 2536, (c) SEQ ID NO: 4955, (d) SEQ ID NO: 5017, (e) SEQ ID NO: 4349, (f) SEQ ID NO: 293, (g) SEQ ID NO: 1576, (h) SEQ ID NO: 2661, (i) SEQ ID NO: 4964, (j) SEQ ID NO: 4314, (k) SEQ ID NO: 4995, (l) SEQ ID NO: 4366, (m) SEQ ID NO: 4545, (n) SEQ ID NO: 4961, (o) SEQ ID NO: 5206, (p) SEQ ID NO: 5092, (q) SEQ ID NO: 3472, (r) SEQ ID NO: 5075, (s) SEQ ID NO: 4059, (t) SEQ ID NO: 4354, (u) SEQ ID NO: 5060, (v) SEQ ID NO: 4288, (w) SEQ ID NO: 4952, (x) SEQ ID NO: 5138, (y) SEQ ID NO: 18, (z) SEQ ID NO: 5030, (aa) SEQ ID NO: 3297, (bb) SEQ ID NO: 4295, (cc) SEQ ID NO: 4363 or (dd) SEQ ID NO: 4963, The VP capsid polypeptide having a sequence which is at least 85% identical to
138. 1. A viral protein (VP) capsid polypeptide, comprising a 581-589 region corresponding to residues 581 to 589 of a VP1 polypeptide, wherein said VP capsid polypeptide comprises a sequence that is at least 85% identical to any one of SEQ ID NOs:4238-4933, or SEQ ID NOs:4934-5233.
139. 139. The VP capsid polypeptide of claim 138, wherein the 581-589 region has a sequence as set forth in any one of SEQ ID NOs: 4238 to 4933 or SEQ ID NOs: 4934 to 5233.
Citation Information
Patent Citations
Adeno-associated virus compositions for targeted gene therapy
JP2022502046A
Adeno-Associated Vectors for Enhanced Transduction and Reduced Immunogenicity
US20160289275A1
Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020069461A1
Redirection of tropism of AAV capsids
WO2020072683A1
Adeno-associated virus with engineered capsid
WO2020205889A1
